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Nasopharyngeal carcinoma (NPC) is a malignant tumour arising from the 
nasopharyngeal epithelium with early metastases to either tissues surrounding it like the 
cervical lymph nodes, eyes, brain and subsequent spread to liver and bone marrow. Due 
to the nasopharynx small size and difficult anatomical location, patients are usually 
diagnosed at the late stage III of NPC. The current treatment of radiotherapy and 
chemotherapy are effective but require management of side effects that affects the quality 
of life of patients. In search of more specific medication for NPC, novel approaches for 
the treatment have been extensively investigated. The gene therapy by targeting specific 
genes involved in cancer is currently under investigation in a variety of cancer models. 
DENN (Differentially expressed in normal and neoplastics cells) or MADD (MAP-kinase 
activating death domain) is mapped to chromosome 11p11.21-p11.22 which interacts 
with tumor necrosis factor receptor 1 through their death domain (C-terminal region) and 
subsequently signals via MAPK pathway. The DENN family consists of seven putative 
splice variants where the main isoforms are separated into two groups, the anti-apoptotic 
(DENN and DENN-SV) and pro-apoptotic (IG20 and IG20-SV2). The important function 
of DENN is reflected by its involvement in many apoptotic-related diseases including 
cancer, Alzheimer’s disease and fetal development.  
  In the present work, the employment of antisense phosphorotioate 
oligodeoxynucleotide (PS-ODNs) targeting death domain of DENN isoforms in 
nasopharyngeal carcinoma CNE-2 cell line model showed promising results of inducing 
apoptosis. CNE-2 cells expressed all four isoforms of DENN at extremely different 
 xvi 
expression levels. There was significant downregulation of DENN isoforms at gene and 
protein level upon transfection of the death domain ODN with observation of apoptosis 
induction after 48hours. The DNA microarray analysis carried out with CNE-2 cells 
transfected with DENN sense or antisense against death domain showed the involvement 
of DENN in signaling pathways leading to apoptotic cell death. The blocking of DENN 
lead to significant upregulation of TNF-R1 death domain competitor, TRADD and TNF 
receptor associated factors, which further may stimulate the downstream signaling 
molecules leading to apoptosis. Besides TNF mediated apoptotic pathway, we identified 
decrease of other signaling molecules such as Rabaptin5, which is an essential 
component of endosome fusion. The decrease in rabaptin-5 had been demonstrated to 
cause the loss of fusion activity, which ultimately leading to apoptosis. These studies 
suggest a novel approach of antisense treatment of DENN for nasopharyngeal carcinoma 


















 Cancer refers the diseases of the body’s cells with uncontrolled, abnormal growth 
and capable of evading healthy tissues1. There are more than 100 different and distinct 
cancer types, involving tissues of the human body in various forms. Most cancers are 
named after where the cancerous cells originated from. Benign growth is not considered 
as cancer as they do not spread to other parts of the body and are seldom life-threatening. 
Cancer can also be called malignancy, a malignant tumor or neoplasm with the ability to 
metastasis and invade other tissues. Metastasis occurs with the spread of cancerous cells 
to another part of the body through blood vessels or lymphatic system. When these 
cancerous cells actively grow into a solid tumour, angiogenesis occurs; with the 
formation of new blood vessels to support additional growth. These are the major causes 
of death after the weakening and dysfunction of normal body systems.  
 Carcinomas (80% of all cancer) are solid malignant growth of the epithelial 
tissues that cover the body’s surface and lining of internal organs and glands (Wingate, 
1988). Adenocarcinoma, subset of carcinoma, arises from epithelium of glandular origin. 
Sarcoma is the cancer of bone, cartilage, muscle, other connective or supportive tissues 
that developed from embryonic mesoderm layer. On the other hand, leukemia begins in 
blood forming tissue like bone marrow, resulting in abnormal proliferation and 
maturation. Lymphoma and multiple myeloma are cancers affecting the cells of the 
immune system2. Blastoma describes a tumour of embryonic origin. 




 http://www.cancer.gov/dictionary/, May 2006 
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Cancer is the second leading cause of death in developed countries with 
epidemiological impact leading to financial burden and numerous social implications. 
Globally, there is constant increasing investment on cancer prevention publicities, health 
screening programmes as well as aggressive research and development improvement.   
Breast cancer is the most prevalent cancer in the world with 4.4 million survivors up to 5 
years following diagnosis. The most commonly diagnosed cancers are lung (1.35 
million), breast (1.15 million) and colorectal (1 million). There are 24.6 million persons 
alive with cancer (within three years of diagnosis), 10.9 million newly cases diagnosed 
and 6.7 million deaths (Parkin et al., 2005). It kills one in eight of those who die 
worldwide and claims twice more than AIDS.  In addition to that, three leading cancer 
killers are lung (1.18 million), stomach (700,000) and liver (598,000).  In Asia, 
nasopharyngeal carcinoma (NPC) is highly endemic amongst male Chinese, originating 
from southern China with age-standardized incidence rates of 15 to 50 per 100,000 
persons-year (Parkin et al., 2002). 
 
1.2 NASOPHARYNGEAL CARCINOMA 
1.2.1  History  
Nasopharyngeal carcinoma (NPC) may have existed in the ancient time as early 
as 3500 to 3000 B.C. These suggestions come from skull examinations of Egyptians 
(Krogman, 1940) and early Iranian of Teppe Hissar (Well, 1963). In 1837, European Dr. 
Durand-Fardel observed and described the first nasopharyngeal carcinoma case based on 
clinical evidence (Muir, 1983). Later in 1845, Dr. Michaux gave a comprehensive 
illustration of nasopharyngeal carcinoma based on strong histopathological evidence. 
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Digby and colleagues (1930) have reported detailed descriptions of an exceptionally high 
frequency (103 cases) of pathological features of nasopharyngeal carcinoma in Hong 
Kong Chinese patients. Singapore’s first histologically confirmed case of NPC was 
reported by Dr. Shanmugaratnam in 1971. 
1.2.2 Anatomical pathology 
 The nasopharynx is a cuboidal space situated behind the nasal cavity between the 
base of skull (above) and the level of soft palate (below). It measures between 3 to 4 cm 
in height, width and antero-posterior dimensions. The nasopharynx has rich vascular 
supply and lymphatic drainage system. These characteristics of the nasopharynx define 
the route of tumor spread and symptomatology (Figure 1.A). 
The nasopharynx consists of three types of epithelium tissue; stratified epithelium 
cells, pseudostratified column ciliated cells and patches of intermediate cells 
(Shanmugaratnam, 1982). The malignant tumour arises from any these epithelial cells 
that accounts for 90% of cases (Altun et al., 1995). It is strongly believed that the Fossa 
of Rosenmuller (FOR); a cone shaped depression, located at the lateral extension of 
nasopharynx is the main site of NPC predilection development (Figure 1.A). 
Nasopharyngeal carcinoma spreads via three routes; direct extension, lymphatic and 
hematogenous network (Prasad, 2000). The most severe form of NPC occurs when the 
carcinoma spreads superiorly into the cranial cavity. This invasion can harm the orbits, 
optic tracts and cavernous cranial fossa that are also surrounded with multiple cranial 
nerves (Li et al., 2006). The nasopharyngeal carcinoma is also capable of entering the 
lymphoid tissue and metastasizes into regional lymph like the node of Rouviere and 
subsequently into the deep cervical nodes (Jiang and Wei, 2005).  Besides that, the 
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neighbouring parapharyngeal space that is enriched with venous plexus network has been 
suggested to be disseminating nasopharyngeal carcinoma (Shin et al., 2001, Cheng et al., 
2005). 
Figure 1.A Anatomical 
location of nasopharyngeal 
carcinoma. ‘T’ represents 
the origin of the 
nasopharyngeal carcinoma 
which is capable of 
metastasis and invading 
surrounding tissues as 




1.2.3 Staging of nasopharyngeal carcinoma 
The nasopharyngeal carcinoma is staged based on standardized American Joint 
Committee on Cancer (AJCC). The following Table 1.1 lists three criteria; Tumour (T), 
involvement of Lymph Nodes (N) and metastasis stages (M) for nasopharyngeal 
carcinoma diagnosis (Fandi et al.¸1994). 
Table 1.1 Criteria for the staging of nasopharyngeal carcinoma 
Tumour in the nasopharynx 
Primary Tumour (T stage) 
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
Tis Carcinoma in situ 
 Nasopharynx     Oropharynx  Hypopharynx 
T1 Tumour confined to 
the nasopharynx 
Tumour 2cm or 
less in greatest 
Tumour limited to one side of 










dimension greatest dimension 
T2 Tumour extends to 
soft tissues of 
oropharynx and/or 
nasal fossa 
Tumour more than 
2 cm but not more 
than 4 cm in 
greatest dimension 
Tumour involves more than one 
subsite of hypopharynx or an adjacent 
site, or measures more than 2cm but 
not more than 4 cm in greatest 
diameter without fixation of 
hemilarynx 
T2a With parapharyngeal 
extension 
- - 




T3 Tumour invades bony 
structures and/or 
paranasal sinuses 
Tumour more than 
4 cm in greatest 
dimension 
Tumour measures more than 4 cm in 
greatest dimension or with fixation of 
hemilarynx 
T4 Tumour with 
intracranial extension 
and/or involvement 
of cranial nerves, 
infratemporal fossa, 





hard plate, deep 
muscle of tongue, 
larynx 
Tumour invades adjaced structures 
(eg. Thyroid/cricoid cartilage, carotid 
artery, soft tissues of neck, 
prevertebral fascia/muscles, thyroid 
and/or esophagus) 
Regional Lymph Nodes (N) 
The distribution and the prognostic impact of regional lymph node spread from nasopharynx 
cancer, particularly of the undifferentiated type, is different with from that of other head and 
neck mucosal cancers and justifies used a different N classification scheme. 
  Nasopharynx    Oropharynx and Hypopharynx 
NX Regional lymph nodes cannot be accessed Regional lymph nodes cannot be 
accessed 
N0 No regional lymph node metastasis No regional lymph node metastasis 
N1 Unilateral metatasis in lymph node(s), 6 
cm or less than greatest dimension, above 
the supraclavicular 
Metastasis in a single ipsilateral lymph 
node, 3cm or less in greatest dimension 
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N2 Bilateral metastasis in lymph node(s), 6 
cm or less than greatest dimension, above 
the supraclavicular 
Metastatsis in single ipsilateral lymph 
node, more than 3cm but not more than 6 
cm in greatest dimension, or in multiple 
ipsilateral lymph nodes, non or more than 
6 cm in greatest dimension, or in bilateral 
or contralateral lymph nodes, not more 
than 6 cm in greatest dimension 
N2a - Metastasis in a single ipsilateral lymph 
node more than 3 cm but less than 6 cm 
in greatest dimension 
N2b - Metastasis in multiple single ipsilateral 
lymph node non more than 6 cm in 
greatest dimension 
N2c - Metastasis in a lymph nodes more than 6 
cm in greatest dimension 
N3 Metastasis in lymph node (s) - 
N3a Greater than 6cm in dimension - 
N3b In the supraclavicular fossa - 
Distant metastasis (M) 
MX Distant metastasis cannot be accessed 
M0 No distant metastasis 
M1  Distant metastasis 
Staging grouping 
Stage T N M 
0 Tis N0 M0 
I T1 N0 M0 
II T2 N0 M0 
T3 N0 M0 
T1 N1 M0 
T2 N1 M0 
III 
T3 N1 M0 
T4 N0 M0 IV 
T4 N1 M0 
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Any T  N2 M0 
Any T N3 M0 
Any T Any N M1 
1.2.4 Histopathology classification 
In 1997, the World Health Organization (WHO) classified nasopharyngeal 
carcinoma into three different histopathological presentations based on the degrees of 
cellular differentiation. 
WHO Type 1: Squamous cell carcinoma (SCC) / keratinizing squamous cell 
carcinoma. These differentiated squamous cells are identified with the presence of 
intercellular bridges and the formation of well-defined keratin pearls. It is further divided 
into three classes: well, moderate or poorly differentiated. It is rare and uncommon in 
Asia (Shanmugaratnam 1971; Shanmugaratnam et al., 1979; Shanmugaratnam, 1982). 
Figure 1.Bi NPC WHO Type I Squamous cell carcinoma: Left: Well-differentiated 
squamous cell carcinoma. 
There are evident of 
differentiation, with distinct 
intercellular bridges.  
Right: Poorly-differentiated 
nasopharyngeal carcinoma (Pathmanatham, 1997) 
WHO Type II: Non-keratinizing epidermoid carcinoma. There is evidence of 
differentiation with additional maturation where the tumors are arranged in a stratified or 
pavemented fashion. The cells are unsyncytial with well defined margin.   
Figure 1.Bii NPC WHO Type II Non keratinizing 
epidermoid carcinoma: It is characterized by a plexiform 
growth pattern and absence of obivious keratinisation 
(Pathmanatham, 1997) 
WHO Type III: Undifferentiated carcinoma 
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nasopharyngeal type (UCNT). These tumor cells show no differentiation with syncytial 
arrangement. These cells are grouped into irregular masses with undefined cell margin. 
UNCT is further distinguished from type II cells with the presence of non-malignant 
lymphoid cells infiltration (Shpitzer et al., 2001). Therefore, UCNT is also known as 
‘lympho-epithelioma or lymphoepithelial carcinoma’. Globally, UCNT shows consistent 
association with Epstein-Barr virus (EBV) particles. This nasopharyngeal carcinoma is 
the most common carcinoma presentation in southern China. Among the three types, 
UCNT patients have better prognosis and survival chances compared to others (Altun et 
al., 1995). 
Figure 1.Biii NPC WHO III 
Undifferentiated carcinoma 
nasopharyngeal carcinoma 
type: (Pathmanathan, 1997) 
Left: Large prominent 
tumour with syncytial growth pattern. Tumours cells are mixed with lymphocytes. Right: 
Spindle-cell pattern of tumour cells 
1.2.5 Epidemiology of NPC 
1.2.5.1 Geographic variation 
 Nasopharyngeal carcinoma (NPC) is a unique, rare (less than 1 per 100,000 
persons per year), malignant tumor of head and neck (Chang and Adami, 2006).  In 2002, 
NPC was rated as the 23rd most common cancer with a total of 80,000 newly diagnosed 
world-wide (0.7% of all cancers) and 50,000 deaths (Parkin et al., 2005). However, the 
overall incidence of NPC is highly prominent in the Chinese population especially those 
of Cantonese descendents (15-50/100,000) regardless of their residing geographical 
regions (Parkin et al., 2005) (Figure 1.C). In China, nasopharyngeal carcinoma varies 
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across the country with low frequency from the northern provinces (Beijing, Tianjin) to a 
50 fold increment in the southern provinces (Guangdong provinces including Hong Kong 
and Taiwan). Besides that, nasopharyngeal carcinoma is also endemic amongst the native 
Eskimos people of Greenland and Alaska with incidence from 15 to 20 per 100,000/year 
(Nielsen et al., 1977; Albeck et al., 1992; 1993). The intermediate rate of approximately 
8/100,000 per year is observed amongst the natives of the Philippines, Thailand, 
Vietnam, Borneo, Mediterranean basin and Central Africa (Fandi et al., 1994; Prasad, 
2000; Parkin et al., 2002).  NPC is relatively low and rare in Europe, America and Asian 
neighboring countries like Japan and India. Table listed in appendix 1.1 shows the 
epidemiology of NPC with age-standardized rates of selected registries. 
Figure 1.C 
Geographical distribution of nasopharyngeal carcinoma for male patients: Left. 
Nasopharyngeal carcinoma is standardized per 100,000 per persons/year. Drawn by 
Garboriau V & Corbex M (Genetic Epidemiology Unit, International Agency for 
Research on Cancer http://www.iarc.fr on GLOBOCAN 2000 (Busson et al., 2004). 
Right. Map of the southern or Guangdong provinces in China where nasopharyngeal 
carcinoma is highly endemic (Yu, 1990) 
B 
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1.2.5.2 Ethnic and dialect group variation 
NPC is marked the fourth most common new malignancy in China where the 
Cantonese from the southern provinces (Guangdong, Guangxi, Hunan and Fujian, Figure 
1.C) have highest relative risk of developing nasopharyngeal carcinoma (Parkin et al., 
2002). The ‘Tankas’, a sub-ethnic group of Cantonese are seafaring people inhabiting 
along the Pearl River delta basin in central Guongdong. They showed the highest rate of 
NPC and twice higher than their neighbouring land dwellers (Ho, 1978; Yu, 1990). 
Among land dwellers, the Cantonese exhibits the highest frequency of nasopharyngeal 
carcinoma followed by other dialect groups like Hakka and Teochew. People living in 
Guangxi, Hunan and Fujian provinces also showed similar incidence of NPC for these 
respective dialect groups. However, the relatively high risk of NPC rates among the 
Hakka, who are migrants from the low-risk north disputed the genetic predisposition as a 
major determining risk for developing nasopharyngeal carcinoma.   
Hong Kong, populated with Cantonese descendents has the highest frequency of 
nasopharyngeal carcinoma cases. Nasopharyngeal carcinoma ranks top fourth newly 
diagnosed malignancy (Parkin et al., 2002). Effective management and preventive 
programmes in Hong Kong have reduced NPC by 30% for the past twenty years (Lee et 
al., 2003). Similar programmes in Taiwan also reduced mortality from nasopharyngeal 
carcinoma, which is also the leading cancer in males (Chen et al., 2002).  
In Singapore, NPC is ranked the 6th most frequently diagnosed cancer3. However, 
Singaporean males showed no significant changes in number of nasopharyngeal 
carcinoma cases over the past 25 years (Chia and Lee, 1997).  This study compared the 
relative risk of nasopharyngeal carcinoma for different races and dialect groups in 




Singapore (Figure 1.D). The Chinese, especially the Cantonese dialect group has the 
highest risk of developing nasopharyngeal carcinoma with the frequency of 18.5-
21.4/100,000 in male and 7.5-8.3/100,000 in female followed by Hokkien (12.3/100,000 
in male, 3.7/100,000 in female), Teochew, Hakka and Hainanese (Chia and Lee, 1997). 
The incidence of nasopharyngeal carcinoma in Malays is 7.1/100,000 in male and 
1.9/100,000 in females (Wang et al., 2004) and relatively rare amongst the Indians 
(Krishna et al., 2004).  
 
Figure 1.D Nasopharyngeal carcinoma in Singapore: Main NPC WHO type III cases 
with age adjusted relative risk by ethnic and Chinese dialect groups in Singapore, 1983-
87 (Chia and Lee, 1997) 
 Abroad, Chinese emigrants from Guangdong provinces to Canada, United States, 
Australia and Cuba have higher incidence of nasopharyngeal carcinoma compared to the 
locals (Grulich et al., 1995; Sun et al., 2005; 2007). The Chinese residing in US Bay 
Area, Los Angeles, Hawaii are mainly Cantonese; develop nasopharyngeal carcinoma at 






















1.2.5.3 Age and sex variation 
 From epidemiology studies, nasopharyngeal carcinoma is two to 3.5 times more 
predominant in males than females (Ireland et al., 1988; Parkin et al., 2002). NPC 
incidences increased gradually with the increase of age for low-risk populations (Devi et 
al., 2004). In contrast, the incidences of NPC peak around age 50 to 59 years and declines 
after this age range (Lee et al., 2003). The average age of NPC diagnosis is lower for 
high risk populations; 41 years for US Chinese, 45 years-Hong Kong Chinese, 45 years–
Tunisians compared to lower risk region; 56 years among the US non-Chinese, 52 years 
among French and 51 years for West Germans (Karray et al., 2005). Besides, patients 
from high risk countries also presented more severe stage of nasopharyngeal carcinoma 
(De-The et al., 1974; Henle and Henle, 1980; Armstrong et al., 2000). Suggestions of the 
association of early life exposure and the involvement of carcinogens might contribute to 
the development of nasopharyngeal carcinoma (Yu, 1990; Lee et al., 1992). 
1.2.5.4 Environmental and dietary factors 
 There are suggestions that NPC patients are more hypersensitive towards dust, 
incense and smoke (Muir, 1983; Hildesheim and Levine, 1993). However, this 
association is inconclusive with continuous diagnosis of new nasopharyngeal carcinoma 
cases among the Chinese population despite global improvement living standard.  
Food habits and traditional customs affect the lifestyle of every population. Diet 
might be responsible for the rate of nasopharyngeal carcinoma development. Studies 
from familial and sporadic cases of NPC have showed association of constant 
consumption of betel nut and salted fish during childhood with increased the risk of 
developing NPC (Poirier et al., 1987; Shao et al., 1988; Ward et al., 2000; Hildesheim et 
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al., 2001, Yang et al., 2005). Preserved food like salted fish, vegetable and fermented 
bean curd contain high concentration of volatile nitrosamines. Studies have demonstrated 
that residents from NPC high risk areas are consuming salted fish with higher level of 
nitrosamines as compared to the lower risk regions of China (Zou et al., 1992; 1994).  
Animals fed with the Chinese salted fish had increased telomerase activity that might 
result in chromosomal instability and gradually leading to cancer (Tang et al., 2001; 
Boukamp and Mirancea, 2007). This might be related to the high telomerase activity in 
85% primary nasopharyngeal carcinoma samples and also coincidently high in Epstein-
Barr virus (EBV) viral load (Liu et al., 2006). 
Eskimos of the Greenland, Alaska as well as the Arabs of North Africa regularly 
consume preserved or fermented food like dried fish, meat and rotten vegetable (Hubert 
and de-The, 1982; Yu, 1990; Hildesheim and Levine, 1993). These food contain elevated 
levels of volatile nitrosamines which strongly activated EBV latent genes activity. 
Though the association of environmental and dietary factors with nasopharyngeal 
carcinoma seemed to be subjective, they might play a facilitator role that interacts with 
one’s genetic predisposition in early development. 
 1.2.5.5 Genetics – HLA 
 The intermediate frequency of nasopharyngeal carcinoma in offspring of mixed 
marriages between the migrant Southern Chinese and non Chinese people in America 
also implicated genetic association (Muir, 1971; Ho, 1978).  Amongst the genetic marker 
systems identified, Human Leukocyte Antigen (HLA) showed the strongest association 
with NPC (Simons et al., 1975). HLA is also known as Major Histocompatibility 
Complex (MHC), mapped to chromosome 6p21.1 to p32.3. It is a cluster of highly 
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polymorphic genes that code for surface proteins for identification, recognition and 
antigen presentation (Tiwari and Terasaki, 1985; Carroll et al., 1987). The enormous 
differences and complexicity of antigen presentation by MHC proteins contributed to 
high specificity and diversity of the immune system (Dausset, 1980). 
 HLA haplotype study suggested increased incidences of HLA A2 and 
undetectable HLA-Sin2 (now known as B46) association with nasopharyngeal carcinoma 
patients (Simons et al., 1975; 1976; 1977). This observation was extended to NPC 
Chinese patients in Malaysia, Hong Kong and United States (Simons, 1982; Hildesheim 
et al., 2002). Two different haplotypes (Figure 1.E) are associated with the diagnosis of 
NPC; A2, Cw11 (formerly known as Cw1), B46, DR9 with a relative risk (RR) of 3.4 and 
Aw33, Cw3, B58, DR3 with a RR of 2.2 (Chan, 1980; Simons and Shanmugaratnam, 
1982; Chan et al., 1983; Chan, 1990). Among these alleles, two pairs; A2 and B46, as 
well as A33 and B58, constantly show strong disequilibrium linkage with statistical 
significance amongst the general Chinese population (Simons, 2003). The first haplotype 
set is associated with older onset (> 30 years) patients while the latter with juvenile cases 
and poor prognosis. Meta-analysis from 13 complied independent studies on 
nasopharyngeal carcinoma patients of Southern Chinese origins showed concordance of 
specific HLA associations. There are significantly positive association between 
nasopharyngeal carcinoma and HLA alleles A2, B14 and B46 and negative association 
for alleles A11, A13 and B22 (Goldsmith et al., 2002). 
Despite the proven strong association of nasopharyngeal carcinoma with specific 
MHC alleles, the HLA-A2-B46 haplotype was no detected among the Alaskan patients.  
Instead, another HLA; BW40 (75%) and a second locus blank (44%) seemed to be more 
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frequent among this population that consists of Eskimos, Aleuts and Indians (Lanier et 
al., 1980). Nasopharyngeal carcinoma presentations of Chinese and native Alaskan 
patients shared similarities in terms of age onset of 30 years old and above, sex ratio, 
clinical presentation and pathological findings (Ho, 1976). This suggests the complexicity 
of the nasopharyngeal carcinoma pathogenesis. The understanding of the contribution of 
HLA to nasopharyngeal carcinoma might advocate a basis for disease prognosis as well 
as the direction of cancer therapy.  
Figure 1.E Simplified map of the human major histocompatibility complex that is 
located on human chromosome 6 (Chan, 1990; Huang and Lo, 1999) 
  
1.2.5.6 Epstein-Barr virus as cofactor in nasopharyngeal carcinoma 
The Epstein-Barr virus (EBV) was first observed and described in African 
Burkitt’s lymphoma biopsy tissue sample using transmission electron microscopy (TEM) 
(Epstein et al., 1964). Burkitt’s lymphoma is a common, malignant childhood sarcoma of 
the jaw in malaria endemic region as well as malnutrition problem in Africa. This had 
lead to a strong suggestion of vector-borne virus in the development of Burkitt’s 
lymphoma (Burkitt, 1958).  Since the discovery of Epstein-Barr virus in 1964, EBV is the 
most widespread human virus, infecting over 90% of human population and persisting for 
a lifetime of the person (Cohen, 2000). It contributes to diversified human tumor 
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aetiology (Pagano et al., 2004). EBV is implicated in B- and T-cell non-Hodgkin’s 
lymphomas, Hodgkin’s disease (HD) (Williams and Crawford, 2006) and several 
lymphoepithelioma-like carcinomas like nasopharyngeal carcinoma (Burgos, 2005). The 
amazing infection rate is achieved by highly efficient transmission route of the virus 
through saliva from persistently infected person to healthy individuals. 
The Epstein-Barr virus (EBV) has been constantly and intimately related to the 
WHO-Type III NPC or UCNT (Spano et al., 2003). The EBV infection exhibits type II 
latency pattern (app. 1.2) with expression of EBV nuclear antigen-1 (EBNA1), latent 
membrane protein-1 (LMP1) and LMP2 in UCNT cases. This EBV genome is present 
and detected most of the nasopharyngeal carcinoma cells (Wolf et al., 1973). Exogenous 
EBV virus is only present exclusively in nasopharyngeal carcinoma cells but not in non-
neoplastic surrounding tissues and is closely related with differentiation status of the 
epithelial cells (Pathmanathan et al., 1995a; Spano et al., 2003). The presence of the EBV 
DNA in preinvasive nasopharynx lesion is suggestive of clonal proliferation from a single 
EBV-infected cell. Besides that, the detection of EBV RNA (EBER) indicates these cells 
are maintaining latency stage (Figure 1.Fi). There might be early transformation 
processes in the nasopharynx epithelial lesion into malignant tumour be EBV latent genes 
(Pathmanathan et al.¸ 1995b). 
Figure 1.Fi Immunostaining pf 
EBER in NPC biopsies: Left panel: 
High magnification of EBER 
positive in NPC cells. There are strong staining in the nucleus and chromatin rimming the 
nuclear membrane. Right Panel: EBER staining in a case of squamous cell carcinoma of 
the nasopharynx (WHO Type I). It is a weak or absent in the foci keratinisation, 
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suggesting squamoid differentiation may be associated with downregulation of EBER 
expression (Pathmanathan and Raab-Traub, 1997) 
Patient with undifferentiated nasopharyngeal carcinoma showed high levels of 
serum IgA and IgG antibodies towards EBV early (EA) and viral capsid antigens (VCA) 
respectively (Lo et al., 2004; Ng et al., 2006). Besides that, viral antigens can also be 
detected using in situ hybridization in nasopharyngeal carcinoma biopsies e.g. Figure 
1.Fii (Pathmanathan and Raab-Traub, 1997). Highly sensitive and specific molecular 
techniques like real-time PCR (Fan et  al.; Shao et al., 2004) or in situ PCR (IS-PCR) are 
capable of detecting EBV viral load within specimen quantitatively and effectively 
(Marziliano et al., 2005). 
Figure 1.Fii Immunstaining of LMP in nasopharyngeal 
biopsy: This positivity is only present in the dysplasic 
epithelial cells. The staining is uniform and more intense in to 
most layers (arrows). The lymphoid cells in the underlying 
stroma and epithelial cells lining the mucus glands do not stain 
(Pathmanathan and Raab-Traub, 1997) 
1.2.6 Fundamental processes in nasopharyngeal carcinoma 
1.2.6.1 Initial loss of heterozygosity 
The etiology of nasopharyngeal is multifactorial (Figure 1.G). It is believed that 
the interplay of the genetic predisposition with constant exposure to environmental 
carcinogens especially consumption of preserved salted fish; containing high 
concentration carcinogenic nitrosamines at an early age increased risks of developing 
nasopharyngeal carcinoma. Concomitantly, initial chromosome alteration of the deletion 
of 3p and 9p might initiate the formation of nasopharyngeal dysplasia. The inactivation of 
tumour suppressor genes on these regions helps to confer growth advantage on these low-
 18 
grade dysplasia lesion cells with no EBV infection detect (Chan et al., 2000; Lo et al., 
2001; Chan et al., 2002). 
 
1.2.6.2 Epstein-Barr virus as cofactor  
EBV infection plays a role in catalyzing deterioration to higher grade lesion in 
early phase of NPC carcinogenesis. The primary infection of the Epstein-Barr virus 
begins in an exposed resting B cells or epithelial cells in the oropharynx region, which in 
turn infect another B cells for viral replication (Figure 1.H). Cytopathic capability of 
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Figure 1.G Proposed tumorigenesis model for nasopharyngeal carcinoma (adapted Huang 
& Lo, 1999; Chan et al., 2002, Young and Rickinson, 2004) There might certain levels of 
interaction between external dietary factors, EBV viral infection and transformation 
activity as well as genetic predisposition, HLA with the weakening of the immune system 
leading the development of carcinoma. 
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vitro assay (Greenspan et al., 1985; Sato et al., 1989). During primary infection, EBV-
infected B cells undergo lytic infection with production of new viruses or release of full 
complement of latent viral proteins into the surrounding lymphatic and hematogous route 
for effective infection. Subsequently, the activation of the cytotoxic T cells and nature 
killers would maintain the population of infected B cells. During convalescence period, 
EBV is present in the peripheral blood with latently infected memory B cells carrying 
latent EBV viral genes. The EBV genome becomes circular by forming an epiosome 
which is maintained by EBNA1 gene (Esptein Barr virus nuclear antigen-1).  
1.2.6.3 HLA genetic predisposition 
In a healthy person, upon the infection of EBV in nasopharynx, the LMP-1 
interacts with unique HLA-A2 molecules on T cells resulting in the activation of 
cytotoxic T lymphocytes that lyses EBV-infected B cells (Khanna et al., 1998). The 
specific binding of site of LMP-1 has been mapped to specific peptide epitopes. The 
majority of the T-cell epitopes of LMP-1 are highly conserved in EBV isolates from 
diverse geographical regions of the world with a unique supertype-restricted epitope 
(Duraisamy et al., 2003). However, NPC patients carrying a HLA A2-supertype that 
expresses a restricted ‘YFL’ epitope of LMP-1 from a variant strain of EBV (Lin et al., 
2004) have poor interaction and lost of protective effect of epitope-specific cytotoxic T 
lymphocytes response (Duraiswamy et al., 2003; Lin et al., 2005). This HLA A2-
supertype is highly prevalence with a percentage of approximately 40% amongst the 
southern Chinese population (Imanishi et al., 1992). 
Besides that, HLA-BW46 is also present in 20% of nasopharyngeal carcinoma 
patients (Imanishi et al., 1992). This unusual HLA is a derivative from the replacement of 
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residues 66 to 76 of the α1 helix region of HLA-B15 by homologues segment from HLA-
C01 (Zemmour et al., 1992). This changes the HLA-Bw46 to HLA-C like molecule and 
dramatically affecting its function, recognition and selection ability (Barber et al., 1996). 
Patients with HLA-Bw46 allele has been showed to have reduction of T cell receptor 
repertoire expression (TCR) and thus restricted T cell response (Chen and Chan, 1994; 
Chen et al., 1995). The change of the MHC function is likely to contribute to weakening 
of the immune system and leading to predisposition to the pathogenesis of 
nasopharyngeal carcinoma. 
In addition, these carcinoma cells also secrete interleukin-18 (IL-18) which 
initiates infiltration of leukocytes of T cells (CD3+), NK cells and macrophages 
(CD68+).  The infiltrated tissues macrophages to express chemokines especially MIP-1α 
and MCP-1 which further recruit even more T lymphocytes (Tang et al., 2001). Further 
activation of T cells also produced cytokine interferon-gamma (IFN-γ) (Hu et al., 2004). 
Most evidences indicated that the T cells infiltration mechanism helps with the 
carcinogenesis of 
nasopharyngeal carcinoma 
with the suppression of the 
immune response. 
  
Figure 1.G Proposed model 
for Epstein-Barr virus 




1.2.6.4 Genetic instability 
Following these, subsequent genomic instability also resulted in the loss of 
chromosomes 11q, 13q, 14q and 16q as well as gain chromosome 1q, 2, 3q, 7q, 8q, 12q 
in a non-random genetic event in carcinogenesis of nasopharyngeal carcinoma (Li et al.; 
Lo et al.; Yin et al., 2004). With the progression of nasopharyngeal carcinoma, the loss of 
many important tumour suppressor genes and oncogene gain-of-function resulted in 
perturbation of these genes homeostasis and disequilibrium of many cellular processes 
which contributed to the nasopharyngeal carcinoma.   
Further evidences from various works also suggested that the interactions of HLA 
associated genes, EBV infections, chemical carcinogens and genetic instability 
contributing to the disequilibrium, thus leading to nasopharyngeal carcinoma 
development. Details understanding of the underlying mechanism of nasopharyngeal 
carcinoma pathogenesis will definitely assist in the more comprehensive preventive 
measurements for healthy individuals while tailoring idealistic treatment for patients. 
 
1.3  Treatment of nasopharyngeal carcinoma 
The primary treatment for NPC is radiation therapy for patients with stage I and II 
NPC lesions (Table 1.1).  High-dose rate intracavity brachytherapy (HDRIB) is common 
radiotherapy method for NPC which is carried out either by concomitantly with external 
beam radiotherapy (EBRT) or administrated alone (Lu et al., 2004). The nasopharyngeal 
carcinoma cells are more sensitive to radiotherapy compared to normal cells, thus 
facilitated the recovery of patients. Ionizing radiation therapy can control 70% of 
nasopharyngeal carcinoma cases from fatality within a 5-year period (Lee et al., 2001).    
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Despite total removal of carcinoma from the local area of the nasopharynx, about 
43% of patients still develop distant metastases within two years (Sultanem et al., 2000).  
Primary recurring NPC tumours can be removed using advanced surgical salvage 
treatment without damaging surrounding tissues (Choi & Lee, 2005). Nasopharyngeal 
carcinoma is located in the oral cavity of the head with limited access and also 
surrounded by vital organs. Approximately 70% of the newly diagnosed NPC cases 
which have local, advanced, non-metastatic tumour classified under stage III or IV (Table 
1.1). Clinical trials supported the combination of radiotherapy with chemotherapy 
therapies for these patients (Agulnik and Siu, 2005).  The concomitant therapy exhibited 
small but significant benefits for better survival in locally advanced nasopharyngeal 
carcinoma in eight randomized trials of 1753 patients (Baujat et al., 2006).   
Current standard therapies for cancer have side-effects that range from general 
mild symptoms (nausea, temporary hair loss, fatigue) to late complications and severe 
life-threatening such as severe infections, secondary tumours, severe blood clots or organ 
damage). To date, the precise mechanism of chemotherapy inducing apoptosis remains 
unclear but it has been hypothesized that anti-neoplastic drugs are capable of inducing 
apoptosis via two prototypic death pathways which will be introduced in the following 
section 1.4.1 (Kaufmann and Earnshaw, 2000). Chemotherapy has drawbacks of lack of 
selectivity and specificity. Thus, novel therapies for nasopharyngeal carcinoma have been 
revolutionized with gene specific therapy (Liu, 2002). Currently, gene therapy for cancer 
is geared towards restoring endogenous cell death mechanism for cell autodestruction. 
Defective apoptosis mechanisms and desensitized immune protection contribute to the 
progression of cancer (Reed, 2006).  
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One of the gene therapies for nasopharyngeal carcinoma exploits the viral 
machinery of Epstein-Barr virus; which uniquely present in cancer cells only for 
differential therapy. Several research groups are trying to develop immunological 
approaches to activate and strengthened EBV-specific cytotoxic T lymphocyte response 
in nasopharyngeal carcinoma (Murray and Young, 2001). Despite the potential of viral 
gene therapy, there are limitations in viral vectors (Dani, 1999). This has lead to the 
development of non-viral, low immunogenicity vehicles like liposomes for the delivery 
of genes (Goyal et al., 2005). Cationic liposome is more effective in the delivery of 
antisense oligonucleotides into cancer cells (Gewirtz et al., 1998). Antisense 
oligonucleotides of targeted gene, binds to specific region of coding mRNA and 
subsequently prevent protein translation. This mRNA bound to oligonucleotide duplex 
also promotes the recruitment of RNase H that degrades the RNA or else this complex 
becomes a steric hindrance to ribosomal assembly (Crooke, 2001). The modulation of the 
expression of gene using antisense therapy helps in restoring normal apoptosis 
mechanism in cancer cells. There are tremendous potential which also has been applied in 
large context of cancer therapy including Epstein-Barr virus associated malignancy. 
Currently, the results have been modest but there is promising future for gene therapy 
treatment (Larsen & Rasko; Phillips, 2005). 
Antisense therapies are gene specific oligonucleotides designed with different 
chemistries namely antisense phosphorotioate oligonucleotides, morpholinos, small 
inhibitory RNA (siRNA) and ribozymes (Zhang et al., 2005). Oblimersen sodium 
(G3139) patented by Genta Incorporation is the first oligonucleotides to demonstrate the 
principles of antisense effect in human solid tumors. Overexpression of Bcl-2 was found 
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in most follicular lymphomas, in some cases of diffuse large cell lymphomas, and in 
chronic lymphocytic leukemia (B-cell lymphatic leukemia [B-CLL]) (Adams and Cory, 
1998).  This antisense oligonucleotide targets the first 6 codons of human bcl-2 mRNA 
and successfully resulting in significant degradation of bcl-2 mRNA and decrease in bcl-
2 protein translation in human tumors (Klasa et al., 2002). Currently, G3139 or 
Genasense has completed clinical trial III for advanced melanoma, myeloma and chronic 
lymphocytic leukemia. Currently, it is undergoing non-randomized trial for pediatric 
solid-tumors, acute myeloid leukemia, and pancreatic, liver, renal cancer, non-Hodgkin’s 
lymphoma, Waldenström macroglobulinemia and colon cancer as well as randomized 
trial for non-small cell lung cancer, small-cell lung cancer and prostate cancer (Stein et 
al., 2005)4. Recently, US Food and Drug Administration (FDA) have accepted the Genta 
Incorporated’s New Drug Application (NDA) for the application of Genasense with 
fludarabine and cyclophosphamide for the treatment of patients with relapsed or 
refractory chronic lymphocytic leukemia (CLL) 5 . These numerous clinical trials on 
G3139 tested solely and in combination with common chemotherapy in a variety of 
malignancy (Tamm, 2005).  
Affinitac/ISIS 3521/LY90003 6  is another oligonucleotide designed by ISIS 
Pharmaceuticals Inc., targeting protein kinase c-alpha (PKC-α) in solid tumors such as 
non-small cell lung cancer (NSCLC). It has completed phase III concomitant trial with 
gemcitabine and cisplatin for patients with NSCLC7  based on its safe administration 
profile from phase I/II (Villalona-Calero et al., 2004). Since 1998, ISIS developed the 
                                                 
4
 http://www.genta.com/Genta/ClinicalProgram/programs1.html (dated 13 May 2006) 
5
 http://www.drugs.com/nda/genasense_060301.html (dated 13May 2006) 
6
 http://search.drugs.com/search.php?searchterm=affinitac&source=inet (13 May 2006) 
7
 http://www.clinicaltrials.gov/ct/action/ChangeQuery=ISIS 3521 (13 May 2006) 
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first FDA-approved antisense therapy, Vitravene that prevents blindness in acquired 
immunodeficiency syndrome (AIDS) patients by inhibiting cytomegalovirus-induced 
retinitis8. The constantly dysregulated MAPK pathway became one of the common target 
for gene therapy (Beeram et al., 2003). The improved antisense oligodeoxynucleotide 
ISIS 5132 showed promising downregulation of c-raf-1 in phase I trial for patients who 
are refractory to standard therapies (O’Dwyer et al., 1999). The ongoing research tries to 
compare the 1st generation ISIS 5132 with the 2nd generation antisense (ISIS13650) 
(Mullen et al., 2006). There are numerous ongoing clinical trials in the application of 
wide variety antisense oligonucleotide chemistries in cancer therapy (Philips, 2005). 
 Currently, the apoptosis based therapy for head and neck cancer including 
nasopharyngeal carcinoma that of adenovirus based delivery has entered phase III trials 
(Reed, 2002). ONYX015, manufactured from Onyx Pharmaceuticals, targets p53 
deficient cells and effectively causes tumor regression in recurrent head and neck patients 
while not affecting normal adjacent cells (Nemunaitis et al., 2000). However, the 
application of ONYX015 has been observed to cause necrosis in patients thus withdrawn 
from clinical trial9 . Despite the discouraging results, there is still urgency to further 
understand the mechanisms, processes activated by these antisense therapies thus 
constantly improving the quality of these antisense therapies. The depth understanding of 
the molecular details and three-dimensional structure of these targeted proteins can 
further treatment of these malignancies by of these (Reed, 2004).  
 
                                                 
8
 http://www.isispharm.com/vitravene.html (dated 13 May 2006) 
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 Apoptosis (Kerr, 2002) plays an important role in the regulation of cell number in 
multicellular organisms by removing unnecessary, damaged and potentially harmful 
cells. This protects healthy cells from any ‘threats’ as well as maintains structural and 
functional tissue homeostasis. Programmed cell death occurs during embryonic 
development, cellular proliferation and homeostasis for proper regulation of all matured 
and differentiated cells (Twomey and McCarthy, 2005). Apoptosis is a tightly regulated 
and highly efficient cell death processs that requires the proper orchestrated mechanisms. 
Upon receiving apoptotic stimulus, the cell undergoes major structural changes like 
protuberance of plasma membrane or ‘blebbing, nuclear chromatin condensation, DNA 
fragmentation, loss of membrane integrity, cell shrinkage, fragmentation into compact 
membrane-enclosed structures called ‘apoptotic bodies’ and finally phagocytosed by 
circulating macrophages (Saraste, 2000). In contrast, necrosis, (nekros) is another 
physiological condition of cell death; occurs due to major insult like injury, infection, 
cancer and inflammation. The secretion of hydrolytic enzymes from lysosomes leads to 
damage of membrane integrity, swelling and disruption of the cells. The uncontrollable 
release of cytosolic contents to the cell’s environment also caused damage the 
surrounding cells and activation of inflammatory response in the corresponding tissue 
(Leist and Jäättelä, 2001). 
1.4.1 Molecular mechanisms of apoptosis signaling pathways  
1.4.1.1 Caspase proteases 
Mammalian caspases (Cohen, 1997; Earnshaw et al., 1999) belong to a family of 
cysteine proteases, which are the central initiators and executioners of apoptosis. The 
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name ‘caspases’ is derived from cysteine-dependent aspartate-specific protease due to 
their catalytical activity at highly conserved pentapeptide (QACRG) motif. These 
enzymes recognized specific cysteine residue and cleaved their substrate after the aspartic 
acid residue at the P1 position. Currently, there are 14 members in the mammalian 
caspase family (Twomey and McCarthy, 2005). The mammalian caspase family is 
categorized into two groups; inflammatory and proapoptotic caspases. Proapoptotic 
caspases are further grouped into initiator and effector caspases. 
 The initiator caspases are procaspases-2, -8, -9 and -10, while the executioner 
caspases includes procaspases-3, -6 and -7. The initiator caspases possess longer  
prodomains which contain distinct motif either death effector domain (DED) found in 
procaspase-8 and -10 or caspase recruitment domain (CARD) in procaspase 2 and 9 as 
well as other proinflammatory procaspases -1, -4 and -5. The longer prodomain is 
required for recognition, binding, oligomerization and autocatalytic activation of these 
caspases. The activated initiator caspases transmit proteolytic signal by cleaving the 
short-prodomain effector caspases (procaspase-3, -6 and -7). These lead to a cascade of 
events mediating death signal and eventually the execution of apoptosis with the 
morphological and biochemical changes as mentioned above (Earnshaw et al., 1999).  
1.4.1.2 Extrinsic apoptosis pathway 
Upstream of caspase activation, the mammalian procaspases receive death signals 
from external or internal environment of the cell. The extrinsic apoptosis signaling is 
mediated by activation of the cell surface receptors and these cells are designated as Type 
I cells. Subsequently, trimerization of death receptors exposed the conserved death 
domain (DD) located at the cytoplasmic part of the receptor. These “death receptors” 
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belong to the tumor necrosis factor receptor superfamily (TNF) known as Fas, TNF-R1, 
TNF-related apoptosis-inducing ligand (TRAILR1/DR4 and TRAILR2/DR5) and DR6 or 
TNFRSF21 (Thorburn, 2004; de Thonel and Eriksson, 2005). They recruit various 
adaptor mediators for various processes like cell proliferation, survival, differentiation, 
homeostasis of immune system which is anti-apoptotic besides ‘apoptosis’ which is the 
focus of this context (Hehlgans & Pfeffer, 2005).  
Fas/CD95/APO-1 (Itoh and Nagata, 1993) is one of the well-defined members of 
the TNFR superfamily that induces apoptosis. Fas interact directly with downstream 
adaptor protein called Fas-associating protein with a novel death domain (FADD) via the 
death domain (Boldin et al., 1995a; b; Chinnaiyan et al., 1995). The FADD protein also 
contains the DED motif which can recruit procaspase-8 or caspase-10. This complex is 
known as death inducing signaling complex (DISC), resulting in auto-activation of 
mainly caspase-8 or caspase-10 to execute downstream transduction for apoptosis (Muzio 
et al., 1996; Vincenz and Dixit, 1997).  
Besides that, another member of TNF family is tumor necrosis factor receptor 1, 
TNFR1; a 55kDa protein (Lewis et al., 1991) also forms the DISC platform upon binding 
of TNFα to TNF-R1. Trimerization also occurs and signals for downstream adaptor TNF 
receptor 1-associated via death domain (TRADD).  TRADD recruits FADD via the death 
domain, followed by the activation of pro-caspase-8/-10. FADD is a common mediator of 
Fas and TNFR-induced apoptosis, implicating cross-talk between the two pathways 
(Chinnaiyan et al., 1996). Fas and TNFR1 share high homology in a region designated as 
‘death domain’ and believed to be responsible for regulating death signals (Itoh and 
Nagata, 1993). 
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The TRAIL receptors consist of four members; TRAILR1/DR4 and TRAILR2/ 
DR5 which contained the death domain and capable of inducing apoptosis in wide variety 
of transformed cell lines. The other two receptors; TRAILR3 and TRAILR4 are decoy 
receptors for TRAIL ligands. Since its identification, TRAIL is still the limelight in 
oncology research due to its selective ability to trigger cell death in cancer cells (Merino 
et al., 2007). TRAIL has been known to induce apoptosis in TRAIL sensitive tumours. 
While novel sensitization agent nitrite oxide have been shown to restore apoptosis in 
combination with TRAIL/DR4 or DR5 monoclonal antibodies in the treatment of 
TRAIL-resistant tumours (Lee et al., 2007). 
The TNFRSF21 or DR6 is the newest member of the TNF superfamily that also 
interacted with TRADD and shown to be associated with TNFR1 (Pan et al., 1998). 
Besides that, DR6 regulated the activation and the differentiation of innate immunity Th 
cells. The JNK activation was significantly affected and impaired in DR6-deficient mice 
(Zhao et al., 2001). 
1.4.1.3 Intrinsic apoptosis pathway 
The caspase cascade is also activated by mitochondria-dependent mechanism 
where cells are designated as Type II cells (Wang, 2006). These cells receive death 
signals from mitochondria because insufficient activated receptors signal for apoptosis 
execution (Scaffidi et al., 1998). Caspase activation is initiated with the release of 
cytochrome c from mitochondria which binds to cytosolic monmeric protein Apaf-1, 
resulting in the assembly of seven-spoked wheel (Acehan et al., 2002; Salvesen and 
Renatus, 2002). This heptameric structure exposes the buried CARD domain of Apaf-1 
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and recruits procaspase-9 for autoactivation. This complex is known as the apoptosome 
that effectively activate executer caspases-3, -7 and -6 (Slee et al., 1999) (Figure 1.H).  
 
Figure 1.H Schematic representation of early events of apoptosis: It that take place 
distal to the entry of cytochrome c to cytoplasm.  The mitochondrial apoptosome is 
formed upon exit of cytochrome c from the mitochondrial intermembrane space, possibly 
triggered by either Bax or Bid. Upon activation, caspase-9 may disengage from the 
cytoplasm c/Apaf-1 complex in order to activate downstream caspases; alternatively 
downstream caspases may also become recruited to this apoptosome via suitable adaptor 
proteins (Slee et al., 1999). 
1.4.2 Regulatory mechanisms in apoptosis signaling 
It has been proposed that cells of a multicellular animal might be intrinsically 
programmed to self-destruct and would die instantaneously unless cell death is 
continuously suppressed by survival signals like growth factors, hormones and nutrients.  
Those survival signals enhanced the expression and or/activity of anti-apoptotic 















1.4.2.1 Bcl-2 family 
The (B-cell chronic lymphatic leukemia) Bcl-2 family is the main regulator of 
caspase activation during apoptosis process, which have either pro-apoptotic or anti-
apoptotic function (Adams and Cory, 2001). The pro-apoptotic members of Bcl2-2 
consists of BH3-only sub-family (bid, bim, bik, bad, bmf, hrk, noxa, puma, blk, BNIP3 
and spike) and Bax sub-family (bax, bak, and bok which posses BH1, 2 and 3 domains). 
The BH3-only containing proteins are recognized as essential initiators of apoptosis 
(Bouillet and Strasser, 2002). For type II cells, bid is cleaved by activated caspase-8 
where truncated bid (tbid) translocates from cytosol to mitochondria. The binding of tbid 
to either bax or bak (which are located on the surface of mitochondria) results in the 
disequilibrium of inner transmembrane potential (∆Ψ) in the mitochondria. The 
transmembrane potential (∆Ψ) is tightly regulated by permeability transition (PT) 
machinery which consists of channels known as VDAC (outer) and ANT (inner) proteins. 
The disruption of the mitochondrial transmembrane potential (∆Ψ) results in the release 
of cytochrome c and other pro-apoptotic factors to the cytosol for execution of apoptosis. 
Anti-apoptotic Bcl-2 subgroup comprises of bcl-2, bcl-XL, bcl-w, a1 and mcl-1 
posses BH1 to 4 domains. The bcl-2 and bcl-XL regulates apoptosis by binding to the 
BH3 domain of the proapoptotic members, thereby preventing bax or bak 
activation/oligomerization (Gewies, 2003). This Bcl-2 inhibitory effect is independent of 
cytochrome c induced apoptosome complex but solely depends on caspase-7 as the 
central effector (Marsden et al., 2002). Many members of the Bcl-2 family of apoptosis- 
have been found to be differentially expressed in various malignancies and some are 
identified as gene therapy for prognostic cancer biomarkers (Thomadaki et al., 2006). 
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1.4.3 Apoptosis and its implications in cancer 
Cancer arises from abnormal cell behavior due to uncontrolled cell proliferation 
with the suppression of apoptosis (Reed, 1999) and senescence (Shay and Roninson, 
2004). The dysregulation of many tumor suppressor genes (function as inhibitors) and 
oncogenes (role of accelerator) contributes to the formation, development and metastasis 
of carcinoma (Gewies, 2003).  Novel gene therapies aim to specifically target and initiate 
the apoptosis machinery in cancerous cells (Reed, 2004). The activation of apoptosis in 
cancer cells led to efficient and rapid clearance of apoptotic remnants by phagocytosis 
and also restoring normal physiological process. On the other hand, any inflammation 
responses bring about sudden cell disruption and massive leakage of intracellular proteins 
and nucleic acids into the extracellular space (Reed, 1999; Leist and Jäättelä, 2001). This 
results in undesirable complications in cancer treatment. 
Preliminary studies on the application of antisense phosphorotioate 
oligonucleotides in hematological cancer model have yielded new insights of the function 
and importance of the human DENN/MADD gene. The expression DENN/MADD has 
been to be found higher in various cancer cell lines than normal (Chow and Lee, 1996; 
Lim and Chow, 2002; Efimova et al., 2003; 2004; Lim et al., 2004). Antisense 
phosphorotioate oligonucleotide targeting death domain of DENN/MADD showed 
significant apoptosis in Jurkat T cells when compared to normal cell lines (Lim and 
Chow, 2002). Besides, anti-apoptotic DENN/MADD has been shown to play a role in the 
death signaling pathway. There was significant regression of K36 induced human tumors 
on AKR mice when antisense DENN death domain was injected intra-tumorally (Lim et 
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al., 2004). In addition to that, transmission electron microscopy of the mice tissues 
exhibited ultra-structural changes that typified apoptosis (Lim et al., 2004).  
1.5 DENN (Differentially Expressed in Normal and Neoplastic cells) 
1.5.1 Discovery of DENN 
The DENN was discovered using GXGKT/S motif from non structural region of 
RNA helicase protein of Flavivirus family. The 4764bp open reading frame of DENN 
codes for a 1588 amino acids with a calculated protein mass of 176 kDa (Lee, 1996). As 
described by the name, there is differential expression of DENN transcript in normal and 
neoplastic cells. DENN also shows higher mRNA expression levels in brain of adults and 
fetal tissues. However, DENN transcript is virtually absent in stomach and bone marrow 
of normal adults.   
The amino acid composition revealed that this protein is relatively rich in leucine 
(10.1%) and serine (12.1%) residues (Chow and Lee, 1996; Lee, 1996). The computer 
analysis of DENN have many interesting motifs like ‘RGD’, cellular adhesion motif (aa 
1057-1059), a leucine zipper like motif associated with protein dimerization (aa 303-324) 
and a short leucine rich motif, LXXXL that mediates nuclear co-activator complexes (aa 
1311-1315). In addition, DENN (nt 913-956) shares partial homology (25%) with 11 
identical amino acids and 63.6% similarity with N terminal of TNFα (nt1-44) ligand. The 
critical amino acid residues that is required for proper binding of TNFα is also identical 
to that of DENN. Besides that, DENN is unique with the presence of a death domain at 
location amino acid 1279 to 1355. Other potential consensus patterns encountered 
including nine N-glycosylation sites, four cAMP- and cGMP-dependent protein kinase 
phosphorylation sites, 26 protein kinase C phosphorylation sites, 34 casein kinase II 
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phosphorylation sites, five tyrosine kinase phosphorylation sites, 18 N-myristoylation 
sites and two amidation sites. The human DENN is mapped to chromosome band 
11p11.21-p11.22 using Flourescence in Situ Hybridization (FISH) (Chow et al., 1998; 
Lim, 1996). Immunoflourescence of DENN from rabbit polyclonal anti-DENN (NP1) 
showed that DENN is localized mainly at the cell membrane and some cytosol (Chow et 
al., 1998; Lee, 1996). This observation is in concordance with bioinformatics prediction 
that DENN is a cell membrane protein. In certain cancer cell lines, an alternative 
transcript of DENN called DENN-SV was documented (Chow and Lee, 1996). The two 
cDNA transcripts differed by 129 nucleotides (spanning nt 2462-2590), encoding for 43 
amino acids (aa 762-804) and situated at exon 7. Exon 7 of DENN carries two potential 
5’ donor splicing junctions, indicating alternative splicing mechanism within the DENN 
mRNA for the smaller counterpart. This 43 amino acid peptide segment is hydrophilic 
and possesses a protein kinase C phospphorylation site at amino acid 762-764 and 
tyrosine kinase phosphorylation site at aa 765-772 (Chow and Lee 1996).  
1.5.2 DENN isoforms of DENN family 
  There are seven DENN variants identified and originated from full length cDNA 
known as Insulinoma Glucagonoma clone 20 (IG20-FL) (accession number AF440100) 
which is of 5995bp long, consisting 36 exons (Al-Zoubi et al., 2001). The splicing of 
exon 34 alone generates a hypothetical sequence KIAA0358 (accession number 
AB002356) of 5942bp. The removal of exons 21 and 26 produced IG20 (accession 
number AF440101) of 5878 bp. IG20 is an extension of DENN/MADD. DENN is also 
known as MADD which stands for mitogen-activated protein (MAP) kinase-activating 
death domain (Schievella et al., 1997) with homology of 99% for protein with 10 
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nucleotides difference thus two amino acid disparities. Additional splicing of exons 16, 
13L and both 13L, 16 from IG20 respectively generate DENN/MADD, IG20-SV2 and 
DENN-SV (Figure 1.I). DENN-SV is alternative isoform that is a result of an additional 
splice junction in exon 7 (Chow and Lee, 1996) or otherwise exon 13 based on exon 
arrangement for IG20 sequence (Al-Zoubi et al., 2001). Finally, the splicing of exon 13L, 
16, 21, 26 and 34 generates the shortest member of the DENN isoforms, 5619 bp, 
designated as IG20-SV4 (accession number AF440434).  
 Expression studies on human normal and neoplastic tissues as well as cell lines 
showed that only four of the DENN isoforms are expressed (namely IG20, 
DENN/MADD, IG20-SV2 and DENN-SV). The DENN isoforms were grouped into two; 
namely the DENN which comprises of DENN/MADD and DENN-SV; IG20 referring to 
IG20 and IG20-SV2 variants. The expression levels of DENN splice variants are 
conspicuously higher than the IG20 isoforms.  In addition, the mRNA of DENN isoforms 
are higher in cancer cell lines than normal (Lim et al., 2004; Efimova et al., 2004). The 
functional relevance of the expression the different DENN isoforms and relative levels 
required further elucidation.  
 The name ‘DENN’ was coined as a protein domain that consists of three highly 
conserved domains, designated as ‘uDENN’, ‘DENN’ and ‘dDENN’. These domains are 
located at the N-terminal of these proteins with divergent of unique, distinct motif 
combinations at the C-terminal. They are found in a variety of signaling pathways but 
their exact function remains undefined (Levivier et al., 2001). The presence of these 
DENN domains at the N terminal with a death domain were implicated to play different 
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roles and are constantly located in the RAB and MAP kinase signaling pathways (Brown 
and Howe, 1998; Levivier et al., 2001) (Figure 1.I). 
 
Figure 1I: Illustration the intron-exons of various DENN isoforms: The additional 
annotation shows the locations of suggested protein domains like ‘uDENN’, ‘DENN’, 
‘dDENN’, leucine-like zipper and death domain (Adapted from Chow et al. 1998; Al-
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Figure 1.J Structural representation of DENN isoforms (Miyoshi and Takai, 2004) 
1.5.3 DENN isoforms interact with TNF-R1 leading to MAPK pathway activation 
 MADD was isolated using Tumor Necrosis Factor-Receptor I (TNF-RI) death 
domain (DD) as ‘bait’ in yeast interaction trap screening (Schievella et al., 1997). The 
employment of protein-protein interaction motif between DENN/MADD and TNF-R1 
showed strong and specific interactions. Mutation exercised on several critical signaling 
residues in the TNFR1-DD dramatically reducing binding affinity. Besides that, 
bioinformatics alignment of death domain of DENN/MADD with other human 
superfamily cell surface receptors like TNF-R1, FAS and adaptor molecule like TRADD 
showed significant homology especially Fas protein. However, DENN/MADD has been 
showed to interact with TNFR1 and TRADD (Schievella et al., 1997; Del Villar & 
Millar, 2004).  The overexpression study of full length DENN/MADD activated the MAP 
kinase extracellular signal-regulated kinase (ERK) activity. While expression of 
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MAP kinases and induced the phosphorylation of cytosolic phospholipase A2 leading to 
the release of arachidonic acid. However, the overexpression of DENN/MADD had no 
effect on induction of apoptosis in these cells. Besides that, Murakami and colleagues, 
1999, implicated the role of DENN/MADD in TNF-R1 mediated ERK activation in the 
proliferation of AIDS –associated Kaposi’s sarcoma cells. 
Different findings indicated that DENN have a neuroprotective role in neuronal 
response regulation during stress. When compared to patients with cerebellar hypoxia, 
immunostaining DENN/MADD showed strongly modified expression with translocation 
to the nucleolus from the cytoplasmic region. Concomitantly, DENN/MADD also shares 
the same localization patterns with c-Jun N-terminal kinase (JNK3) or stress activated 
kinase 3. Besides that, DENN was also identified as substrate for JNK3 (Zhang et al., 
1998). In hypertension rat model, similar observation of DENN/MADD translocation into 
the nucleolus was recorded after ischemia-reperfusion injury (Smrcka et al., 2003). 
Besides that, endogenous levels of DENN/MADD in Alzheimer’s patients’ brains were 
significantly reduced. This suggested neuroprotective ability of DENN which might be its 
role in result of blocking apoptosis in neuronal cells under cytotoxic stress (Miyoshi & 
Takai, 2004). DENN/MADD was suggested and showed to be involved with 
‘excitotoxicity’, referring to the activation of the various mechanisms caused by (JNK) 
activation in NMDA-mediated  neuronal death with its involvement in the neuronal stress 
and injury pathways (Centeno et al., 2007). 
The IG20 also interacts with TNF-R1 and activates ERK and nuclear factor κappa 
B (NFκB) signal transduction pathways. However, stable isolates of IG20, 
DENN/MADD and DENN-SV in Hela cells showed contrasting effect of TNF-α induced 
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apoptosis. Enhanced activation of caspases especially caspase-8 and -3 were observed 
upon the addition of TNF-α in IG20-Hela cells. In addition to that, IG20 HeLa cells have 
shown increased susceptibility to γ-irradiation, chemotherapy drug and soluble mediators 
with increased or spontaneous apoptosis induction and slowed-down cell proliferation. 
On the other hand DENN-SV conferred resistance to apoptosis with the lowest level of 
caspase activity indicating anti-apoptotic behaviour in the TNF pathway (Al-Zoubi et al., 
2001). Besides that, the DENN-SV exhibited the activation of the NF-κB pathway 
(Efimova et al., 2003; 2004). Thus, IG20 splice variant has anti-proliferative/proapoptotic 
and DENN-SV proproliferative/anti-proliferative roles especially in malignant cells. 
Tumor necrosis factor (TNF) alpha is a soluble cytokine ligand that exerts 
pleiotrophic effects via multiple pathways leading to diverse biological phenomena 
including cell proliferation via cell cycle activation and otherwise apoptosis induction.  
TNF acts on target by binding to TNF receptor 1 (TNFR1) or 2. Upon the binding of TNF 
to TNFR1, the oligomerization of the receptor signals the recruitment of downstream 
molecules like TNFR-associated death domain (TRADD) or DENN/MADD.  In addition, 
DENN/MADD also binds to TNFR-associated factor 2 (TRAF2) which also leads to the 
activation of cell survival NF-κB. The NF-κB is a strong inhibitor of TNFα-induced 
apoptosis in neuronal cells with activation of anti-apoptotic genes like FLICE inhibitory 
protein (FLIP), inhibitor of apoptosis protein (IAP) and TRAF1. Besides that, TRADD 
signals downstream molecules like Fas-associated death domain (FADD) and activates 
caspases cascade leading to apoptosis (Figure 1.K).   
Antisense DNA treatment targeting the death domain of DENN, shared by all four 
splice variants had perturbed the equilibrium in Jurkat, acute T cell leukemia (Lim et al., 
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2002). It caused apoptosis in vitro and tumour regression in vivo (Lim et al., 2004).  
Besides, antisense of DENN has been shown to alter the transcription of genes involved 
in apoptosis and cell cycle (Lim et al., 2004). The abrogation of DENN isoforms resulted 
in apoptosis, strongly supported the notion that DENN may be intimately involved in 
anti-apoptotic and cell-survival processes. 
 
Figure 1.K DENN interacting with tumour necrosis factor-receptor 1 (TNF-R1) 
leading to MAPK pathway 
 
1.5.4 Conservation of DENN in evolution as Rab3 GEP function 
 The first non-human DENN protein was isolated in Caenorhabditis elegans, 
named AEX-3, with ORF of 1409 amino acids. The C-terminus of AEX-3 includes an 
extension of 295 amino acids, which is not found in DENN. Furthermore, a portion of 
AEX-3 is proline rich (aa 925-1069) and has the potential to function in SH3 binding or 
cytoskeleton association but is not well conserved in DENN.  From C. elegans studies, 
AEX-3 mutants suggested that it is a novel regulator of presynaptic activity that interacts 

























 Concurrently, another DENN homolog was isolated from rat brain with lipid-
modified Rab3A and characterized to be a Rab3 GDP/GTP exchange protein (Rab3 GEP) 
(accession number U72995). This protein shares 95% homology with DENN/MADD and 
mouse Rab3 GEP, Rab6IP1. Rab3 GEP plays a role in conversion from GDP-bound 
inactive and GTP-bound active forms of Rab3a between cytosol and pre-synaptic 
membrane for vesicle exocytosis at nerve terminal (Wada et al., 1997).   
 The generation of Rab3 GEP-/- mice provided better insight of DENN/MADD 
role in synaptic vesicle trafficking at neuromuscular junctions. The mice developed 
normally but died immediately after birth due to lung failure. Embryos at E18.5 showed 
normal phrenic and sciatic nerves responses.  However, there was significant reduction of 
the number of synaptic vesicles with impaired structures and disorganized localization in 
the pre-synaptic plasma membrane (Tanaka et al., 2001). In addition to that, Rab3 GEP 
knockout has resulted in a ~2.5 fold increase of Rab3A level and 25% decreased in 
Rabphilin-3 protein. Similar observations in AEX-3 mutants of reduced synaptic 
transmission (Iwasaki et al., 1997) but defects in defecation motor were not observed in 
Rab3 GEP-/- mice. Both studies supported the involvement of Rab3 proper 
developmental and regulation postsynaptic processes. Further elucidation of Rab3 GEP-/- 
mice in cell culture provided evidence of Rab3 GEP functioned in the post-docking 
process and is distinct from Rab3A activation (Yamaguchi et al., 2002). 
 Rab are the largest branch of the small Ras superfamily G proteins and recognized 
as the key molecules in vesicle trafficking and organelle dynamics in eukaryotic cells. 
The Rab3 is the only family which consists of four members namely Rab3A, -3B, -3C 
and 3D. Rab3A has been extensively studied and played a pivotal role in Ca2+-dependent 
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exocytosis of neurotransmitter release. The cycling of Rab3A coupled to synaptic vesicle 
trafficking as follows: (i) GDP-Rab3A complexes with Rab3 GDI as an inactive form in 
the cytosol of nerve terminals, (ii) GDP-Rab3A released from Rab GDI and converted to 
GTP-Rab3A by Rab3A GEP, (iii) GTP-Rab3A binds to effector molecules like 
Rabphilin-3 and Rim, localized at synaptic vesicle and active zone respectively, (iv) 
GTP-Rab3A converted to GDP-Rab3A by hydrolysis of Rab3 GAP when vesicles fused 
with the pre-synaptic membrane and finally (v) GDP-Rab3A associated with Rab3 GDI is 
retrieved from the membrane to the cytosol (Yamaguchi et al., 2002). The Rab3A-/- mice 
showed an increased in synaptic depression after short trains of repetitive stimuli in the 
CA1 region of the hippocampus. In the same CA1 region, the Rab3GDIα-/- mice 
displayed larger enhancement of synaptic potentials. This observation is consistent with 
human X-linked mental retardation caused by mutation of the Rab3 GDIα gene with 
epileptic seizures in Rab3 GDIα-/- mice.  
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1.6  THE OBJECTIVES OF CURRENT PROJECT:   
 
This study aimed to determine the role of DENN in cancer. The molecular basis of 
DENN in inducing apoptosis could be applied in novel therapeutic interventions of 
cancer. 
 
The major objectives includes:- 
 
 The comparative analysis of expression of different isoforms DENN isoforms in 
various transformed and cancerous cell lines. 
 To evaluate the inhibitory effects of DENN gene leading to apoptosis in CNE-2 
cells using antisense phosphorotioate oligonucleotides (PS-ODNs) targeting 
various regions of DENN molecule. 
 To map out the signaling pathways initiated/influenced by down regulation of 
DENN by cDNA microarray analysis. To further verify those genes involved in 
apoptosis induced by downregulation of DENN by real-time PCR and western 
blot analysis 
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2. MATERIALS AND METHODS 
2.1 CELL CULTURE 
2.1.1  CNE-2 cell line and cell culture (app.2.1) 
CNE-2, an adherent cell was kindly provided by Dr. Malini Carolene Olivo, National 
Cancer Centre, Singapore. CNE-2 is a poorly differentiated epithelial, highly metastatic 
nasopharyngeal carcinoma (NPC) (Gu et al., 1982). Cells were maintained in RPMI 1640 
medium (Sigma R4130) supplemented with 10% fetal bovine serum (FBS), 2g/l sodium 
bicarbonate, 2mM sodium pyruvate, 2mM L-glutamine, 100units/ml penicillin and 
100µg/ml streptomycin (Invitrogen, CA) and designated as NPC media.  
2.1.2  Thawing of CNE-2 cells 
All cell culture procedures were performed in sterile condition of a standard class II 
biohazard laminar flow hood.  For long term storage purposes, CNE-2 cells were stored 
in liquid nitrogen storage tank. Cells were rapidly thawed in a 37ºC water bath. The cell 
suspension of approximately 2 X 106 cells was added dropwise into a 10ml RPMI 1640 
serum free medium (app. 2.1). The suspension was centrifuged at 1500rpm for 5 minutes 
at room temperature. After centrifugation, the supernatant was discarded and the pellet 
was gently resuspended in thawing media (RPMI 1640 medium supplemented with 20% 
FBS). The cell suspension was pipetted into a T25 flask and incubated at 37ºC, 5% CO2 
incubator, overnight. Subsequently, the spent media was changed with 5ml fresh 20% 
FBS supplemented RPMI medium. The cell morphology, rate of growth and culture 
sterility were constantly monitored. CNE-2 cells were passaged and incubated with NPC 
medium. 
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2.1.3 Passaging of monolayer cells (CNE-2) 
All cell culture reagents were kept at 4ºC and warmed to 37ºC prior to use. Cells were 
passaged upon reaching 80-90% confluency. The spent medium was carefully removed 
and the cell monolayer was gently rinsed with 1x PBS. After removal of PBS, cells were 
trypsinized with 1x trypsin/EDTA (app. 2.1). Then, the flask was gently rocked to ensure 
that trypsin covers of the cells evenly. The trypsinization was stopped using 10ml of NPC 
media. The cells were gently pipetted up and down to dislodge cell clumps into a single 
cell suspension. Next, the cell suspension of CNE-2 was transferred and diluted to a ratio 
of 1:5 in a sterile T75 flask containing 15ml of fresh NPC medium. The cells were 
incubated at 37ºC, 5% CO2 incubator. 
2.1.4 Cell count by Trypan blue exclusion method 
50µl of single cell suspension was aseptically pipetted into 1.5ml microcentrifuge tube 
containing 50µl 0.4% trypan blue and mixed gently. 10µl of cell mixture was pipetted 
into a clean Neubauer haemocytometer. The viable cells are distinct, circular, shinny, 
non-stained while dead cells will be stained blue due to compromised membrane 
integrity. The numbers of viable cells were counted from four large squares at the corner 
of the haemocytometer and the mean is calculated. 
Number of cells (cells/ml) = Average count of cells of four big square X 104 X      
dilution factor of 2  
2.1.5  Freezing of CNE-2 cells 
When cells reached 80-90% confluency, cells were trypsinized as described previously 
and resuspended in 5ml NPC medium. Cells were counted using 0.4% trypan blue. The 
cells were centrifuged at 1500rpm for 5 minutes at 4°
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cold freezing media (RPMI 1640 medium supplemented with 20% FBS and 10% 
dimethyl sulphoxide DMSO) was added dropwise to cells. This allows DMSO to replace 
intracellular water. Final concentration of 2 X 106 cells in 1ml of cell suspension was 
transferred into a cryogenic vial. The vial was labeled with CNE-2 as cell line name, date, 
passage number, source of cell line and type freezing medium. The cryogenic vials were 
placed in -80ºC overnight before transferring to liquid nitrogen for long term storage. 
2.1.6    Seeding of CNE-2 cells 
Cells reaching 60 to 75% confluency were harvested using procedure stated above. The 
cell density was determined using trypan blue exclusion method. 5ml of CNE-2 cells with 
density of 1.25 x 104 cells/ml of single cell suspension was seeded into T25 flask where 
the number of flasks required depends on the treatments. Cells were incubated at 37ºC, 
5% CO2 incubator for 36 hours prior to transfection with antisense DENN 
oligodeoxynucleotides (in continuation with section 2.2 ANTISENSE 
PHOSPHOROTIOATE TRANSFECTION OF CELLS). 
2.1.7 Harvesting of CNE-2 cells for flow cytometry 
All procedures were performed under sterile conditions in standard class II biohazard 
laminar flow hood. After antisense phosphorotioate oligonucleotides treatment on CNE-
2, spent media was carefully aspirated from flask and transferred to clean 15ml centrifuge 
tube for collection. Next, cells were washed twice with 4ml 1x PBS. The spent media 
contains floating cells.  
For the monolayer CNE-2 cells, 1ml trypsin/EDTA was carefully added to cells and 
incubated at 37°C for 5 minutes.  The enzymatic activity of trypsin was stopped using 
5ml NPC and transferred to the same collection tube. The cells were gently resuspended, 
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centrifuged at 1500rpm, 5 minutes at room temperature and then supernatant aspirated. 
Next, pelleted cells were washed twice with 5ml 1x PBS and thoroughly resuspended 
before centrifuging at 1500rpm for 5 minutes at room temperature. The cells were 
resuspended with 500µl 1x PBS and transferred to fresh 1.5ml microcentrifuge tube. The 
cells were kept on ice before further analysis (in continuation with section 2.8 FLOW 
CYTOMETERY). 
2.1.8 Preparation of CNE-2 cells for transmission electron microscopy (TEM) 
Cells for transmission electron microscopy (TEM) observation were incubated with fresh 
cold, double strength fixative agent for one hour at 4°C. The fixative was carefully 
removed and replaced with single strength fixative agent (app.5) for one hour incubation, 
at 4°C. After fixation, cells were gently scrapped in one single constant movement and 
transferred to 15ml centrifuge. The cells were pelleted at 3500rpm for 8 minutes at room 
temperature. The fixative was discarded and the cells were washed twice with cold 1x 
PBS.  These harvested cells were ready for further post-fixation processing for TEM (in 
continuation with section 2.10 TRANSMISSION ELECTRON MICROSCOPY).  
2.1.9  Harvesting of CNE-2 cells for western blot 
The monolayer cells were washed twice with 1x PBS and gently scrapped using sterile 
scrapper in single constant movement in the presence of cold protein lysis buffer (app. 
4). The cell lysate was then transferred into 1.5ml microcentrifuge tube, kept on ice and 
further processed for western blot (in continuation with section 2.13 PROTEIN WORK). 
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2.2 ANTISENSE PHOSPHOROTIOATE TRANSFECTION OF CELLS  
2.2.1 Synthesis of antisense phosphorotioate (PS) oligodeoxynucleotides  
The following antisense oligonucleotides were synthesized from PROLIGO Primers and 
Probes with phosphorotioate chemistry in between all nucleotides. The phosphorotioate 
chemistry refers to the replacement of oxygen molecule of the oligonucleotide backbone 
with sulphur. ‘DENNse’ oligonucleotide targets the sense sequence of the DENN death 
domain while ‘aDENN’ is the negative strand or antisense of the same location. Besides 
that, the ‘5UTR’ is the antisense phosphorotioate oligomer aimed to block the 5’ 
upstream region of the DENN gene while ‘AUG’ refers to antisense of the start region of 
the DENN gene. The following are the sequences of the antisense phosphorotioate 
oligonucleotides: 
DENNSe:  5’ CACAACCTCATCTCCTACA 3’ (19 oligomer at nucleotide 3959-3977)  
aDENN: 5’ TGTAGGAGATGAGGTTGTG 3’ (19 oligomer at nucleotide 3959-3977) 
5UTR: 5’ AGAGAAGCATCAGGGCACCAA 3’ (21 oligomer at nucleotide -31 to -11) 
AUG: 5’ CATGGTTCCAATTCATCAGTTTA 3’ (23 oligomer at nucleotide -6 to +16) 
These sequences were sent to of NCBI, BLAST programme to check the location and 
gene specificity as well as orientation. All sequences were adapted from Lim and Chow, 
2002. 
2.2.2 Transfection in CNE-2 cells using Oligofectamine 
CNE-2 cells were incubated with 3ml transfection media, RPMI 1640 serum free medium 
with respective 0.4µM antisense phosphorotioate oligodeoxynucleotides coupled with 
Oligofectamine (app. 2.2) for 6 hours at 37ºC, 5% CO2 incubator. 5ml fresh NPC media 
replaces transfection media for continuation to 24 or 48 hours before further analysis. 
50µg/ml cycloheximide treatment was performed concurrently on CNE-2 with the 
antisense oligodeoxynucleotides experiment as a positive inducer of apoptosis. 
 49 
2.3 TOTAL RNA EXTRACTION 
Total RNA was extracted from untreated or antisense phosphorotioate oligonucleotides 
treated samples using SV Total RNA Isolation Kit (Promega Corporation, USA). CNE-2 
cells were washed twice with sterile 1x PBS. After washing, trypsin-EDTA was added to 
the cells and incubated for 5 minutes in 37°C incubator. The activity of trypsin was 
neutralized and cells were collected in sterile 15ml centrifuge tube. Next, the cells were 
washed twice with 1x PBS and transferred to 1.5ml sterile microcentrifuge tube for lysis. 
For 5 X 106 cells, 175µl of SV RNA lysis buffer was added and homogenized using 
sterile syringe and 21G needle. 350µl of SV dilution buffer was added to cell lysate and 
inverted 3 to 4 times and further incubated at 70°C for 3 minutes. After incubation, lysate 
was centrifuged at 13,200rpm for 10 minutes at 25°C. The clear cell lysate was 
transferred into a fresh 1.5ml tube and 200µl of 95% ethanol was added and mixed by 
pipetting. The sample was then transferred into the spin column assembly and centrifuged 
at 13,200rpm for one minute and the liquid in collection tube was discarded. Then, the 
column was washed with 600µl of SV RNA wash solution and centrifuged at 13,200rpm 
for one minute. 50µl DNase I enzyme mixture containing 40µl of core buffer, 5µl 0.09M 
MnCl2 and 5µl of DNase I enzyme was added directly onto membrane inside the column 
and incubated at 25°C for 30 minutes. After incubation, 200µl SV DNase stop solution 
was added and centrifuged at 13,200rpm for one minute. Then, the column was washed 
with 600µl of SV wash solution and centrifuged the column at high speed for one minute. 
The wash was repeated with 250µl SV wash solution and spun at 13,200rpm for two 
minutes.  Finally, 75µl of nuclease-free water was added onto the membrane inside the 
column and centrifuged at 13,200rpm for one minute into new sterile RNAse free 1.5ml 
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microcentrifuge tube. The eluted total RNA was quantitated in quartz cuvette at A260 and 
A280 using spectrophotometer and stored at -80°C.  
The concentration of the RNA (ng/µl) = OD260 X 40ng/µl X dilution factor 
Purity of RNA is estimated to have a ratio between 1.8-2.2 from OD260 /OD280 
calculations 
The integrity of the total RNA was also checked by visual evaluation for the presence of 
28S and 18S ribosomal RNA bands by using 1.2 % RNA denaturing agarose gel 
electrophoresis (app. 3.1). 
 
2.4 REVERSE TRANSCRIPTION CDNA SYNTHESIS 
Reverse transcription (RT) converts coding mRNA present in total RNA into 
complementary DNA (cDNA). The cDNA synthesis was carried out by using M-MLV 
reverse transcriptase (Promega Corporation, USA). The concentration of total RNA 
(TRNA) used was standardized at 2µg. 40µl reaction mixture was prepared.  
In a RNase free 0.2ml thin wall tube, the following components were added: 
 5 x M-MLV buffer                                     8µl 
     10 mM dNTPs (2.5mM dATPs, 2.5mM dTTPs, 2.5mM dCTP, 2.5mM dGTPs)      5µl 
   100-500ng random primer 1µl 
 RNase inhibitor                  0.5µl 
      DEPC RNAse free water                                 15µl 
      Total RNA x µl 
 ddH20 y*µl 
 * : (x + y=25 µl)        36µl 
The tube was placed in ABI PCR machine and heated to 65°C, 5’; 25°C, 5’ 
 M-MLV RTase (200units/µl)  1µl 
 ddH20  3 µl 
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4µl of reverse transcriptase mix was added to 0.2ml RT tube, mixed gently and quickly 
short pulsed. The tube was incubated at 37°C, 2 hours; 70°C, 10’ (heat inactivated the 
activity of reverse transcriptase); 10°C, ∞.  
 
2.5 CLASSICAL SEMI-NESTED POLYMERASE CHAIN REACTION  
The mRNA expression of DENN isoforms were studied using classical semi-nested PCR 
employed on a panel of cancer cell lines. Total RNA of each cell lines were extracted 
from healthy, proliferating and converted to cDNA using M-MLV reverse transcription 
process (Section 2.4 REVERSE TRANSCRIPTION FOR cDNA SYNTHESIS). The 
concentration of each cell lines were standardized as 50µg/µl.  
In a thin wall 0.2 ml PCR tube, 
 10X PCR buffer (50 mM KCl, 10mM Tris-HCl (pH 9.0, 25°C), 0.1%  
 Triton X-100) 5µl 
      10mM dNTPs (2.5mM dATPs, 2.5mM dTTPs,  
       2.5mM dCTP, 2.5mM dGTPs)  2µl 
 25mM MgCl2 3µl 
 10µM Forward primer 1µl 
 10µM Reverse primer 1µl 
 ddH20 35.5µl 
 cDNA 2µl 
 Taq Polymerase in storage buffer B (5U/µl) Promega             0.5µl   
                                                                                                          Total          50µl 






Table 2.1 Primers used for DENN isoforms study 
PCR Primers Primer sequence 
ADenn  5’ GAGCCAACTCTGAACCTGCT3’ 
DEN60(-) 5’ CTGGGGTGATGGAGGTTCTC 3’ 
1st 
95°C, 1’/ 95°C, 30”; 58°C, 45”; 72°C, 45”/ 72, 10’; 10°C, ∞  40 cycles 
DEN66cm 5’ GATAAGGCAGCAGTAGGCGTCT 3’ 
DEN60(-) 5’ CTGGGGTGATGGAGGTTCTC 3’ 
2nd 
95°C, 1’/ 95°C, 30”; 50°C*, 45”; 72°C, 45”/95°C, 45”; 58°C, 45”; 72°C, 45”/ 
72°C 10’; 10°C, ∞  5* +25 cycles 
* : Touchdown PCR where 1°C increment for annealing temperature for every cycle 
Concurrently with 1st DENN PCR, housekeeping HUEL was also amplified for every cell 
line. 
Primers Sequence 
HUEL 5R2 5’ AAGTATGTAATGGAAAGTCGTG 3’ 
HUEL 3R3 5’ ACTTCAGCTCCTAAAGTATCAATA 3’ 
95°C, 1’/95°C, 20”; 58°C, 20”; 72°C, 20”/ 72°C 10’; 10°C, ∞  40 cycles 
After 1st PCR, the amplicons were loaded and separated by 3.5% 2.5:1 NuSieve and 
agarose mix in 1x TBE gel to separate respective DENN isoforms (refer section 2.7.1 
AGAROSE GEL ELECTROPHORESIS for details).   
Under ultraviolet light, traces amount of respective PCR amplicons from each cell lines 
were extracted using sharpened tip and transferred to a clean X-Spin column. The PCR 
DNA fragment was eluted with 30µl ddH20 by centrifugation at 13,200rpm, 2 minutes at 
room temperature. 5µl of eluate was used for 2nd semi-nested PCR. PCR products were 
separated on 1.25% normal agarose gel in 1x TBE running buffer (refer section 2.7.1 
AGAROSE GEL ELECTROPHORESIS for details). 
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 The gel photo of the electrophoresized PCR products was taken under uv light exposure.  
Subsequently, the PCR bands were excised from gel and purified using Qiagen QIAquick 
Gel Purification kit. 30µl ddH20 was used to elute the respective PCR products from each 
cell line. The eluate was sequenced separately using forward and reverse primers (refer to 
section 2.6 DIRECT CYCLE SEQUENCING for details). 
12µl of the 2nd PCR product was also electrophorized in 8% vertical PAGE gel at 200V, 
3h, cold (refer to section 2.7.2 8% POLYACRYLAMIDE GEL FOR RT-PCR 
PRODUCT for details). The gel was stained using DNA gel Star and visualized under 
ultra violet light. The PAGE gel was scanned using Typhoon machine and analyzed by 
ImageQuant software for densitometry measurements. 
The following table 2.2 shows the DENN isoforms from PCR amplification. 













AF440101 IG20 2312-2961 650 2350-2961 612 
U44953 DENN 2326-2915 590 2364-2915 552 
AF440102 IG20-SV2 2312-2832 521 2350-2832 483 
AF440103 DENN-SV 2312-2772 460 2350-2772 423 
Table 2.2   Amplified PCR products size for DENN isoforms. 
 
2.6 DIRECT CYCLE SEQUENCING 
Direct cycle sequencing was performed for all four isoforms of DENN family and other 
DENN-related genes to check for authenticity. Sequencing reaction comprised of 3.2µl of 
1µM primer, 200ng of column purified PCR template, 4.0µl ABI PRISM BigDye 
Terminator Cycle Sequencing ready reaction mix Version 3.1 and ddH2O to have a final 
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volume of 20µl. Forward and reverse primers were used to separately sequence each 
product in both directions. The reaction mixture was mixed and centrifuged briefly before 
subjecting to a cycling profile of 96°C, 1’/96°C, 10”; 50°C, 5”; 60°C, 4’/10°C, ∞, 35 
cycles. After cycle sequencing, the sample was subjected to purification to remove 
contaminants. 
2.6.1 Purification of sequencing products  
20µl of sequencing product was transferred to a clean 0.6ml or 1.5ml microcentrifuge 
tube. 2µl of 3M sodium acetate (pH 4.6) and 62.5µl of non-denatured 95% ethanol and 
14.5µl ddH2O were added to the sequencing product. It was gently mixed and incubated 
at room temperature for 30 minutes and then centrifuged at 13,200rpm for 20 minutes at 
20°C.   The supernatant was carefully removed and 250µl of 70% ethanol was added to 
wash precipitated DNA. The mix was gently tapped and incubated at room temperature 
for 5 minutes. This was followed by centrifugation at 13,200rpm for 5 minute at 20°C. 
Next, the supernatant was carefully aspirated from tube. The sample was speed vacuumed 
for drying at 60°C for 15 minutes until the ethanol is completely evaporated. The 
precipitated DNA product is ready for sequencing. After sequencing, the DNA sequence 
was confirmed using NCBI, BLAST to check gene specificity. 
 
2.7 ELECTROPHORESIS 
2.7.1 Agarose gel electrophoresis 
2.5% FMC NuSieve + 1.0% agarose mix (~ 3.5% gel) 
 FMC NuSieve low melting temperature agarose 6.87g 
 Agarose 2.75g 
 1x TBE 275ml 
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1.25% Agarose Gel 
 Agarose (Seakem Le Agarose for gel electrophoresis 3.4375g 
 1x TBE 275ml 
Both agarose gels used same method of preparation. The agarose powder was carefully 
measured, mixed and thoroughly dissolved in 1x TBE via boiling (app. 3.2). The agarose 
was cooled to approximately 60°C. Then, 10µl ethidium bromide (10mg/ml) was added 
to agarose solution, mixed before pouring into a gel castor for solidification.  
2µl of 6x DNA gel loading buffer (app. 3.2) was mixed with 10µl of each RT-PCR 
product before loading into solidified wells. The gel electrophoresis was run at 125V, 2 
hours, 1x TBE room temperature. The gel was observed under ultra violet light and gel 
photos were taken. 
2.7.2 8% polyacrylamide gel for RT-PCR product  
The Hoefer glass plates were carefully stationed vertically onto the gel castor assembly 
(app 3.3). The 8 % polyacrylamide was prepared with the following reagents: 
  1 gel (40ml) 2 gels (80ml) 
 Acrylamide/bisacrylamide 30% 10.65ml 21.3ml 
 10x TBE 4.0ml 8.0ml 
 Glycerol 2.0ml 4.0ml 
 dH20  23ml 46ml 
 10% APS 320µl 640µl 
 TEMED 20µl 40µl 
2µl of 6x DNA gel loading buffer was mixed with 12µl of each the classical 2nd PCR 
product before loading into wells. The gel electrophoresis was run in cold room (4°C) at 
185V for 5 hours in 1x TBE. The gel was stained using Gelstar nucleic acid stain (app 
3.3). Next the gel was observed, scanned and analyzed using densitometry programme. 
Gel photo was also taken under ultra violet light. 
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2.8   FLOW CYTOMETERY 
2.8.1  Caspase-3 activation assay 
The extrinsic and intrinsic signal transduction for apoptosis merges at the same executer 
caspase, caspase-3. Active caspase-3 is a marker for cells undergoing apoptosis. This key 
executer is responsible to either partially or totally cleavage of many key proteins as well 
as other caspase family members (Cohen, 1997). In this experiment, the activation of 
caspase-3 activities were detected using flow cytometery with FITC-conjugated 
monoclonal active caspase-3 antibody apoptosis kit from BD-Biosciences Pharmigen. 
After treatment of antisense oligonucleotides, the cells were carefully harvested from T25 
flask as mentioned in section 2.1.7 Harvesting of CNE-2 cells for flow cytometry.  At 
room temperature, the cells from respective treatments were washed with 1x PBS and 
transferred into clean 1.5ml microcentrifuge tube. All samples were resuspended in 500µl 
of 1x PBS with an approximate concentration of 1 X 106 cells. After washing, the cells 
were equilibrated in 500µl 1x Cytofix/Cytoperm (provided by kit). It was incubated on 
ice for 20 minutes. Next, the cells were pelleted at 1500rpm for 5 minutes at room 
temperature. After discarding the supernatant, the pelleted cells were gently resuspended 
in 500µl in Perm/Wash buffer (kit) twice. For ‘untreated’ sample, 50µl of cell suspension 
was aliquoted into another 1.5ml microcentrifuge tube as baseline control for gating cells 
size and viability. Mixture of 100µl Perm/Wash buffer with 20µl FITC-conjugated 
monoclonal active caspase-3 antibody was prepared for every treatment (T25 flask). 
Thus, single cell suspension was incubated with 120µl of antibody mix for 30 minutes at 
room temperature, protected from light source. Excess unbound antibody was washed 
with 1.0ml Perm/Wash buffer. The cells were pelleted at 1500rpm for 5 minutes at room 
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temperature. The supernatant was discarded and cells were resuspended in 500µl 
Perm/Wash buffer.  The cells were filtered and analyzed using Dako Cytomation, 
CyAN, Denmark.  
2.8.2 Analysis of flow cytometry data  
All flow cytometry data were analyzed using Windows Multiple Document Interface 
(WinMDI) version 2.8 copyright© 1993-1998 Joseph Trotter and Summit version 3.3, 
CyAn™ Dako Cytomation, Denmark software to detect for FITC positive counts from 
antisense phosphorotioate oligonucleotides transfection.  
 
2.9 DNA FRAGMENTATION ASSAY (TUNEL) 
In this assay, the enzyme terminal deoxynucleotidyl transferase (TdT) actively 
incorporates fluorescein-dUTP to free 3’-hydroxyl ends of fragmented DNA, rendering it 
detectable by fluorescence microscopy. In this experiment, the DNA fragmentation 
positive cells were detected using BD APO-Alert DNA Fragmentation Assay kit (BD 
Biosciences-Clontech).  
After treatment of respective antisense phosphorotioate oligonucleotides, the cells in T25 
flask were washed twice with 1% Bovine Serum Albumin (BSA) 1x PBS. Next, the cells 
were fixed in 3.5ml of 1% paraformaldehyde/1% BSA/1x PBS for 1 hour at 4°C. Next, 
cells were washed twice with 1% BSA/1x PBS. Then, cells were permeabilized using 
5ml 50% ice-cold ethanol for 1 hour at 4°C. The excess ethanol was aspirated and cells 
were washed twice with 1% BSA/1x PBS. Subsequently, 150µl equilibrium buffer 
(provided by kit) was evenly distributed onto monolayer of cells and incubated for 5 
minutes at room temperature with constant shaking. Thus, a master mix of TUNEL 
reaction solution was prepared, kept on ice and protected from light where every 
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experimental sample (T25 flask) contains 45µl equilibration buffer, 5µl nucleotide mix 
and 1µl TdT. After equilibration, excess equilibration buffer was removed from flask. 
50µl TUNEL reaction solution was gently added onto cells. Using forceps, plastic 
coverslip was carefully placed on top of cells to spread the TUNEL reaction mix evenly 
and incubated in dark, 37°C for 1 hour. Next, the plastic coverslip was gently removed 
from cell surface. Then, 2.5ml of 2x SSC was added to cells and incubated at room 
temperature for 15 minutes with constant shaking to terminate the reaction. Cells were 
washed twice with 4.5ml of 1% BSA/1x PBS for 5 minutes at room temperature. The 
cells were observed using fluorescence microscope using a standard fluorescein filter set 
(520 ± 20 nm). The nucleus of apoptotic cells will exhibit strong green fluorescence. 
Next, 10µl of anti-Fade or DAPI stain was carefully added onto the same surface of cells 
treated with TUNEL reaction mix. Using forceps, fresh plastic coverslip was added on 
top of cells to reduce evaporation. Under ultra violet light, DAPI stains nucleus blue. 
Region of more than 150 cells were counted. Cells undergoing apoptosis can be identified 
as strongly stained green-emitting FITC positive under fluorescein filter and 
counterstained as blue under ultra violet light. The number of FITC-positive and DAPI 
stained cells (reference) were counted and percentage of apoptotic nuclei determined. 
 
2.10 TRANSMISSION ELECTRON MICROSCOPY 
2.10.1 Post-Fixation of CNE-2 cells (in continuation with 2.1.8 Preparation of CNE-2 
cells for TEM 
After washing with 1x PBS and pelleting, cells were post-fixed with fresh 0.5ml 2% 
Osmium tetraoxide (OsO4) with 0.1% potassium ferrocyanide for one hour at room 
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temperature. The cells were carefully rinsed twice in 1x PBS (15 minutes each change, 
spun at 3000rpm, 10 minutes at room temperature).   
2.10.2 Ethanol dehydration of cells 
Next, the osmium fixed cells were dehydrated in series incubations with incremental 
ethanol percentage:  1ml 50% - 20 minutes, 1ml 70% - 20 minutes, 95% - 20 minutes, 
100% - 30 minutes and the latest repeated trice at room temperature. For each ethanol 
interval, cells were carefully resuspended in ethanol. After incubation of ethanol, cells 
were pelleted by centrifugation at 3000rpm for 10 minutes at room temperature and 
supernatant was removed before the next ethanol change.  
2.10.3 LVER infiltration into cells 
Next, cells were infiltrated at room temperature with ‘aged’ resin Low Viscosity Epoxy 
Resin (LVER) (app. 5) of the following proportions: 1ml of 3 parts 100% ethanol to 1 
part LVER – 30 minutes, 1ml of 1 part 100% ethanol to 1 part LVER – 30 minutes, 1ml 
of 1 part 100% ethanol to 3 part LVER – 30 minutes and finally, 1ml LVER overnight at 
room temperature. For each infiltration interval, cells were carefully resuspended with 
thoroughly mixed LVER/ethanol solution using dried wooden stick. After incubation, 
cells were pelleted by centrifugation at 3500rpm for 10 minutes at room temperature and 
supernatant was removed before the next LVER infiltration.   
2.10.4 LVER resin penetration into cells 
Then, cells were resuspended at room temperature for three continuous changes of fresh 
1ml LVER for 1 hour incubation respectively. For each interval, cells were carefully 
resuspended with freshly prepared LVER using dried wooden stick. For each wash, cells 
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were pelleted by centrifugation at 3500rpm for 10 minutes at room temperature before 
removing supernatant for the next resin penetration.   
2.10.5 Embedding of cells in BEEM capsules 
Finally, cells were resuspended with 100 to 500µl LVER and carefully transferred to 
BEEM capsules (approximately two to four capsules per samples depending on the 
density of cells). The cells were incubated at 60°C for 10-15 minutes before 
centrifugation at 4000rpm, 40°C for 20 minutes.  Finally, BEEM capsules were incubated 
at 60°C on BEMM capsule holder for 16-20 hours for polymerization. When BEMM 
capsules are polymerized, they are ready for sectioning and stored at room temperature. 
2.10.6 Sectioning of BEEM blocks 
Cleaned, dried glass strips were prepared and precisely cut into glass knifes using 
Knifemaker, Reichert-Jung, Austria. The glass knife was carefully placed on the knife 
holder of the microtome, Ultracut E (Reichert-Jung, Austria). Embedded samples were 
trimmed by ravor blade into trapezium-based pyramids to remove uneven surfaces. 
Trimmed blocks were viewed under the microscope and carefully calibrated for further 
trimming. The surface of the block was trimmed until smooth and flat. Semi-thin sections 
of 0.5µm thickness were sectioned (3.0mm/second), collected and dried on glass slides at 
55°C prior to staining with methylene blue. Sections were stained with methylene blue 
for 5 minutes at room temperature. Excess dye was carefully washed and sections were 
dried again. The quality of LVER infiltration and penetration into these cells sections 
were checked using a light microscope.  
Ultrathin sections (600-900Å) were sectioned at 1.0mm/second at 96nm thickness with 
the appearance of silver to golden colour under the reflection of yellow and white light. 
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Sections were carefully straightened using a heated filament. The best ultrathin sections 
were selected and collected onto a cleaned dull side of 400 sized copper grids (TAAB).  
The copper grids were dried before storage in plastic capsules.  
2.10.7 Staining of ultra-thin section of cells 
Sections were stained with saturated aqueous uranyl acetate for 5 minutes on wax cubes. 
Excess stains were carefully washed off using deionised water and dried on a hot plate at 
60°C. Sections were further stained with lead citrate for another 5 minutes, rinsed and 
dried. The copper mesh was separately viewed using Philips EM208S Transmission 
Electron Microscope (Holland) at 2800 to 18000X magnification. 
 
2.11 DNA MICROARRAY STUDIES OF CNE-2 TRANSFECTED WITH 
ANTISENSE aDENN IN COMPARISON WITH DENNSE AT 48 HOURS  
25µg of total RNA extracted from CNE-2 treated with negative control DENN sense 
(DENNse) and treatment group antisense DENN (aDENN) samples were reverse-
transcribed into cDNA. They were labeled with Cy3- and Cy5-dCTP respectively using 
CyScribe first-strand cDNA labeling kit (Amersham Biosciences, Piscataway, USA) with 
anchored oligo (dT) and random hexamers. Labeled cDNAs were purified using a 
CyScribe GSK column purification kit (Amersham Biosciences, Piscataway, USA) and 
resuspended in 60µl of elution buffer. The amounts of Cy-3 and Cy-5 labeled cDNAs 
were estimated by absorbance at 550nm and 650nm respectively and calculated based on 
the formula (with volume of cDNA used for measuring as 5µl): 
(Absorbance/extinction coefficient) X volume of cDNA X dilution factor X 106   
The extinction coefficients for Cy-3 and Cy-5 were 150,000 litre/mol/cm and 250,000 
litre/mol/cm respectively. The experiments were performed using the Altas Glass 
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Human 7.6K cDNA microarray set (BD, Clontech, Palo Alto, CA) which comprised of 
7600 human genes spotted onto 2 slides where each consisting of 3800 genes. This oligo-
based array consists of an average 80bp fragments representing a wide range of known 
genes. The Cy-3 and Cy-5 labeled cDNA samples (100pmols each) in 2ml BD GlassHyb 
Hybridization Solution (pre-warmed at 50°C) were hybridized to each microarray slide in 
an upright position at 50°C for 16 hours. The slides were washed according to the 
manufacturer’s recommendations. Each slide was scanned with GenePix 4000B image 
scanner and the data were collected with the GenePix Pro 4.1 software (Axon 
Instruments, Union City, USA). The raw data were analyzed using Acuity software 
version 3.1 (Axon Instruments, Union City, USA). The experiment was duplicated with 
the reversal of Cy dyes labeling of the samples.  
 
2.12 REAL-TIME RT-PCR ANALYSIS  
The differential expressions of 32 genes obtained from microarray analysis were further 
validated by real-time quantitative RT-PCR using SYBR Green detection with light 
cycler system (Roche, Basel, Switzerland). Each 10µl reaction included 1µl cDNA 
(125ng), 5nM of each forward and reverse primer pair, 2.5 - 3mM MgCl2 and 1µl of 
ready to use 10x  FastStart DNA Master SYBR Green I reaction mix (Roche, Basel, 
Switzerland). The reactions were subjected to an initial denaturation at 95°C, 10”, 
followed by amplification with 95°C, 10”; 52-65°C, 5”; 72°C, 8-10” for 30 to 45 cycles 
before subjected to melting curve analysis. The annealing temperature and elongation 
time depends on percentage of GC and length of amplicon. Amplified products were also 
analyzed by agarose gel electrophoresis and further verified by automated cycle 
sequencing (Section 2.6 DIRECT CYCLE SEQUENCING). The conserved HUEL gene 
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was selected as the housekeeping gene. To ensure consistency in threshold cycle (CT) 
values, every reaction were duplicated. For each sample, the threshold cycles (CT) for the 
gene of interest were normalized by HUEL from the same sample. Next, the differences 
between aDENN from DENNse (reference) were analyzed. The normalized values of 
each gene were subjected to Student’s t-test with two tailed distribution to determine the 
significance at the 95% confidence level. 
Table 2.3 Sequences of primers for the amplification of selected genes 
Gene  Primer sequence (5’ → 3’)                          TM 
(°C)  -----------------------------------------------------------------------------       
  Forward   Reverse 
 
HUELa AAGTATGTAATGGAAAGTCGTG    ACTTCAGCTCCTAAAGTATCAATA 55 
DENNiso CATCCACAGAATCCACATC GCAACATCCACAGAATCC  58 
 
Selected genes from microarray analysis of antisense DENN death domain 
oligodeoxynucleotides compared to sense orientation fragment transfected into 
CNE-2 
ALDA CTCGCATCGTAGCTCTG CCGGTTCTCCTCGGTATT  55 
ARID3A GCGACTGGACTTACGAGGA GATCTCACGCCACAGCTTCT 55 
ARR2 CAGGTATCTCCCAGCTCCACA CCAGCTTCACCTTGACCCTGT   58 
ASAH1 CGTACAGAGGTGCAGTTCCA GTTGCCAAGTAGGCCAGGCAA 55 
AGTR2       CTTCCCTTCCATGTTCTGACC AAACACACTGCGGAGCTTCTG 59 
BCL7B CCTGTGACAGACAGCAAGGAG GCTCAGGGACTCACTCTGCT  56 
BUB1 CTTCGTCTGAGCCACCT GGTGATGGACATAGACCAGCT 55 
CAV1 CAAGGAGATCGACCTGGTCAA GATGGAATAGACACGGCTGATG 57 
CD52 CGCTTCCTCTTCCTCCTAC GAGGTGGATTATGGCATTGG 55 
CYCB1 TGCACTTCCTTCGGAGAGCAT CCAGGTGCTGCATAACTGGAA 61 
ESW1 CGAGCAGCTATGGACAGCA CCACTCATGCTCCGGTTCT  55 
FK506 GGGATGCTTGAAGATGGAA CAGTGGCACCATAGGCATA 55 
GBAS GGTCTTACCAACTCCGACCA  CCCTGGTCTGAAGATCCCTGT 57 
GSK-3B  GCTGGAGTATACACCAACTG  TGCAGAAGCAGCATTATTGG 57 
HNH1 CGTGCAGTTTGCTTCACAGGA CAGGTCTGTCATAAGGACCTG 55 
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IL-18 GCTGCTGAACCAGTAGAAGAC GCCGATTTCCTTGGTCAATGAA 58 
IL-32 CCGAATGCACCAGGCCATA CAGCATGGCCTGGAACCAT 55 
KLF9 CCAAGAGCTTGTTGGACCTG CTTCGCAGCCACTCCAGGAT  56 
KUA CTGAAGCCCTGGAGCAGCTATA CTGTGGTGATGCAGAAGTAGGT  55 
ODC1 ATACTCTATGACCACGCACA GCCCTGACATCACATAGTAG 58 
NDUF2 CCTCTACATCGGCTTCTTGG CATTTCACGGTCCCTCACAG 58 
PAK1 ATACTGGATGGCACCAGAGG   TGGTGGCAATGAGGTACAAG 59  
PAK3 GGAACACAGTGAGGAGTTGG GCTCTTTCCTCTTCCGGACT 58 
PFKFBP2 GCAGATGAGCTACCATACTTG CGAACTGGACAGAGGCGTA 58 
RAB3A ACTGGTCCACCCAGATCAAG GTCCAACGACTCGGACATCT 58 
RHO GAGTCAGCCACCACACAGAA CATGAAGATGGGACCGAAGT 58 
RABEP1 CCAGCCTGACGTTTCTCTTC CCATCTCTGCTTGAGCTTCC 58 
STM1 CCAGGTGAAAGAACTGGAGA CATTTGTGCCTCTCGGTTCTC 56 
TRADD TGCAGATGCTGAAGATCCAC GGGCTAGGATGCAACTCAAA 59 
TRAF4 AGAGCCATGAGGGTATGTGCC CAGCCTTGGGCACTGGTACTG 60 
TRAP3 AAGAATACGAGAGCTGCCACG TTCTCACCCTCTACCGTCTC  59 
UBC    GCACCTGGTGCTCCGTCTTAGAG  CCTCTGAGACGGAGTACCA  58 
 
Additional genes for real-time RT-PCR analysis 
BID GACAGCATGGACCGTAGC GAAAGACATCACGGAGCAAG 55 
FAIM   ACTACATCAGGCAGACGAGT GCACCATACGTCCATAGCAT 65 
GADD34 CACCCTTTCTTCCTCCTG CTG TCTTCAGCCTCCTC  60 
IAP CAGAAGACACAGACGTCTTTA CGAACTGTACCCTTGATTGTA 55 
IGFBP4 GCTGGCACGTAGTACATGGT TGCTACTCCTGTGCTCTGGA 61 
NANOG CAAAGGCAAACAACCCACTTC TCTGCTGGAGGCTGAGGTAT  52 
NF-KB1a ACCTGGTGTCACTCCTGTTG AGCTCGTCCTCTGTGAACTC 55 
P53 CTGAGGTTGGCTCTGACTGTACCACCATCC 
 CTCATTCAGCTCTCGGAACATCTCGAAGCG  60 
PAK2 GCGAATGAGCAGCACCATCTT GGCATGCCAGTGAATTCTCCA 59 
TRAF19 GCCCACCAGGAAGCAAAG CCTTGTTCTGATACCTTCTC 55 
v-ABL CGTCTGGGCATTTGGAGTAT     CAAAGGCTTGGTGGATTTC  55 




Additional genes for the detection of Epstein Barr Virus Latent genes 
EBNA2  CTCTGCCACCTGCAACACTA GAGGGTGCATTGATTGGTCT 55 
LMP1 TATCTTCAGAAGAGACCTTCT ATCAACCAATAGAGTCCACCAG 55 
a Housekeeping gene transcript serving as a the normalization control for real-time RT-
PCR 
 
2.13   PROTEIN WORK 
2.13.1 Protein extraction 
Protein extraction was carried out from actively growing or treated cells in T25 
(continuation from section 2.1.9 Harvesting of CNE-2 cells for western blot). The total 
cell lysate was incubated on ice for 15 minutes.  Then, the cell lysate was centrifuged at 
2000rpm for 10 minutes at 4°C to obtain the total crude protein lysate. The supernatant of 
crude lysate was pipetted into another fresh tube, kept on ice. The protein concentration 
from respective antisense phosphorotioate oligonucleotides were determined using Bio-
rad Protein DC Lowry kit. 
2.13.2 Western Blot (app. 4.2) 
Protein samples were prepated in sample buffer (5x) and heated at 100°C for 5 min. 60µg 
of total crude protein lysate was added in each well and performed western blot analysis. 
The samples from CNE-2 samples namely ‘untreated’, ‘oligofectamine’, ‘0.4µM 
DENNse’ and ‘0.4µM aDENN’ after 48 hours of incubation. The samples were separated 
in 10% SDS-Polyacrylamide gel alongside with Kaleidoscope Broad Range Protein 
Standard Ladder (BioRad) in 1x SDS-PADE, 100 V, until the dye front had reached the 
end of gel. Prior to electrobloting, 0.2µm nitrocellulose membrane (6cm x 8cm), 
Whatman 3MM filter papers were equilibrated in transfer buffer.   
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After separation, the gel was carefully removed from glass plates and washed with 
deionised water before equilibration in cold Tris-Glycine-Methanol buffer. The 
electroblotting procedure was carried out at a constant rate of 100mA for 2½ hours with 
frozen cooling unit next to the electrotransfer cassettes. After the transfer onto 
nitrocellulose membrane, the membrane was stained with Ponceau S staining for 5 
minutes to check for transfer and washed away with TBST. The left-over SDS-PAGE gel 
was stained with Coomassie Blue for 30 minutes to verify the transfer and destained 
solution overnight.  
The membrane containing protein lysate were blocked in 5% milk-TBST for one hour on 
a rocker platform at room temperature, to saturate unbound area with proteins. For 
detection of genes of interest, the membrane was incubated with respective antibodies 
IgG (monoclonal or polyclonal) in 5% milk-TBST, overnight at 4°C with constant 
rocking (Table 2.4). Unbound primary antibody was removed using TBST for five 
minutes with shaking and repeated twice. Next, the membrane was incubated with goat 
anti-mouse IgG horse radish peroxidase (HRP) tagged or donkey anti-rabbit IgG HRP 
(Santa Cruz, USA) at 1:5000 in 5% milk-TBST, room temperature with constant shaking. 
After one hour of incubation, the solution was decanted and the membrane was washed 
thrice with TBST buffer. Finally, blot was visualized using enhanced chemiluminescence 
(ECL) reagent detecting system. The membrane was exposed to autoradiography film 
(Kodak), developed and the autoradiograph was then scanned for densitometry analysis. 
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antibody Source Company 
Catalog 
No Dilution Size (kDa) 
1 DENN Rabbit polyclonal Sigma M5683 1:200 200-220 
2 Actin Mouse monoclonal Sigma AC-15 1:2000 42 
3 Caveolin 1 Rabbit polyclonal 
BD 
Sciences 610059 1:500 22 
4 ODC Goat polyclonal Santa-Cruz sc-21515 1:250 53 
5 PCNA Mouse monoclonal Santa-Cruz sc-56 1:250 36 
6 RAB3a Rabbit polyclonal Santa-Cruz sc-308 1:250 31 
7 RAB5a Rabbit polyclonal Santa-Cruz Sc-309 1:250 24 
8 RABAPTIN Rabbit polyclonal Santa-Cruz sc-15351 1:250 100 
9 Rabphilin-3A Goat polyclonal Santa-Cruz sc-14687 1:250 77 
10 TRADD Goat polyclonal Santa-Cruz sc-1163 1:250 34 




3.1 Expression of DENN isoforms in CNE-2 cells 
The constitutive expressions of different isoforms of DENN including IG20, 
DENN/MADD, IG20-SV2 and DENN-SV (approximately 610, 550, 480 and 420bp 
respectively) in cancerous and transformed cell lines were determined by reverse 
transcribed classical semi-nested polymerase chain reaction (RT-PCR). Semi-nested PCR 
utilized two forward primers and the same reverse primer to amplify low expression 
DENN isoforms. These primers flanked exon 13 until 16 that differentiated all four 
isoforms in these samples. Equal concentration of total RNA was reverse transcribed into 
complementary DNA (cDNA). The concentrations of each cDNA of each cell lines were 
standardized throughout the experiment. The polyacrylamide gel shows (Figure 3.A) 
intensity of all four different isoforms of DENN in different cell lines. Densitometry was 
performed to check the abundance of each isoforms and normalized using classical RT-
PCR of prototype housekeeping HUEL gene. HUEL or C4orf1 encodes for a polypeptide 
that mediates basic cellular function as a nuclear transcription factor and ubiquitously 
expressed in diverse human tissues and cancer cell lines (Sim and Chow, 1999).  
As shown in Figure 3.A, most of the cancer cell lines; HK-01, TW-01, CNE-2, 
Hep2, KatoIII, CaCo2, PP5, Hep2G, Hep3B, Jurkat, HL60, U937, MCF-7, Hela, PC3 and 
RD expressed the DENN and DENN-SV as the major isoforms. However, U937 (Lane 2) 
and HL-60 (Lane 6) lymphoma cell lines, expressed only DENN and DENN-SV isoforms 
in the absent of IG20 and IG20-SV2. The expression pattern in these two cell lines differs 







Among the three nasopharyngeal carcinoma cell lines, CNE-2 (Figure 3.A, Lane 5 
and 17) showed higher levels of DENN, DENN-SV and uniquely IG20-SV2. In cell lines, 
TW01 (Lane 4) and HK-01 (Lane 3), DENN-SV was the highest among the four DENN 
isoforms. There is significantly low expression of IG20 in all three nasopharyngeal 
carcinoma cell lines. CNE-2 cell line was selected to further probe for the functional role 




Lane  M: 1kb+ marker       10: Hep 2 Laryngeal carcinoma 
 1: RD Rhabodomyosarconoma (muscle)    11: Hela Cervical carcinoma 
 2: U937 Macrophage histocytic lymphoma    12: ECV304 Umbilical cord endothelial-like cells  
3: HK-1 Highly differentiated nasopharyngeal carcinoma   13: MCF-7 Breast carcinoma 
 4: TW-01 Moderated differentiated nasopharyngeal carcinoma  14: Hep3B Hepatocellular carcinoma 
 5: CNE-2 Poorly differentiated nasopharyngeal carcinoma   15: MRC-5 Embryonic lung fibroblast (normal) 
 6: HL-60 Human acute promyelocytic leukemia 16: Jurkat Acute T lymphoblastic leukemia 
 7: CaCo2 Colorectal carcinoma     17: CNE-2 Poorly differentiated nasopharyngeal carcinoma 
 8: PP5/PF/5 Heptoma       18: PC-3: Prostrate adenocarcinoma 
 9: Hep2G Heptocytoma      19: Kato III: Gastric carcinoma 







RT-PCR of DENN 
isoforms in a panel 
of cancerous and 
normal transformed 
cell lines: Primers 
DEN66cm and 
DEN60(-) amplified 
PCR products of 
approximately 610, 
550, 480 and 420bp 
correspond with IG20, DENN, IG20-SV2 and DENN-SV. Bar graph showing the percentage of respective DENN isoforms based on densitometry analysis that 
were normalized with prototype housekeeping gene, HUEL (amplified from 5R2 and 3R2)






































































































3.2  Downregulation of DENN with antisense against different regions of DENN 
To further understand the functional importance of DENN in cell homeostasis, 
DENN was dowenregulated using antisense oligonucleotides. These antisense DENN 
ODNs were targeting various regions namely 5’ untranslated region (5UTR), 
translational start site (AUG), death domain (aDENN) as well as the sense orientation of 
the death domain (DENNse). After 24 and 48hours of treatments, total RNA were 
extracted and reverse-transcribed using MMLV reverse transcriptase into complementary 
DNA (cDNA). Quantitative real-time PCR was performed using SYBR Green based 
detection assay. All crossing point values (CT) for DENN gene for respective samples 
were normalized using CT values of prototype housekeeping HUEL gene 
After 24hour of DENN antisense phosphorotioate oligonucleotides treatment in 
CNE-2, there was no significant downregulation of DENN was observed. Subsequently, 
at 48 hours of incubation, a decrease in DENN gene expression was observed (Table 3.1). 
Among the three antisense transfection targeting different regions of DENN, aDENN, 
inhibiting the death domain region showed a 2.32 fold decrease in DENN expression 
when compared with sense orientation ODN, DENNse. Antisense against 5’UTR showed 
about 1.71 fold decrease in DENN expression and treatment with antisense against AUG 
did not alter the DENN expression. There was no significant change in DENN expression 





Sample    Fold change (p-value) 
48hours  
 0.4µM DENNse  1.000 (REF. for 48hours) 
 0.4µM aDENN  -2.32±0.027 (<0.001)* 
 0.4µM 5UTR   -1.71±0.032 (0.008) 
 0.4µM AUG   -1.37±0.024 (0.2) 
 
REF.: Reference sample 
 
Table 3.1 Relative expression of DENN gene from real-time RT-PCR after 48hours 
antisense of ODNs transfection: Primers 3DF (nt 1364-1381) and DR3 (nt 1642-1625) 
were employed and normalized with HUEL, F3.5 (nt 457-481) and R9 (nt 587-562). 
Threshold crossing point (CT) of DENN genes was detected using ROCHE SYBR Green 
Master mix kit. Oligofectamine was used as a transfection agent for the delivery of all 
four oligonucleotides. The fold changes of DENN gene expression was compared among 
the various antisense DENN namely 5’ untranslated region (5UTR) (5’ 
GAAGCATCAGGGCACAA 3’), translational start site (AUG) (5’ 
CATGGTTCCAATTCATCAT 3’), death domain aDENN (5’ 
TGTAGGAGATGAGGTTGTG 3’) as well as sense orientation of the death domain, 
DENNse (5’CACAACCTCATCTCCTACA 3’). Average CT value ± standard errors were 
obtained from two independent cell treatments in triplicates. Student’s T test analysis on 
different ODN treatments determined the significance of the statistically differences with 
95% confidence. 
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3.3 Induction of apoptosis in CNE-2 cells after treatment with antisense against 
different regions of DENN 
To explore the possibility of antisense phosphorotioate DENN capability to 
induce apoptosis in CNE-2, various apoptosis assay were performed. TUNEL assay was 
carried out in CNE-2 cells after treatment with antisense against different regions of 
DENN. TUNEL positive cells were detected by presence of fluorescein bound to 
fragmented DNA and quantified. Fragmentized DNA is one of the key characteristic of 
apoptosis. There was no noticeable cell death after 24hours of transfection of DENN 
antisense phosphorotioate oligonucleotides. As shown in Fig 3.Bi & Bii, 17.14 % cells 
showed TUNEL positive in aDENN transfected cells after 48hours in CNE-2 cells. There 
was no significant cell death was observed in 5UTR or AUG transfected cells. 
Cycloheximide treated cells was used as a positive control for apoptotic cell death. The 
apoptotic cell death was further observed by transmission electron microscopy.  
Figure 3.Ci and ii showed transmission electron microscopy (TEM) of CNE-2 
after transfection with antisense PS-ODNs. The left panel showed untreated CNE-2 cells 
of epithelial origin exhibited high nuclear to cytoplasm ratio with many protrusions like 
cilia at the cell plasma membrane. The cells have circular and elongated mitochondria 
with clear cristea folding. Oligofectamine treatment and DENNse transfected CNE-2 
cells have the same ultrastructure as untreated cells, thus showing no cytotoxic effect. 
The transmission electron micrograph of cells transfected with aDENN ODN and 
cycloheximide treatment in CNE-2 revealed ultrastructural changes that typify apoptosis 
with significant reduction of the size of mitochondria and lost of cristae folding. Besides 
that, transfection with aDENN, 5UTR, AUG and cycloheximide, CNE-2 portrayed many 
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cell debris and chromatin condensation in the nucleus. The ultrastructural features of 
apoptotic cell death in CNE-2 cells with aDENN transfection are in line with the 
quantification from TUNEL assay.   
 















































Figure 3.Bi Graph showing percentage of TUNEL positive CNE-2 cells. This is an 
indicative of the presence of DNA fragmentation stained with FITC after transfection 
with various antisense phoshphorotioate oligodeoxynucleotides targeting various regions 
of DENN gene. The data are presented as the means of TUNEL positive ± SD obtained 
from three independent separate experiments where each time was performed in triplicate 
after 48hours of treatment were tested statistically significant (p<0.01). Cycloheximide 
treatment is a positive control for this experiment. Cells transfected with antisense 
phosphorotioate aDENN showed significant TUNEL positive counts. This indicates that 

















Figure 3.Bii Microscopy observation of TUNEL DNA assay 
fragmentation in CNE-2 cells after 48 hours transfection of 
various antisense DENN phosphorotioate 
oligodeoxynucleotides: CNE-2 cells transfected with DENN 
sense or antisense with aDENN, 5UTR, AUG and cycloheximide. 
Cells transfected with oligofectamine or DENNse did not show 
any TUNEL positive cells, comparable to untreated cells. Cells 
transfected with aDENN showed clear TUNEL positive cells with 
the highest counts among antisense treated groups. 











DAPI                              FITC
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 Figure 3.Ci Transmission electron microscopy (TEM) of poorly 
differentiated nasopharyngeal carcinoma: WHO type III, UNCT 
designated as CNE-2. CNE-2 was isolated from a 68 year old male patient 
with NPC; stage III (Gu et al., 1982). This cell line is characterized with 
large cells with high nuclear-cytoplasm ratio with protrusion structures at the 
cell membrane like cilia based on its epithelium origin. Cells were treated 
and were fixed at 48hours in osmium tetraoxide. The ultrathin sections of 
cells were stained with lead citrate followed by uranyl acetate and finally by 
lead citrate. The left panel shows the whole presentation of CNE-2. There is 
distinctive presence of hairy protrusions at the cell membrane of CNE-2 
(x5600). The middle panel (x5600) exhibited the low magnification of 
mitochondria and right panel (x11, 000) higher magnification of 
mitochondria. The mitochondria in CNE-2 cells are circular and elongated 
mitochondria; with evidence of clear cristae foldings in A: untreated, B: 
oligofectamine treated and C: DENNse transfetected CNE-2 cells where CM 
stands for plasma membrane; Cy: cytoplasm; N: nucleus and M: 
mitochondria.
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Figure 3.Cii Transmission electron microscopy (TEM) of poorly 
differentiated nasopharyngeal carcinoma: WHO type III, UNCT 
designated as CNE-2. The left panel (x5600) shows the changes in the 
plasma membrane with numerous shedding of cell debris after treatments. 
All treatment (D, E, F and G) have are condensation of chromatin; which are 
the heavily stained structures in the nucleus region (N). Besides that, the 
middle panel (x5600) exhibited cells with arrangement of mitochondria (M) 
at low magnification. Right panel displays higher magnification (x11000) of 
variations in mitochondria structures. Mitochondria in D, anti-DENN death 
domain transfected cells, have shrunk and loss cristae folding. After 24hours 
of cycloheximide treatment (G), similar observation was noted for 
mitochondria. However, most of the mitochondria in E: anti-5UTR and F: 





















































To further understand apoptosis induction by antisense DENN oligonucleotides in 
CNE-2, caspase-3 activity was quantitated by flow cytometry. The FITC positive cells in 
three different antisense treatments aDENN, 5UTR and AUG showed 16%, 12% and 
11% respectively (Figure 3.D). There were slight increments of caspase-3 positive 
activity after 48hours incubatetion when compared to basal level of negative controls 
namely DENNse, Oligofectamine and untreated. Cycloheximide treatment showed 50% 
FITC positive. The IG20 has been implicated with the enhanced of caspase-8 and -3 upon 
TNFα induced apoptosis.  






























































Table 3.D Flow cytometric analysis of active caspase-3 FITC tagged in CNE-2 after 
48 hours incubation of different antisense DENN phosphorotioate oligonucleotides 
treatments. The data presented as the means of active caspase-3 ± SD obtained from 
triplicates in three independent transfections of aDENN, 5UTR, AUG, DENNse using 
Oligofectamine as the delivery agent. The statistical significant (p<0.01) were determined 
using one-way anova analysis. 
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In addition to that, protein expression levels of proliferation cell nuclear antigen 
(PCNA) were determined by western blot. Cell lysates from untreated, oligofectamine 
transfected, DENNse, aDENN, 5UTR and AUG transfected cells were compared to 
determine the proliferation status of these cells. The PCNA level was significantly 
decreased after treatment with aDENN and 5UTR indicating the arrest of the cell 
proliferation in CNE-2 after blocking DENN (Figure 3.E). The level of PCNA protein in 
AUG transfected sample was comparable to negative controls (lane A, B and C). 
Among the three DENN antisense phosphorotioate oligonucleotides, aDENN is 
most effective in downregulating the gene expression of DENN in CNE-2 cells. Besides 
that, CNE-2 cells subjected to aDENN antisense phosphorotioate oligonucleotides (ODN) 
induced apoptosis based on the observations from transmission electron microscopy of 
the reduction of the size of mitochondria as well as the loss of cristae foldings. In 
addition to that, FITC positive TUNEL counts and detection of caspase-3 in the CNE-2 
treated with aDENN antisense also strongly supported the above notion. Concomintantly, 
there is also reduction in the level of proliferation marker, PCNA. In short, targeting 
DENN at the death domain induces apoptosis in highly metastactic, highly differentiated 
nasopharyngeal carcinoma CNE-2 suggesting that DENN has the potential to be a cancer 













Figure 3.E Western blot analysis of apoptotic feature of CNE-2 
Western blot was performed for proliferation cell nuclear antigen 
(PCNA). The beta actin (β-actin) was used to normalize the protein 
concentrations. An equal amount of cell lysate was loaded and the 
lanes represent as A-control, ‘untreated’; B-‘oligofectamine’ 
transfeted cell lysate; C-48hrs DENN sense death domain 
‘DENNse’; D-48hrs anti-sense death domain; E-48hrs anti-sense 5’ 
untranslated region, ‘5UTR’ and F-48hrs anti-sense transcriptional 
start site, ‘AUG’. There are downregulation of the PCNA protein 
















































3.4 Microarray analysis 
To understand the global effect of the downregulation of DENN leading to the 
induction of apoptosis, cDNA microarray analysis was carried out. CNE-2 cells were 
transfected with DENNse and aDENN where both target the same region, death domain 
of DENN but opposite orientation. The slides were scanned for cy3 and cy5 signals with 
a dual color image scanner. Stringency was exercised by flagging individual spots of poor 
quality which were omitted from analysis. Under the statistical analysis program, low 
intensity filtering based on the sum of medians of the foreground intensities of both 
channels less than 50 and then 200 were conducted. This criterion effectively ignoring 
low intensity spots while retaining those of sufficient quality to be analyzed. The filtered 
data was normalized by using LOWESS analysis during execution of the Acuity 
software. Finally, threshold greater than 1.96 (i.e. equivalent to those more than 1.96 
standard deviations from the local mean) based on the duplicated set. 160 genes were 
identified to be differentially expressed at 95% confidence level where about 100 genes 
exhibited upregulation and 57 genes demonstrated a decrease in expression level greater 
than 2-fold based on the Acuity analysis. Table 3.2 showed the fold changes of the gene 
transcripts that were significantly altered after 48hours treatment with aDENN antisense 
phosphorotioate oligonucleotide, in reference to DENNse.  
Genes with altered transcriptional patterns belonged to a wide range of functional 
classes. The major group of genes altered including genes involved in signal transduction, 
cell metabolism and transcription factors. We identified different intermediate molecules 
involved in TNF mediated apoptotic pathway. When DENN was blocked, TRADD, a 
downstream molecule which interacts with TNF receptor showed upregulation together 
 88 
with other TNF adaptor molecules. This is suggesting and supporting their role in 
apoptotic pathway. Besides that, there was downregulation of rabaptin-5, a member of 
the rab5 GDP/GTP exhange protein gene (Rab5 GEP) involved in endosome fusion 
which also implied the possible involvement in apoptosis.  
 Many genes like NADH dehydrogenase (ubiquinone) 1, subcomplex unknown 2 
(+13.95), NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 8 (2.41) which 
belongs to complex I and ATPase, H+ transporting, lysosomal (vascular proton pump) 
(+4.95), a subunit of ATP synthase (complex V) of the respiratory chain were affected 
after the blocking of DENN.  The upregulation of oxidative phosphorylation is hinting 
the possibility of mitochondrial damage and thus contributing to respiratory burst which 
is one of the characteristic features of apoptotic cell death. Genes involved in the cellular 
metabolism liked 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase (PFKFB2) 
(10.11),  aldolase A, fructose-bisphosphate (ADLA) (-1.10), carbohydrate (chondroitin 
6/keratan) sulfotransferase -3 (-2.06), galactose-4-epimerase, UDP- (-3.93), 
glucuronidase  beta (2.14), hexosaminidase A (alpha polypeptide) (-2.16),  hexose-6-
phosphate dehydrogenase (glucose 1-dehydrogenase) (-2.29), orthinine deoxycarboxylase 
1 (ODC1) (+3.36) and acid ceramidase (-3.52) were dysregulated after the abrogation of 
DENN antisense at the death domain region. Many transcription factor genes including 
general transcription factor II, I (+2.9), heterogeneous nuclear ribonucleoprotein A/B 
(+4.9), heterogeneous nuclear ribonucleoprotein A1 (+2.83), heterogeneous nuclear 
ribonucleoprotein H1 (HNRPH1) (+5.93), high-mobility group (non-histone 
chromosomal) protein 14 (+3.15) Kruppel-like factor 9 (KLF9)/Basic transcription 
element binding protein 1 (BTEN) (+10.34) were altered during the downregulation of 
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DENN.  There were upregulation of apoptosis related genes like caspase recruitment 
domain 4 CARD (+3.19) and death associated protein 3 (+2.22) after the blocking of 
DENN.  Cyclin B1, a cell cycle and developmental gene showed upregulation of 3.89. 
This microarray analysis of CNE-2 transfected with aDENN in comparison to DENNse 
showed the involved of genes from different signal transduction pathways as well as 
cellular metabolism regulation.  
3.5 Real-time PCR analysis to confirm modified transcription of genes 
To verify the microarray results of the CNE-2 cells after transfection with DENN 
sense and antisense, real-time PCR was performed for 40 interesting genes whose 
expression was upregulated or downregulated. The transcription expression of HUEL 
was used to normalize the expression levels of each gene and the P values calculated 
using Student T-test are listed in the Table 3.2. Real-time PCR analysis of HUEL gene 
expression showed no difference of Ct values between the DENN sense and antisense 
thus justified to be used for gene normalization.  On the whole, expression levels of 25 
genes out of 32 (78%) were verified by real-time RT PCR many of the genes verified by 
real-time PCR showed same trend with the microarray data where 17 genes that showed 
upregulation and 8 displayed downregulation. On the other hand, real-time PCR of 4 
genes showed opposite trend from microarray analysis (Figure 3.Fi). Besides that, most 
of the real-time RT-PCR verified genes functioned as signal transducers especially in the 
Tumour Necrosis Factor pathway as shown in Figure 3.Fii. Since the downregulation of 
DENN affects the expression many signal transduction molecules, DENN itself might be 
an essential upstream modulator. 
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 Among the genes involved in signal transduction in TNF mediated apoptosis, 
TRAF-2, TRAF-4, TRADD and DENN showed at least 2 fold change and in concurrence 
with the microarray data. This supports the evidence of the possible involvement of 
downstream signaling of TNF pathway in the apoptosis pathway in antisense transfected 
cells. Other signal transduction molecules including RAB3a and rabaptin, an effector 
protein of Rab5, members of the GTPase family were confirmed by real-time PCR.  
DENN/MADD plays a role as a GTP exhange factor (GEP/GEF) that promotes 
hydrolysis of Rab3a-GDP to Rab3a-GTP in the neuronal cells. β-arrestin2 showed the 
highest fold change in microarray and follows the same trend in real-time PCR although 
the fold change was less compared to the microarray results.  
 The expression profile of additional genes which are absent in microarray (p53, 
Nipah (ESTs), p21-activated kinase 2 (PAK2), nuclear factor of kappa light polypeptide 
gene enhancer in B cells inhibitor, alpha (NFKBIA), programmed cell death 5 (TRAF19), 
insulin like factor binding protein 4 (IGFBP4), Fas apoptotic inhibitory molecule 
(FAIM), transcript variant 4, human inhibitor of apoptosis protein (IAP), protein 
phosphatase 1, regulatory (inhibitor) subunit 15A (PPP1R15A)/GADD34, Nanog 
homeobox (NANOG), v-abl abelson murine leukemia viral oncogene homolog 1 (v-
ABL1), transcript variant a) were tested for differential gene expression after antisense 
DENN death domain. Some of the listed genes were upregulated after DENN blocking 
using the same ODN in Jurkat cells, human acute leukemia. Most of these genes play 
have close association with the regulation and induction apoptosis. NF-κB is common 
transcription factor is upregulated after the downregulation of DENN. The DENN-SV 
was suggested to have exerted its pro-survival effect via NF-κB activation.  
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Table 3.2 List of categorized human genes displaying altered transcription profiles 
after 48 hours incubated antisense DENN phosphorotioate ‘death domain’ 
transfection in comparison to sense DENNse from cDNA microarray analysis. The 
LOWESS normalized microarray data represented two independent cell preparation for 
each hybridization, n = 2 for two hybridization. For the real-time RT-PCR data, the 
values in brackets indicate the P-values at 95% confidence level (Student’s T test). The 
test of significance was performed based on the difference between data from aDENN 
transfected samples in reference to DENNse transfected CNE-2 samples. Real-time PCR 
are in duplicate for each assay. 
 
GenBank 
Accession no. Gene               Acuity     Real-time 
     PCR 
 
Adhesion integral proteins and angiogenesis 
 
NM_003801 Anchor attachment protein 1 (Gaa1p, yeast) homolog                   2.36   
X63629  Cadherin 3, type 1, P-cadherin (placental)       2.50   
NM_001753 Caveolin 1, caveolae protein, 22Kd (CAV1)      2.36           1.86 (0.012) 
NM_001803 CDW52 antigen (CAMPATH-1 antigen) (CD52)      -3.797       -1.60 (<0.001) 
AF031385 Cysteine-rich, angiogenic inducer, 61       2.47 
NM_012278 integrin beta 1 binding protein (melusin) 2       2.25 




NM_006092 Caspase recruitment domain 4         3.19 
X83544  Death associated protein 3          2.22 
NM_006785 mucosa associated lymphoid tissue                                         -2.05 
                             lymphoma translocation gene 1 
NM_003217 testis enhanced gene transcript (BAX inhibitor 1)       2.50 
 
Cell cycle and development 
 
NM_001184 Ataxia telangiectasia and Rad3 related        2.08  
NM_004336 Budding uninhibited by benzimidazoles 1 (yeast homolog)      3.01         1.72 (<0.001) 
  (BUB1) 
NM_001743 Calmodulin 2 (phosphorylase kinase, delta)        4.24 
NM_005185 Calmodulin-like 3          2.82 
NM_004344 Centrin, EF-hand protein, 2         2.66 
M25753  Cyclin B1 (CCB1)          3.89           1.63 (0.001) 
NM_003948 Cyclin-dependent kinase-like 2 (CDC2-related kinase)     -2.77 
NM_002709 protein phosphatase 1, catalytic subunit, beta isoform       2.47 
NM_002719 protein phosphatase 2, regulatory subunit B (B56),                    3.05 
                             gamma isoform 
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Cellular metabolism (carbohydrate) 
 
NM_006212  6-phosphofructo-2-kinase/fructose-2,6-biphosphatase       10.11        2.015 (0.003) 
   2 (PFKFB2) 
NM_000034 Aldolase A, fructose-bisphosphate (ADLA)         1.10          1.56 (0.016) 
NM_004273 Carbohydrate (chondroitin 6/keratan) sulfotransferase 3       -2.06 
NM_004388 Chitobiase, di-N-acetyl-            2.07 
NM_000403 Galactose-4-epimerase, UDP-          -3.93 
NM_000181 Glucuronidase, beta            2.14 
NM_000520 Hexosaminidase A (alpha polypeptide)         -2.16 
NM_004285 Hexose-6-phosphate dehydrogenase (glucose 1-dehydrogenase)     -2.29 
NM_002539 Orthinine deoxycarboxylase 1 (ODC1)    3.36           1.70 (0.007)  
Cellular metabolism (lipid) 
NM_000695 Aldehyde dehydrogenase 8           3.55 
NM_012122 Carboxylesterase 3 (brain)            3.14 
NM_001444 Fatty acid binding protein 5 (psoriasis-associated)        -3.09 
NM_005357 lipase, hormone-sensitive           -2.26 
NM_004315 N-acylsphingosine amidohydrolase (acid ceramidase) (ASAH1) -3.52     1.044 (0.852) 
NM_006229 pancreatic lipase-related protein 1           2.07 
NM_006214 phytanoyl-CoA hydroxylase (Refsum disease)        -2.46 
AF010316 prostaglandin E synthase            2.60 
NM_000329 retinal pigment epithelium-specific protein (65kD)         3.11 
 
Immunoregulation modulators and proteins 
 
NM_000410 Hemochromatosis             3.13 
J03909  Interferon, gamma-inducible protein 30           2.80 
AF029213 Interleukin 1 receptor accessory protein          -2.43 
X17543  Interleukin 9              3.53 
M65291  Interleukin 12A (natural killer cell stimulatory factor 1,          4.43 
cytotoxic lymphocyte maturation factor 1, p35) 
U03187  Interleukin 12 receptor, beta 1            2.73 
U14407  Interleukin 15              2.27 
NM_001562 Interleukin 18 (interferon-gamma-inducing factor) (IL-18)         3.06 
NM_004221 Interleukin 32 (IL32), transcript variant 2/Natural                     -2.33     2.30 (<0.001) 
                             killer cell transcript 4 
NM_012218 Interleukin enhancer binding factor 3, 90Kd          3.61 
NM_004828 lymphocyte antigen 95 (activating NK-receptor ; NK-p44)       -4.17 
NM_005516 major histocompatibility complex, class I, E          2.06 
AB004904 STAT induced STAT inhibitor 3           2.49 
 
Mitochondrial-related proteins (respiratory) 
 
NM_003945 ATPase, H+ transporting, lysosomal (vacuolar proton pump) 9Kd     4.95 
NM_004888 ATPase, H+ transporting, lysosomal (vacuolar proton pump),         -3.09 
member J 
NM_000350 ATP-binding cassette, sub-family A (ABC1), member 4          2.15 
NM_004255 Cytochrome c oxidase subunit Va            -2.19 
NM_005004 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 8           2.41 
(19kD, ASHI) 
NM_004549 NADH dehydrogenase (ubiquinone) 1, subcomplex unknown,     13.95   6.124 (0.041) 
2 (14.5kD, B14.5b) (NDFU2) 
NM_006004 ubiquinol-cytochrome c reductase hinge protein          -2.37 
NM_005662 voltage-dependent anion channel 3             2.79 
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Protein degradation mediators and modulators 
 
M26880  ubiquitin C (UBC)              5.15      1.84 (<0.001) 
NM_003349 ubiquitin-conjugating enzyme E2 variant 1 (KUA-UEV)          -2.77    1.86 (0.018) 
NM_003348 ubiquitin-conjugating enzyme E2N (homologous to yeast UBC13)  -2.03 
NM_004667 hect domain and RLD 2              2.27 
NM_012216 midline 2               2.15 
NM_003958 ring finger protein (C3HC4 type) 8             3.73 
NM_002805 proteasome (prosome, macropain) 26S subunit, ATPase, 5          2.07 
NM_002818 proteasome (prosome, macropain) activator subunit 2 (PA28 beta)    4.21 
 
Signal transduction and modulators 
 
NM_000676 Adenosine A2b receptor            -2.38 
NM_001619 Adrenergic, beta, receptor kinase 1           2.822 
NM_000684 Adrenergic, beta-1-, receptor           -2.25 
NM_000686 Angiotensin receptor 2 (AGTR2)           6.83         1.834 (<0.05) 
NM_000490 Arginine vasopressin (neurophysin II, antidiuretic hormone,        -3.66 
diabetes insipidus, neurohypophyseal) 
NM_004313 Arrestin, beta 2 (ARR2)            57.18        1.93 (0.036) 
NM_005224 AT rich interactive domain 3A (BRIGHT- like) (ARID3A)       -5.89         -1.6 (<0.001)  
NM_006340 BAI1-associated protein 2           -2.15 
NM_012295 Calcineurin binding protein 1           2.98 
NM_001741 Calcitonin/calcitonin-related polypeptide, alpha         7.87 
NM_000388 Calcium-sensing receptor (hypocalciuric hypercalcemia 1,        2.79 
severe neonatal hyperparathyroidism) 
M38690  CD9 antigen (p24)            2.41 
U03905  Chemokine (C-C motif) receptor 2           2.03 
J05081  Endothelin 3             4.43 
NM_004826 Endothelin converting enzyme-like 1         -2.17 
L08187  Epstein-Barr virus induced gene 3           3.74 
M58051  Fibroblast growth factor receptor 3            2.031 
(achondroplasia, thanatophoric dwarfism) 
NM_000806 gamma-aminobutyric acid (GABA) A receptor, alpha 1        2.67 
NM_001483 Glioblastoma amplified sequence (GBAS1)         2.00           1.83 (0.005) 
NM_002093 Glycogen synthase kinase 3 beta (GSK-3B)         3.26           1.82 (0.001) 
AF038499 Guanylate cyclase 1, soluble, beta 2          2.08 
AF005216 Janus kinase 2 (a protein tyrosine kinase)         -2.16 
NM_000894 luteinizing hormone beta polypeptide         -3.70 
NM_005563  leukemia-associated phosphoprotein p18 (stathmin) (STMN)    -5.00     -1.60 (<0.001) 
X59727  mitogen-activated protein kinase 4           2.44 
NM_004822 netrin 1             -2.29 
NM_003722 tumor protein 63 kDa with strong homology to p53         3.13 
Z15114  protein kinase C, gamma            2.04 
NM_006741 protein phosphatase 1, regulatory (inhibitor) subunit 1A        2.23 
NM_006915 retinitis pigmentosa 2 (X-linked recessive)          2.88 
NM_000539 rhodopsin (opsin 2, rod pigment) (retinitis pigmentosa 4,        6.40           2.42 (0.002) 
autosomal dominant) (RHO) 
NM_004350 runt-related transcription factor 3          2.10 
S62045  tachykinin receptor 1           2.61 
NM_003213 TEA domain family member 4         -4.20 
L12350  thrombospondin 2           2.14 
D17517  TYRO3 protein tyrosine kinase         -2.28 
NM_004704 U3 snoRNP-associated 55-kDa protein        -2.11 
NM_003574 VAMP (vesicle-associated membrane protein)-       -2.01 
associated protein A (33kD) 
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NM_004738 VAMP (vesicle-associated membrane protein)-       -3.35 
associated protein B and C 
NM_015930 vanilloid receptor-like protein 1         -2.36 
NM_003979 G protein-coupled receptor, family C, group 5,)                      3.62 
                             member A (GPRC5A 
NM_003947 Kalirin, RhoGEF kinase (KALRN), transcript variant 2      -2.59 
NM_002866 RAB3A, member RAS oncogene family (RAB3A)       -3.38          -2.02 (0.028) 
NM_004703  rabaptin, RAB GTPase binding effector protein 1 (RABEP1)  -3.34      -1.82 (<0.001) 
M22995  RAP1A, member of RAS oncogene family         2.57 
NM_175744 ras homolog gene family, member C (RHOC)        3.06 
NM_005086 sarcospan (Kras oncogene-associated gene)        -3.01 
NM_004706 Rho guanine nucleotide exchange factor (GEF) 1       -3.40 
NM_007061 CDC42 effector protein (Rho GTPase binding) 1 (CDC42EP1),     4.41 
 transcript variant 2 
 
Signal transduction and modulators (TNFR superfamily) 
 
NM_003811 tumor necrosis factor (ligand) superfamily, member 9     2.03 
U12597  TNF receptor-associated factor 2 (TRAP3)     2.04           1.70 (0.003) 
NM_004295 TNF receptor-associated factor 4 (TRAF4)     -2.01           -2.08 (0.007) 
L41690  TNFRSF1A-associated via death domain (TRADD)    6.38           2.19 (0.001) 
NM_003682  MAP-kinase activating death domain (DENN/MADD)   -3.22         -2.82 (0.023) 
U24152  p21/Cdc42/Rac1-activated kinase 1 (yeast Ste20-related)    2.11           1.54 (0.220) 
NM_003899 PAK-interacting exchange factor beta (PAK3/PIXb)    -2.04             1.16 (0.149) 
 
Transportation and Trafficking protein 
 
NM_001652 Aquaporin 6, kidney specific        2.12 
NM_006816 Endoplasmic reticulum glycoprotein      -3.67 
NM_002003 Ficolin (collagen/fibrinogen domain-containing) 1      2.08 
NM_000801 FK506-binding protein 1A (12kD)       -2.10     -1.09 (0.522) 
NM_006305 putative human HLA class II associated protein I     -2.07 
NM_007159 Sarcolemmal-associated protein        2.86 
NM_003025 SH3-domain GRB2-like 1        -2.03 
 
Transcription and transcriptional regulators 
 
U43188  E74-like factor 2 (ets domain transcription factor)       5.34 
NM_004432 ELAV (embryonic lethal, abnormal vision, Drosophila)-like 2      2.62 
NM_004956 ets variant gene 1           2.42 
NM_005243 Ewing sarcoma breakpoint region 1 (ESW1)       -3.54     -1.87 (0.012) 
NM_001436 Fibrillarin           2.14 
NM_001518 General transcription factor II, I         2.90 
NM_004499 Heterogeneous nuclear ribonucleoprotein A/B       4.93   
NM_002136 Heterogeneous nuclear ribonucleoprotein A1       2.81 
NM_005520 Heterogeneous nuclear ribonucleoprotein H1 (HNRPH1)      5.36      1.99 (0.019) 
NM_004965 High-mobility group (nonhistone chromosomal) protein 14      3.15 
NM_006898 homeo box D3           -2.55 
NM_006075 Kruppel-like factor 2 (lung)         -2.10 
NM_004235 Kruppel-like factor 4 (gut)          -2.71 
NM_001206 Kruppel-like factor 9 (KLF9)/           10.34      -1.90 (<0.001) 
Basic transcription element binding protein 1 (BTEN) 
NM_003685 KH-type splicing regulatory protein                                     -2.00  
                             (FUSE binding protein 2) (KHSRP) 
NM_016202 LDL induced EC protein            -4.06 
NM_004289 nuclear factor (erythroid-derived 2)-like 3           4.27 
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NM_015885 PCF11p homolog             -4.59 
NM_005034 polymerase (RNA) II (DNA directed) polypeptide K (7.0kD)          2.23 
NM_003075 SWI/SNF related, matrix associated, actin dependent regulator         2.81 
 
Protein related to diseases 
 
X89984  B-cell CLL/lymphoma 7A             -2.06 
NM_001707 B-cell CLL/lymphoma 7B (BCL7B)           -2.06       1.90 (0.001) 
X87212  Cathepsin C              -2.78 




X_16384 p53                                        1.78 (0.005) 
NM_018147 Fas apoptotic inhibitory molecule (FAIM), transcript variant 4        1.55 (0.138) 
NM_020529 Nuclear factor of kappa light polypeptide gene enhancer in         1.89 (0.006) 
 B-cells inhibitor, alpha (NFKBIA) 
AF_070674 human inihibitor of apoptosis protein (IAP)         1.47 (0.129) 
AF_254670 Nipah (ESTs)                                                                             1.60 (<0.001) 
NM_024865 Nanog homeobox (NANOG)               6.29 (0.011) 
AF_014955 Programmed cell death 5 (TRAF19)                            2.83 (0.023) 
NM_014330 protein phosphatase 1, regulatory (inhibitor) subunit              1.93 (0.013)  
 15A (PPP1R15A)/GADD34 
NM_062403 Insulin like factor binding protein 4 (IGFBP4)        1.45 (0.006) 
NM_005157  v-abl Abelson murine leukemia viral oncogene homolog 1        1.93 (<0.001) 
 (v-ABL1), transcript variant a 
NM_002577 p21-activated kinase 2 (PAK2)           1.16 (0.149) 
AF_042083 BH3 interacting domain death agonist (BID)                -2.15 (0.008) 
D84476 Apoptosis signal-regulating kinase 1 (ASK1)         1.92 (0.011) 
NM_139049 c-Jun N-terminal kinase 1 (JNK1)         2.08 (0.048) 
NM_138982 c-Jun N-terminal kinase 3 (JNK3)         2.05 (0.047) 
NM_002866 Rab3a, member RAS oncogene family       -1.75 (0.011) 
NM_004162 Rab5a, member RAS oncogene family         2.03 (0.003) 
AF389880 Rabconnectin3           1.86 (0.015) 
NM_000882 Natural killer cell stimulatory factor 1, cytotoxic lymphocyte maturation 
 (IL-12)                  1.71 (0.007) 
 
       
  
Column diagram showing the % of gene from cDNA expression 


















































Figure 3.Fi Bar graph showing the percentage of genes from cDNA microarray 
verified using RT real-time PCR 
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Figure 3.Fii Pie chart showing the ontology of genes showing significant pattern 
from microarray to RT real-time PCR after downregulating of DENN 
 
3.6 Western blot analysis 
 Western blot analysis was carried out in order to correlate the transcription level 
of genes with protein expression. The protein expression of DENN, TRADD, TRAF2, 
RABEP1 (Rabaptin 5), Rab3a, Rab5a, Rabphillin, caveolin-1 and ODC-1 were evaluated 
in CNE-2 after transfection of antisense DENN death domain, aDENN. They were 
compared with untreated, oligofectamine and sense DENN death domain, DENNse. 
Western blot analysis showed significant decrease in expression of DENN protein after 
transfection with aDENN. The cells transfected with DENN sense did not show any 
change in the level of DENN protein (Figure 3.G). This gave the strong evidence for the 
inhibition of the DENN by the antisense death domain. TRADD expression was 
significantly increased after aDENN transfection, which is in correlation with the 
microarray and real-time PCR results. Besides, the increase in TRADD expression 
supports the evidence for the participation of TNF pathway induced pathway apoptosis 
Pie chart shows the ontology of genes showing significant pattern from 
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and suggesting competitive interaction for the same binding site of the death domain of 
the TNF-R1. However, there was no change in the protein level of TRAF2 after antisense 
DENN death domain when compared to DENNse. 
 RAPEP1 expression showed decrease at protein level and followed the same trend 
as microarray and real-time PCR results. The decrease in rabaptin-5 level has been shown 
to result in apoptotic cell death. After DENN downregulation in CNE-2, there was slight 
downregulation of Rab5a protein level, though not significant. Other vesicle 
transportation proteins like Rab3a and Rabphilin showed no significant changes in 
protein concentrations after downregulation of DENN. No alteration in ODC1 was found 




Figure 3.G Western blot analysis of protein expression after 
48 hours of aDENN transfection in comparison with DENNse 
Western blot was performed for DENN associated molecules 
including DENN, TRADD and TRAF2 of Tumour Necrosis Factor 
(TNF) signaling pathway, regulators of vesicle transportation 
including RABAPTIN, RAB3a, RAB5a, RABPHILIN and other 
protein molecules like caveolin and ODC. The beta-actin was 
used to normalize the protein concentrations. An equal amount of 
cell lysate was loaded and the lanes represent as A-control, 
‘untreated’; B-‘oligofectamine’ cell lysate; C-DENN sense death 
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4.  DISCUSSION 
Nasopharyngeal carcinoma is highly endemic amongst male Southern Chinese 
population especially those from the Cantonese speaking group. Complication and bad 
prognosis arises with late diagnosis, usually Stage III, including local invasion to orbit, 
cranial nerves, intracranial involvement, lymph nodes and hematogous network. Early 
signs and symptoms vary from patient to patient, with frequent cold sessions to headache 
to asymptomatic. Despite the advancement of the standard radiotherapy and 
chemotherapy for NPC, there is still constant need of improving the quality of treatment. 
One of the strategies for cancer therapy is exploiting transcriptional regulation of 
potential dysregulated genes via antisense technology. 
 One of possible gene target for nasopharyngeal carcinoma is DENN 
(Differentially Expressed in Neoplastic and Normal cells). The DENN family consists of 
seven putative splice variants which are differentially expressed. The largest isoform, 
IG20 (insulinoma-glucagonoma 20) is mapped to chromosome 11p11 region and 
expanded to 36 exons when compared to DENN (Lim, 1996/1997; Chow et al., 1998; Al-
Zoubi et al., 2001). The splicing of exon 21 and 26 from IG20-Full length (IG20-FL) 
forms IG20. Subsequent mRNA splicing of IG20 generates either DENN/MADD; lacks 
exons 16, IG20-SV2 have exon 13S instead of 13L and IG20-SV3 (DENN-SV) has exon 
13S but lacking exon 16 (Figure 1.J).  Besides that, the hypothetical protein, KIAA0358 
is lacking exon 34 while the smallest member of DENN family, IG20-SV4 is spliced of 
exon 13L, 16, 21, 26 and 34.  The exon 13 of IG20 maps to exon 7 in DENN which 
contains two splicing junctions (Chow et al., 1998; Al-Zoubi et al, 2001). The shorter 
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variant harbours a deleted hydrophilic 43 amino acid region, possessing a protein C and 
tyrosine kinase phosphorylation sites.  
In the present study, we used antisense phosphorotioate oligonucleotide (PS-
ODN) fragments of 19-23 bases to target DENN transcripts and evaluate the 
mechanism(s) of apoptosis in nasopharyngeal carcinoma CNE-2 cell line. Apoptosis was 
determined by TUNEL assay, caspase-3 activity and observed in transmission electron 
microscopy. Further DNA microarray analysis from antisense DENN death domain 
treated CNE-2 cells was performed to identify specific genes interacting with DENN and 
additional genes involved in signaling pathways leading to cell death. The transcriptional 
changes from microarray results were further confirmed by real-time PCR and western 
blot analysis. 
4.1  DIFFERENTIAL DENN ISOFORMS GENE EXPRESSION LEVEL IN 
CELL LINES 
First, the relative mRNA expression of four DENN isoforms namely IG20, 
DENN, IG20-SV2 and DENN-SV were evaluated in different cancer and normal 
transformed cell lines. It is interesting to note that the cancerous cell lines showed high 
DENN and DENN-SV isoforms, but not IG20 or IG20-SV2. Besides that, lymphoma cell 
lines like U937 and HL-60 only expressed the DENN and DENN-SV isoforms. The 
differential expression patterns, concentrations and probably the mutual interactions of 
these DENN isoforms may play an important role for cell homeostasis, survival, 
proliferation and apoptosis. 
Northern blot analysis showed no expression of the IG20 group, IG20 and IG20-
SV2, in normal adult and fetal tissues (Lee, 1996, Chow and Lee, 1996; Zhang et al., 
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1998; Al-Zoubi et al., 2001). The IG20 group was detected in transformed and cancerous 
cell lines at extremely low levels. The appearance of IG20 maybe associated with 
acquired immortalization characteristic and strengthens survival ability in cancerous cell 
lines. 
DENN including DENN and DENN-SV have been demonstrated to have cell 
survival function where as IG20 and IG20-SV2 are pro-apoptotic (Al-Zoubi et al., 2001; 
Lim, 2002; Lim et al., 2002). It has been suggested that the differential expression of the 
DENN isoforms may increase the risk of any malignancy (Sellick et al., 2007). Treatment 
with antisense DENN phosphorotioate in malignant cancer cell lines like Jurkat and 
hepatoma PP5/PLC/PRF/5 showed significant reduction in cell proliferation as well as 
marked apoptosis when compared non-malignant MRC-5 transformed cell line (Lim and 
Chow, 2002). These observations were attributed to differentially higher DENN and 
DENN-SV expressions in malignant cell lines. The DENN/MADD alone and not DENN-
SV isoform has been suggested to be required for cancer cell survival (Mulherkar et al., 
2006). However, the DENN-SV overexpression in Hela cells have confers more 
resistance to tumor-necrosis factor-induced apoptosis (Al Zoubi et al., 2001), γ-
irradiation (Efimova et al., 2003) as well as chemotherapy (Efimova et al., 2004). The 
opposite observations, with increased susceptibility to apoptosis activating agents and 
enhanced caspase-8 and -3 acitivities were documented in IG20 transfected Hela cells. 
Interleukin-6 (IL-6) was suggested to be one of the requirements for growth suppression 
but not the sole contributor during apoptosis induction in Hela-IG20 (Efimova et al., 
2003). In addition to that, all three Hela clones including Hela-DENN cells also showed 
enhanced ERK and NF-κB activation upon the addition of TNFα 
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Apoptosis can be induced by TNFα in many cell lines including nasopharyngeal 
carcinoma cell line, CNE-2. Electron microscopy of CNE-2 of TNFα treated cells 
showed intact cells with destroyed mitochondria (Zhao, 1990). Besides that, the 
administration of recombinant human TNFα known as NrhTNFα with carboplatin in 
CNE-2 induced nasopharyngeal carcinoma in nude mice showed positive effect. Mice 
showed prolonged survival time, tumour regression, marked hemorrhage and cellular 
necrosis after administration (Dong et al., 1999). It has been commonly observed that 
fibroblast and epithelial cells require the presence of protein synthesis inhibitors together 
with TNFα to induce apoptosis (Sheikh and Huang, 2003). Therefore, it is postulated that 
the dysregulation of DENN by antisense phosphorotioate ODN treatment with the 
presence of TNFα could intensify the level of apoptosis in CNE-2 nasopharyngeal 
carcinoma cell line.  
4.2  TARGETING DENN GENE IN CNE-2 CELL LINE WITH ANTISENSE 
PHOSPHOROTIOATE ODNS 
Among the three highly metastatic nasopharyngeal carcinoma cell lines namely 
CNE-2: poorly differentiated NPC WHO III (Gu et al., 1982), TW01: moderate-
differentiated NPC WHO I and HK-01: well-differentiated NPC WHO I (Huang et al., 
1980), CNE-2 alone showed high expression of DENN and DENN-SV isoforms as well 
as IG20-SV2.  The IG20 expression was low in all three cell lines. The distribution of 
DENN isoforms (DENN and DENN-SV) is uniform, unlike TW01 and HK-01, which 
showed higher expression of DENN-SV alone. Hence, CNE-2 cell line was selected to 
further probe for functional role of DENN in cancer cells.  
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Epstein - Barr virus nuclear antigens were detected in the original nasopharyngeal 
carcinoma tissue where CNE-2 was isolated from. However, the expressions of EBV 
latent genes were subsequently detected until the 10th passage as a pure cell line (Gu et 
al., 1982). EBV implicated in NPC has been suggested to also promote infiltration of 
lymphocytes that further enhanced carcinogenesis. The latent genes like EBV nuclear 
antigen (EBNA) and latent membrane protein-1 (LMP1) were not detected using real-
time RT-PCR in the genome of CNE-2 cell line used in this project. This confirms the 
observation of the original isolators of CNE-2 cell line (Gu et al., 1982). The 
maintenance of the EBV genome requires an in vivo system while adaptation to culture 
environment (Tsao et al., 2006). CNE-2 is lymphoblastoid, a common feature of EBV 
transformation with high chromosome number 87-107 and modal number 104-103 
(Zhang et al., 1982). 
The use of antisense oligodeoxynucleotides (ODNs) against the gene of interest 
has been commonly employed to determine the functions of targeted gene with high 
efficiency and reproducibility. Besides that, antisense oligonucleotides have been 
aggressively promoted as an alternative, promising drug as gene cancer therapy (Orr and 
Dorr, 2005). Downregulation of DENN was compared and semi-quantified after 
transfection of antisense DENN ODNs targeting various regions namely 5’ untranslated 
region (5UTR), translational start site (AUG) and death domain (aDENN). All crossing 
points (CT) from SYBR Green based on real-time RT-PCR for DENN gene for respective 
samples were normalized using CT of HUEL gene. Among the three regions targeted 
with antisense, ‘aDENN’ which inhibit the DENN death domain, showed the most 
significant downregulation. Oligofectamine alone treated CNE-2 cells did not show any 
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changes with the maintenance of healthy cell morphology as those of untreated cells. This 
indicated that the transfecting agent does not cause toxic effect on CNE-2 cell line. 
DENNse (sense orientation of the DENN death domain) ODN served as a good negative 
control for effect of phosphorotioate chemistry (PS) in this experiment with no 
downregulation of DENN transcript and no induction of apoptosis in CNE-2 cells. 
Therefore, any morphological changes observed and detected after the transfection of the 
other antisense phosphorotioate oligonucleotides might suggest the specificity of the 
employed sequences. The phosphorotioate chemistry is a modification on the phosphate 
backbone to sulfur atoms It helps to increase nuclease resistance and subsequently induce 
RNase H activity to degrade the specific mRNA species (Zhang et al., 2005).  Lim and 
Chow, 2002 showed downregulation of DENN expression when targeting 5’ untranslated 
region (5UTR), 3’ untraslated region (3UTR), translational start site (AUG) and death 
domain (aDENN) in Jurkat cells with marked induction of apoptosis. The administration 
of antisense DENN death domain into AKR mice model with K36 induced tumours 
showed significant regression of tumour sizes and prolonged survival. Besides that, 
transmission electron micographs on aDENN treated tumours harvested from AKR mice 
showed ultrastructural changes that typified apoptosis (Lim et al., 2004). Although all the 
antisense ODNs of different regions of DENN inhibited the DENN expression, antisense 
‘aDENN’ death domain induced most prominent apoptosis. 
4.3  QUALITATIVE & QUANTITATIVE MEASUREMENTS OF APOPTOSIS 
INDUCTION IN CNE-2 AFTER aDENN ODN TRANSFECTION 
The induction of apoptosis in CNE-2 cells after transfection with antisense against 
DENN was evaluated by TUNEL DNA fragmentation assay. Antisense against death 
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domain ‘aDENN’ showed highest TUNEL positive cells compared to other DENN anti-
sense PS-ODNs. These observations are in concurrence with the previous studies in 
different cell lines where antisense aDENN also showed the highest cell death induction 
compared the rest (Lim and Chow, 2002, Lim et al., 2004). Thus, these data suggested 
that DENN may have role in signaling pathways leading towards cell death. The blocking 
of DENN expression with antisense against death domain showed most significantly 
TUNEL positive cells indicated that this particular region in DENN may have a key role 
in regulating cell survival. The earlier studies from this laboratory showed that the 
overexpression of a partial DENN fragment including the death domain at the C terminal 
showed enhanced cell proliferation and could reverse the apoptotic effect of antisense 
aDENN and staurosporine treatment in Jurkat (Lim, 2002). Schievella et al., 1997 
demonstrated that the overexpression of death domain sequence of DENN (amino acid 
1281-1356) alone interacted with TNFR1 via its death domain. This further stimulateed 
the activities of ERK and JNK as well as induces the phosphorylation of cytosolic 
phospholipase A2 (cPLA2), leading to the release of arachidonic acid. On the other hand, 
the overexpression of full length DENN induces the ERK activity only (Schievella et al. 
1997). This observation suggested that the N-terminal of MADD function as a negative 
regulatory domain for JNK activation.  This is independent of TNF activation, these 
enzymes further activates transcription factors such as AP-1 and ATF-2, with 
concomitant downstream effects. The activation of MAP kinase upon TNF activation via 
DENN molecule may subsequently influences many cellular responses such as regulation 
of gene expression, proliferation and apoptosis (Chang and Karim 2001; Rao 2001). 
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Electron microscopy was used to further evaluate the apoptotic cell death in 
antisense treated CNE-2 cells for possible morphological and intracellular changes. The 
apoptotic changes observed were mitochondria damge with the disappearance of cristea 
with significant size shrinkage. Besides that, massive ‘shredding’ of cellular membrane 
was prominent after anti-sense treatment. Cells treated with oligofectamine alone and 
DENNse did not show any cytopathological effects. They maintained similar cell 
morphology observed in untreated cells. 
Based on these results, human cDNA microarray was carried out to understand 
the mechanisms of apoptosis after transfecting with antisense against DENN death 
domain in comparison to DENNse PS-ODN. 
4.4  TRANSCRIPTOMIC PATHWAYS OF APOPTOSIS ACTIVATED BY DENN 
In the present study, we performed cDNA microarray to evaluate the expression 
profile of different genes involved in DENN downregulation mediated signaling leading 
to cell death and to identify novel genes interacting with DENN cell signaling pathway. 
Total RNA isolated from control DENNse and aDENN antisense transfected CNE-2 cells 
were converted into cDNA before performing cDNA microarray slides. From the 
microarray analysis, altered genes were classified them according to their functional 
roles. Genes involved in signal transduction was the distinguished groups of altered 
genes. Others included genes involved in cellular metabolism, immune-modulation, 
adhesion and trafficking, transcription factors and cell cycle regulation.  
DENN binds to TNFR1 affecting TRADD expression 
TNFα exerts its action through two receptors including the ubiquitously expressed 
TNF receptor 1 (TNFR1) or p55 and TNFR2 or p75 in neuronal cells. The canonical view 
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involves the activation of TNFR1 promotes the binding of TRADD to TNFR1 and 
subsequent recruitment several adaptor molecules that results in apoptosis, JNK and NF-
kB activation (Hsu et al., 1996a; b). It has been widely accepted that the formation of 
DISC takes place upon the activation of TNFR1 with the recruitment of TRADD, Fas-
associated death domain (FADD) protein, caspase 8 or 10 that results in the induction 
apoptosis. When TRADD binds to either receptor-interacting protein (RIP) or TNFR 
associated factor 2 (TRAF-2), antiapoptotic effect of TNF is mediated by NF-κB 
activation that enhanced cell survival via the production of inflammatory mediators 
(Chen and Goeddel, 2002).  
The blocking of DENN gene with antisense significantly decreased the expression 
of both mRNA transcripts and protein level of DENN. Concomintantly, there was also 
upregulation TRADD from mRNA expression down to protein level. Downstream of 
TRADD, TRAP3/TRAF2 showed upregulation while TRAP4 exhibited dowregulation at 
the gene expression level after antisense DENN inhibition from microarray and real-time 
RT-PCR data. Bioinformatics matching have shown that TRAP3 is identical to TRAF2. 
However, downstream signaling molecule like TRAF2 showed no significant changes at 
protein level. Both TRAP3/TRAF2 and TRAF4 shares strong homology at RING ZINC 
finger and TRAF domain that plays a role in downstream signaling pathway (Lee and 
Lee, 2002). 
Thus, these observations further supported the association of DENN with tumour 
necrosis factor superfamily (TNF) pathway in inducing apoptosis. All four DENN 
isoforms interacts with TNF-R1 via the death domain (Schievella et al., 1997; Al-Zoubi 
et al., 2001; MacEwan, 2002). DENN has been previously shown to be associated with 
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the TNFα by sharing identical amino acid that are critical for proper binding and believed 
to be responsible for the biological acitivity based on bioinformatics analysis (Chow et 
al., 1998).  
There is a competition between TRADD and DENN/MADD for the same death 
domain of the TNF-R1 which affected expression level of the mRNA transcripts and 
subsequently down to protein. In neuronal cell culture, N2A cells, strong TNF-R1-DENN 
interaction was capable of blocking the TNF-R1-TRADD interactions which is capable 
of TRADD-induced apoptosis. Besides that, there was significant downregulation of 
DENN gene with upregulation of TNF-R1 protein, TRADD and downregulation of 
TRAF2 proteins in the hippocampal tissues of Alzheimer’ patients when compared to 
healthy controls. Similar observations in Alzheimer’s disease (AD) transgenic, Tg2576 
APP overexpressing amyloid precursor protein, showed downregulated DENN and 
upregulated TRADD (Del Villar and Miller, 2004). Patented small molecule, CEP-1347, 
is capable of modulating the expression of DENN and its interaction with TNFR1, thus 
suggested to be used for treating neurological disorder 10 . Besides that, downstream 
interacting proteins like FADD and RIP expression remained unchanged in these 
neuronal tissues. Upstream signal transduction molecules like Fas, FADD and Fas 
apoptosis inhibiting molecule (FAIM) showed little or no association with DENN 
(Schievella et al., 1997). In this study, the real-time RT-PCR of the expression of FAIM 
was not affected during apoptosis with the downregulation of DENN isoforms.  
Abrogation of DENN using the antisense phosphorotioate oligonucleotide 
targeting the death domain in Jurkat cells showed alternation of the expression of gene 
involved in apoptosis. There were upregulation of Fas, TNF-R2, TRAIL and 




downregulation of TNFα, TNF-R1 and cyclin D3. On the other hand, overexpression of 
DENN isoform in Jurkat showed otherwise. DENN expression is intimately 
interconnected with the TNF pathway. Thus, there might be a feedback-loop in the 
regulation of TNF receptors (Lim et al., 2004). Overexpression of proapoptotic IG20 in 
Hela rendered cells more susceptible to TRAIL-induced apoptosis with recruitment of 
FADD and caspase-8 to the DISC complex (Ramaswamy et al., 2004). Downregulation 
of MADD showed similar susceptibility to ‘spontaneous’ and TRAIL induced apoptosis 
with caspase-8 activity without apparent recruitment of the DISC (Mulkerkar et al., 
2007).  
Based on these results, we proposed a signaling pathway for DENN involvement 
in tumour necrosis factor pathway leading to apoptosis as depicted in Figure 4.A. The 
downregulation of DENN further activated TRADD mediated pathway can be the 
possible cause of apoptotic death observed in the present model. In addition, there might 
be the involvement of other signaling pathways that also might support apoptotic cell 

































DENN affects the equilibrium of the endocytosis and exocytosis 
 DENN/MADD has been shown to have an important physiological role in 
exocytosis by regulating the Rab3, small G proteins between GDP- and GTP- bound 
forms. It plays a role as a Rab3 GDP/GTP exchange protein (Rab3 GEF) that is 
implicated in Ca2+ dependent exocytosis especially in facilitating the release of 
neurotransmitter (Wada et al., 1997; Sakisaka and Takai, 2005). The Rab3 GEP is 
essential for neonatal survival as knockout mice died immediately after birth due to acute 
respiratory failure (Tanaka et al., 2001). There was no evidence of the embryonic 
lethality indicating DENN/MADD is not involved in mouse embryonic development. At 
E18.5, embryos of Rab3 GEP-/- had no impairment of axonal conduction of spinal cord 
and the phrenic nerves. There was a significant reduction of synaptic vesicles at the 
neuromuscular junction compared to controls. From these observations, there might be a 
possibility of involvement of Rab proteins in the apoptosis of CNE-2 cells in DENN 
function as a Rab3a GDP/GTP exchange factor (GEF) protein. 
RabGEF is one of the regulators proteins of Rab3 where the literature is mainly 
referring of Rab3a. There is another two Rab3 regulators: Rab GDP dissociation inhibitor 
(GDI), Rab GTPase-activating protein (GAP) while Rabphilin is one of the downstream 
target or effector protein of Rab3 (Sudhof, 2004). During the transportation of vesicles 
from cytosol to membrane, it requires lipid modified Rab3a-GTP bound to Rabphilin for 
association with synaptic vesicles (Jin-no et al., 1997) as shown in Figure 4.B.  
Both Rab3a and Rab5 have undergone geranylgeranylation or lipid 
postmodication at adjacent residues for recognition and transportation of these proteins to 
their respective target membrane (Farnsworth et al., 1994; Ulrich et al., 1994). 
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Subsequently, Rab proteins like Rab3a and Rab5 cycled between cytosolic GDP (inactive 
form) to membrane associated GTP form (activated), with the regulation of GEF 
proteins; Rab3A GEP/DENN and Rabaptin 5/Rab GTPase binding effector protein 1 
(RABEP1) respectively. One of the downstream regulating effector molecules that might 
be involved in exocytosis and endocytosis, Rabphilin3 binds to GTP-Rab3A and interacts 
with Rabaptin 5 at N-terminal at amino acid 1-280 (Ohya et al., 1998).  
These was downregulation of Rab3a, Rabaptin-5 and upregulation of Rab5a at 
mRNA level after the inhibition of DENN/Rab3 GEF using antisense DENN death 
domain from microarray analysis. At protein level, there is downregulation of Rab5 and 
Rabaptin 5 at protein level thus suggesting the disturbance in both endocytosis and 
exocytosis may occur thus leading to cell death. However, there were no changes in the 
protein level of Rab3a and Rabphilin despite the downregulation of Rab3 GEP/DENN 
protein. Cultured hippocampal neurons from Rab3 GEF knout-out mice showed that it 
might be playing a role in the priming of vesicle during postdocking processs which is 
distinctively from Rab3a protein; Ca2+ triggered fusion of these synaptic vesicles 
(Yamaguchi et al., 2002). On the other hand, Rabphilin knout-out mice revealed that 
Rabphilin is not required for Rab3a function in regulating neurotransmitter release but 
endowed with the properties of an effector (Schluter et al., 1999).  
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 The downregulation of Rabaptin-5 which is an essential and rate-limiting 
component of endosome fusion has been implicated in apoptotic cell death. The 
dissociated Rabphilin from Rab3a, it interacts with Rabaptin 5 to promote endocytosis 
(Coppola et al., 2001). Since Rabaptin 5 play a regulator role by stabilizing the complex 
Rab5-GTP formation, the downregulation of both would definitely reduce the rate of 
endocytosis pathway. This was observed in immunodepletion of Rabaptin 5 is a novel 
early fusion (Stenmark et al., 1995). Besides that, Rabaptin 5 is also a novel caspase-3 
substrate during apoptosis where inactivation of Rabaptin 5 leads to fragementation of 
endosomes and inhibition of endocytotic pathway (Sabina et al., 1997; Cosulich et al., 
1997). These disturbances in both exocytosis as well as endocytosis organization after the 
downregulation of DENN/Rab3 GEP are likely to contribute to cell death. 
Figure 4.B Individual Rab proteins are associated with distinct intracellular 
compartments: Left: proposed molecular model for DENN signaling as a Rab3A GEF 
protein in the regulation of apoptosis (Adapted from Ohya et al., 1998). Right: Rab5 is 
localized in trafficking from plasma membrane to early endosomes while Rab3a is found 
predominantly in donor compartment – exocytosis of secretory granules, neurotransmitter 
(Tuvim et al., 2001). 
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DENN affecting other signal transduction 
The upregulation of caveolin-1 was observed in microarray analysis and further 
confirmed by both real-time PCR and western blot analysis. Caveolin-1 is involved in the 
caveolea formation, vesicle transport (transcytosis, endocytosis and pinocytosis) and 
implicated in the pathogenesis of oncogenic cell transformation, tumorigenesis and 
metastasis (Razani et al., 2002). Caveolin1 has been shown to have tumor suppressor 
function through different signaling intermediates such as EGF tyrosine kinase, PDGF 
receptor tyrosine kinase and Src tyrosine kinase (Smart et al., 1999). The increase in 
caveolin-1 expression has been shown to induce apoptosis in macrophages. The induction 
of caveolin-1 increase the externalization of phosphatidylserine (PS) and cause apoptotic 
death independent of caspase activation and nuclear DNA fragmentation (Gargalovic and 
Dory, 2003). 
β-arrestin2, a regulatory protein located within the membrane or intracellular 
membrane along with G-protein-coupled receptor kinases (GPCR) and G protein. It is 
involved in the termination of the activation of GPCR action via phosphorylation, 
desensitization and internalization of the receptor (Pierce et al., 2002). During receptor 
internalization, β-arrestin2 functions as endocytic adaptor that links receptors to clarithin-
coated pits (Luttrell and Lefkowtiz, 2002). Besides, arrestins also bind and scaffold 
member members of the signal transduction cascade of mitogen-activated protein kinases 
(Shenoy and Lefkowitz, 2005). The downregulation of DENN resulted in the 
upregulation of β-arrestin2 but also upstream GPCR like angiotensin receptor 2 (AGTR2) 
that activates the MAPK extracellular kinase 1 and 2 pathways (Ahn et al., 2004). The 
overexpression of AGTR2 association with breast disease suggested its contribution to 
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breast cancer aetiology with increase iNOS expression (De Paepe et al., 2002). AGTR2 
has been implicated in programmed cell death (Yamada et al., 1996) with the interaction 
of AGTR2 with ceramide, a secondary lipid messenger involved in cytokine-induced 
apoptosis (Berry et al., 2001). Close family member of β-arrestin2 called visual arrrestin 
interacts with rhopdopsin (Oakley et al., 2000) that was upregulated in this microarray.  
Stable interaction between Drosophila arrestin2 with phosphorylated rhodopsin complex 
leads to endocytosis. Dysregulation of these proteins would lead a defect of the 
endocytosis but also extensive cellular degeneration and necrotic cell death (Acharya et 
al., 2003). 
The stimulation of beta-adrenergic receptor leads to the requirement of beta-
arrestin, adaptor proteins leading to a dynamic actin cytoskeleton arrangement for 
endocytosis (Volovyk et al., 2006). There is upregulation of beta-adrenegic receptor 
kinase 1 and downregulation of beta-adrenergic receptor after DENN downregulation 
with the upregulation caveolin-1 at mRNA and protein level.  
The contribution of glycolysis to cancer progression or an adaptation to the 
generate more energy has been described as the ‘Warburg’ effect (Garber, 2004). Cancers 
cells have upregulated glycolysis where increased glucose consumption for the fueling of 
other mechanisms like invasiveness and metastatic behaviour (Gatenby and Gillies, 
2004).  However, the glycolysis is an inefficient where 2 ATPs per glucose is produced 
when compared to 38 ATPs per glucose in complete oxidation process. The anaerobic 
metabolism as a result of glycolysis produces hydrogen ions (H+), oxides species that 
causes the acidification of extracellular with accumulation would lead to cellular toxicity 
and finally apoptosis (Schomack and Gillies, 2003). The expression of bifunctional 
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enzyme 6-phosphofructo-2-kinase [EC 2.7.1.105]/fructose-2,6-biphosphatase 2 [EC 
3.1.3.46], which catalyzes the synthesis and degradation of fructose-2, 6-biphosphate (F2, 
6-BP) is increased after antisense DENN death domain. F2, 6-BP is a key regulatory 
molecule that control of glycolysis. The biphosphatase domain of 6-phosphofructo-2-
kinase/fructose-2, 6-biphosphatase exhibited a structural similarity with phosphoglycerate 
mutase 2 (PGAM2) (EC 5.4.2.1) (Tauler et al., 1987). PGAM2 is isomerase shows higher 
level in breast cancers estrogen/progresterone receptors negative breast tumours and it is 
not regulated by steroid hormones (Durany et al., 2000). PGAM was upregulated in 
microarray analysis after the downregulation of DENN. 
Aldolase A (EC 4.1.2.13) or fructose-1, 6-biphosphate aldolase catalyzed the 
conversion of fructose-1, 6-biphosphate to gleceraldehyde-3-phopshate and 
didhydroxyacetone phosphate which part of the glycolysis. The aldolase A is 
downregulated in microarray after the blocking of DENN treated cells with significant 
upregulated in real-time PCR. The upregulation of aldolase A has constantly associated 
with various types of carcinoma especially liver carcinoma, lung carcinoma as an early 
state cancer marker (Li et al., 2006). 
All three enzymes; 6-phosphofructo-2-kinase/fructose-2, 6-biphosphatase 2, 
fructose-1, 6-biphosphate aldolase or aldolase A and phosphoglycerate mutase 2 were 
affected and elevated by glucose consumption and lactate production in the presence of 
oxygen. The elevated of glycolysis may affect the substrate levels for the tricarboxylic 
acid cycle and the subsequent oxidative phosphorylation; in turn the ATP levels as well 
the production of reactive of oxidative species (Jeong et al., 2003). The downregulation 
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of DENN might have led to accelerate the glycolysis pathway to anaerobic respiration 
that subsequently induced oxidative stress leading to apoptosis.  
There was disturbance of oxidative phosphorylation in mitochondria with the 
upregulation of complex I namely NADH dehydrogenase (ubiquinone) 1, subcomplex 
unknown 2 and beta subcomplex 8 after the downregulation of DENN. The 
overexpression of NADH dehydrogenase subunit 2 (ND2) contributed to CNE-2 drug 
resistant towards ciplastin (Jiang et al., 2003). Besides, that ATPase H+ transporting 
lysosomal (vascular proton pumps), located at the complex V was also altered. These 
pumps belong to a multisubunit enzyme that mediates acidification of eukaryotic 
organelles like protein sorting, zymogen activation, receptor-mediated endocytosis as 
well as synaptic vesicle proton gradient generation. This is leads upregulated of the 
respiratory chain located at the mitochondria would lead to the production of reactive 
oxygen metabolites like superoxide and hydroxyl radicals. The excessive production of 
reactive metabolites causes lipid peroxidation, DNA damage and protein oxidation that 
would have been signals for the induction of apoptosis. Thus, the mitochondrion is a 
major organelle that controls apoptosis; alterations in expression of mitochondrial genes 
may be involved in the regulation of apoptosis. This is supports the suggestion made by 
Del Villar and Miller, 2004, that DENN blocks TRADD interaction with TNF-R1 and 
protects neuronal cells from death by oxidative stresses. In summary, the Figure 4.C 
shows different possible signaling pathways contributing to apoptotic cell death in CNE-
2 after downregulating DENN. 
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Figure 4.C Summary proposed model of suggested pathways of apoptosis induced by 
DENN gene downregulation in epithelial cells 
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5. SUMMARY AND CONCLUSIONS 
Nasopharyngeal carcinoma (NPC) is a distinct malignant tumor of head and neck 
tumor which is highly endemic in especially Southern Chinese population. The difficulty 
of diagnosis at early stages of NPC due to its location of origin can be diagnosed only at 
the late stage III. Although current treatment of radiotherapy and chemotherapy are 
effective, cause severe adverse effects thus affecting the quality of life of patients. In 
search of more specific medication for NPC, novel approaches for the treatment have 
been extensively investigated. The gene therapy by targeting specific genes involved in 
cancer is currently under investigation in a variety of cancer models. DENN 
(Differentially expressed in normal and neoplastics cells) interacts with tumor necrosis 
factor receptor 1 (TNF-R1) through their death domain (C-terminal region), that leads to 
activation in MAPK pathway and downstream transcription molecules. The DENN 
family consist of anti-apoptotic DENN-SV, pro-survival DENN, and pro-apoptotic (IG20 
and IG20-SV2) isoforms.  
 CNE-2 is a unique poorly differentiated nasopharyngeal carcinoma cell line. All 
four isoforms of DENN are presence in CNE-2 cells at different expression levels where 
the pro-survival DENN isoforms (DENN and DENN-SV) are prominently higher that the 
pro-apoptotic IG20 and IG20-SV2. This is compared to gene expression observed in 
other of nasopharyngeal cell lines like TW-01 and HK-1.   
In the present study, we evaluated the effect of different antisense PS-ODNs 
targeting different regions of DENN including the 5’ untranslated region (5UTR), 
translation start codon (AUG) and DENN death domain (aDENN) on the expression of 
DENN gene. Sense orientation of DENN death domain (DENNse) was used as control. 
 123 
The induction of apoptosis was evaluated by semi-quantitative real-time PCR, TUNEL 
microscopy detection and active caspase-3 FITC assay. The overall changes of the gene 
expression level upon transfection of aDENN in contrast to DENNse after apoptosis were 
arrayed in microarray. Confirmatory real-time RT-PCR data and western blot of selected 
genes from the microarray supported these observations. 
 
 The major observations o these studies include: 
 
  Among the three antisense PS-ODNs inhibiting different regions of DENN, 
aDENN was adapted at 0.4 µM as the most effective ODN in the downregulation of 
DENN to 2.8 fold at mRNA level and 6 fold for protein expression in CNE-2 cells.  
There was significant and prominent observation of TUNEL positive cells of 
approximately 20% after 48hours transfection of aDENN PS-ODN.  This was supported 
with the apoptotic features observed in transmission electron microscopy, the activation 
of activation of caspase-3, an important executer of apoptosis and the downregulation of 
proliferation cells nuclear antigen (PCNA) by western blot analysis. 
  DNA microarray comparing DENNse reference sample to aDENN showed 
involvement of DENN involvement of signaling pathway leading to apoptotic cell death. 
The blocking of DENN lead to significant upregulation of TNF-R1 death domain 
competitor, TRADD and TNF receptor associated factors, which further may stimulate 
the downstream signaling molecules leading to apoptosis.  
  Besides TNF mediated apoptotic pathway we identified decrease of other 
signaling molecules such as RABEP1/Rabaptin5, which is an essential component of 
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endosome fusion. The decrease in rabaptin-5 has been demonstrated to cause the loss of 
fusion activity, which ultimately leads to apoptosis. These results may suggest the 
coupling of endocytosis (Rab5) to Rab3a that is hydrolyzed to its active form with the 
conversion to GTP by Rab3a GEP which DENN/MADD in this context.  
  In conclusion the employment of antisense oligodeoxynucleotide targeting the 
death domain of DENN isoforms in nasopharyngeal carcinoma CNE-2 cell line model 
showed promising results by inducing of apoptosis. These studies suggested a novel 
approach of antisense treatment of DENN for nasopharyngeal carcinoma. 
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6.  FUTURE DIRECTIONS 
1.   Improvement of the efficacy of antisense phosphorotioate oligonucleotide 
The observations from this antisense phosphorotioate oligonucleotide aDENN targeting 
the death domain of the DENN gene provide some preliminary understanding of the role 
of DENN in nasopharyngeal carcinoma. Antisense technology has expanded to different 
chemical modifications and mechanisms of inhibiting gene expression. One new gene 
therapy approach is exploiting small interfering RNA (siRNAs) (Zhang et al., 2005). 
siRNA of DENN death domain may be more effective in inhibiting gene expression. 
Besides that, the high specificity of siRNA can be incorporated to downregulate specific 
groups of isoforms e.g.either the DENN (DENN and DENN-SV) or IG20 (IG20 and 
IG20-SV2). Such experiment would be challenging to target mRNA of large size, thus 
proper negative controls (scrambled and missense siRNA) must be included. Besides 
that, sensitive detection method like real-time PCR can be employed to differentiate the 
various isoforms. 
 
2.  Expansion of cell culture work of DENN silencing to nude mouse model 
 Though the cell culture of CNE-2 provides a convenient and fast model to study the 
effect of DENN silencing, it has some disadvantages. Monolayer, pure cell culture does 
not reflect the true nature and interactions of the solid tumour with its surrounding 
tissues. Besides that, the toxicity level (especially towards healthy tissues) and side-
effects can only be studied in whole animals like nude mice. For nasopharyngeal 
carcinoma, CNE-2 can be injected onto nude mice to induce the formation of solid 
tumour in a short period of time. The administration of antisense DENN, targeting the 
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death domain with suitable delivery agents can give a more in-depth understanding of the 
its function.  
 
3.   Development of specific antibody for respective splice variants of DENN 
Interestingly, the estimated size of DENN is 176kDa but the detected size is 
approximately 200 to 220kDa. Specific antibody for each isoform of DENN is not 
available commercially.  The availability of these antibodies can facilitate further 
research on DENN protein expression. Immunostaining of the DENN protein expression 
level and location can be studied in cell lines and tissues sections of human carcinomas. 
Besides that, the association of DENN in different histopathological stages of carcinomas 
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7. APPENDICES 
APPENDIX 1: NASOPHARYNGEAL CARCINOMA 
1.1 Age-standardized (world) incidence rates of nasopharyngeal cancer in selected 
populations 
Incidence rate (per 100,000 person-years) Region and population (if 
applicable) Years Males Females 
China and East Asia ’93-’97     
China, Hong Kong 1997 21.4 8.3 
China, Taiwan ’93-’97 8.9 3.4 
China, Shanghai ’93-’97 4.2 1.5 
China, Tianjin ’93-’97 1.7 0.5 
China, Beijing ’93-’97 1.0 0.6 
Japan, Osaka prefecture ’93-’97 0.5 0.1 
Korea, Seoul ’93-’97 1.0 0.3 
Southeast Asia 
      
Singapore, Chinese ’98-02 12.5 4.2 
Singapore, Malay ’98-03 5.7 2.0 
Singaporem, Indian ’98-‘04 1.5 0.1 
Malaysia, Sarawak Bidayuh (native) ’96-‘98 31.5 11.8 
Malaysia, Sarawak Chinese ’96-‘98 12.0 4.1 
Malaysia, Sarawak Malay ’96-‘98 7.8 1.9 
Vietnam, Hanoi ’93-’97 10.4 4.6 
Vietnam, Ho Chi Minh City ’95-‘97 4.8 1.7 
Thailand, Bangkok ’95-‘97 4.5 1.6 
Philippines, Manila ’93-’97 7.2 2.5 
Asia and Asia Pacific region 
   
India, Madras 1992 0.7 0.4 
Australia, New South Wales 1992 0.8 0.2 
New Zealand, Maori 1992 1.2 0.0 
New Zealand, Non Maori 1992 0.5 0.3 
Arctic 
     
Canada, Northwest Territories ’83-‘97 8.2 6.0 
Greenland, native ‘92-‘02 12.7 9.2 
United States, Alaska native ‘92-‘02 7.8 2.4 
Middle East/North Africa 
      
Algeri, Algiers ’93-’97 2.7 1.3 
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Israel, Jews born in Africa or Asia ’93-’97 1.4 1.9 
Israel, non-Jews ’93-’97 1.0 0.5 
Kuwait, Kuwaitis ‘94-‘97 2.6 0.9 
Kuwait, non-Kuwaitis ‘94-‘97 0.5 0.4 
North America 
     
Canada ’93-’97 0.8 0.3 
United States, White ’98-‘02 0.4 0.2 
United States, Black ’98-‘02 0.8 0.3 
United States, Hawaii Chinese ’93-’97 10.7 3.8 
United States, Hawaii Filipino ’93-’97 3.5 1.5 
United States, Hawaii native ’93-’97 1.3 0.9 
United States, Los Angeles Chinese ‘93-’97 7.6 2.4 
United States, Los Angeles Filipino ’93-’97 3.7 1.6 
European 
   
UK, all ’93-’97 0.2 0.1 
Denmark, Danish ’93-’97 0.7 0.3 
Adapted by Chang and Adami, 2006, summarized from following references: McDermott 
et al., 2001; Albeck et al., 1992; Parkin et al., 2002; Seow et al., 2004; Devi et al., 2004; 
http://seer.cancer.gov/ 
1.2 Epstein-Barr virus 
(EBV)  
Source: Young and Murray, 2003 
(a) Diagram showing the 
location and transcription of 
the EBV latent genes on the 
double-stranded viral DNA 
episome where the origin of 
plasmid replication (oriP). 
The large solid blocks and 
arrows show represent 
coding exons and direction 
in which they are transcribed 
for each of 6 nuclear 
antigens (EBNAs 1, 2, 3A, 3B, 3C and EBNA-LP) 3 latent membrane proteins 
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(LMPs 1, 2A, 2B) and highly transcribed nonpolyadenylated RNAs EBER1 and 
EBER2 (top). 
(b) Diagram showing the location of ORFs for EBV latent proteins on a BamHI 
restriction endonuclease map of the prototype B95.8 EBV genome  
Expression of EBV latent genes in disease 
Pattern of 
latency EBNA-1 EBNA-2 EBNA-3 LMP-1 LMP-2 EBER Disease 
Type I + - - - - + Burkitt's lymphoma 
Type II + - - + + + 
Nasopharyngeal carcinoma,  
Hodgkin's disease,  
peripheral T-cell lymphoma 
Type III + + + + + + 
Lymphoproliferative diseas,  
X-linked lymphoproliferative disease,  
infectious mononucleosis 
Other ± - - - + + Healthy carrier 
Source: Cohen, 2000 
 
EBV gene nomenclature and functions  
 
Names Function 
EBNA1 EBV plasmid replication and maintenance 
EBNA2 Transcription factor, Notch pathwaym binds RBP-JK 
EBNA3A, EBNA3 Transcription repressor, binds RBP-JK 
EBNA3B, EBNA4 Unknown, binds RBP-JK 
EBNA3C, EBNA6 Transcription repressor, binds RBP-JK, cell cycle effects 
EBNALP, EBNA5 Cooperates with EBNA2 in transcription 
LMP1 Signals through TRADD and TRAFs to NF-kB and JNK 
LMP2A, TP-1 Blocks Lyn and Fyn, prevents virus reactivation 
LMP2B, TP-2 Unknown 
CST,BARTs, BARF0 Unknown 







APPENDIX 2: REAGENT FOR CELL CULTURE 
2.1 Growth and maintenance media 
2.1.1 RPMI 1640 (Sigma R4130) HEPES modification with L-glutamine and 25mM 
HEPES, without sodium bicarbonate 16.4g/L (powdered) 10x 1L 
This powdered RPMI 1640 was reconstituted with 1000ml double-distilled water (tissue 
culture grade) and supplemented with additional 2g sodium bicarbonate before filter 
sterilized with 22µm disc filter-syringe and stored in 4°C. 
2.1.2 Fetal Bovine Serum (FBS) 
FBS was inactivated by heating at 56ºC for 30min, aliquoted into sterile 100ml universal 
bottles and stored at -20ºC. 
2.1.3 10X Phosphate Buffered Saline (PBS), pH 7.4 
per litre 
Sodium chloride NaCl (FW 58.44)       80.0g 
Potassium chloride KCl (FW 74.55)      2.0g 
Potassium phosphate monobasic KH2PO4 (FW 136.1)   2.0g 
Potassium phosphate dibasic Na2HPO4 (FW 174.2)    11.5g 
To prepare the 10x PBS stock solution, the constituents were added and dissolved to 
900ml nanopure water and pH adjusted to 7.4. The solution was top up to 1L and 
autoclaved at 121ºC for 15min. The stock solution was stored at room temperature. 
To prepare the working 1x PBS, 10x PBS stock solution was diluted 1:10 with nanopure 
water. The solution was filtered sterilized with 0.22µM bell filter. 
2.1.4 Trypsin/EDTA solution 
To prepare to 1X, 10X stock trypsin-EDTA was diluted 1:10 with nanopure water and 
filtered sterilized with 0.22uM filter. The filtered solution was aliquoted into sterile 50ml 
centrifuge tube and stored at -20ºC. 
2.1.5  200mM L-glutamine solution (Sigma Cat. No. G8415, Biotechnology Performance 
Certified) C5H9NO4 FW145.13 
  1M C5H9NO4 = 145.13 g in 1000ml ddH20 
               = 14.513 g in 100ml 
  200mM C5H9NO4 =2.9026g in 100ml ddH20 
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To prepare 200mM C5H9NO4, dissolve 2.9g C5H9NO4 in ddH20.  The solution was 
filtered using 0.22µm disc filter-syringe, stored in -20°C. 
2.1.6 100mM sodium pyruvate solution (Sigma Cat No. GP4562, Embryo Culture 
tested)  C3H9NaO4 FW 110.04 
  1M C3H9NaO4 = 110.04 g in 1000ml ddH20 
     = 11.004 g in 100ml  
  100mM C3H9NaO4 = 1.1004 g in 100ml ddH20 
To prepare 100mM C3H9NaO4, dissolve 1.1g C3H9NaO4 in ddH20.  The solution was 
filtered using 0. 22µm disc filter-syringe and stored in -20°C. 
2.2       Transfection of cells 
2.2.1    Transfection protocol for Oligofectamine 
Oligofectamine (Invitrogen, Cat. No. 12252-011) is a proprietary formulation for the 
transfection of oligonucleotides and short interfering RNA (siRNA) into eukaryotic cells.  
The formulation enhances its stability at cold temperature and provides highest specific 
activity and lowest non-specific effect on cell growth.  The following table is given as a 
thumb of rule for scaling up experiment for Oligofectamine transfection. 
The next table shows optimized transfection using Oligofectamine for transfecting CNE-
2 seeded in T25 flask. 
 Reagent A (ODNs) Reagent B (Transfection agent) 




Vol. of Oligofectamine  
(µl) 
Vol. of  
OPTI-MEM (µl) 
Oligofectamine - 550 µl 5 µl 45µl 
DENNse 12 µl 538 5 45 
aDENN 12 538 5 45 
5UTR 12 538 5 45 
AUG 12 538 5 45 
Total vol. of reagents 
for each treatment 
550 µl 50 µl 
Reagent A and B were incubated in respective 2.2ml tubes at 37°C for 5mins.  Next, 50 
µl reagent B was pipetted into A and incubated for another 20mins, 37°C.  Meanwhile, 
spent media was removed from flask before adding 2.5 ml of OPTI-MEM 1 serum free 
media.  Then, reagent AB mix was pipetted into respective flask for transfection.  The 
cells were incubated at 37ºC, 5% CO2, 95% humidity for 6 hours before replacing media 
with fresh NPC media.   
 165 
APPENDIX 3: REAGENT USED IN MANIPULATION OF NUCLEIC ACID 
3.1 RNA denaturing agarose gel electrophoresis 
2.1.1 Diethylpyrocarbonate (DEPC) treated dH20 
To make 1L of DEPC treated (RNAse-free) water, 1ml of DEPC (Sigma) was to add to 
1L of ddH20 for final 0.1% (v/v). The treated water was incubated overnight at room 
temperature with stirring. The water used for treatment for pipette tips for RNA 
extractions and then autoclaved at 121ºC for 15min. 
2.1.2 10X Formaldehyde-agarose (FA) gel buffer 
3-[N-morpholino]propanesulfonic acid (MOPS) (free acid)             200mM 
Sodium acetate C2H3NaO2  FW82.03      50mM 
Ethylenediaminetetraacetic acid EDTA (FW 292.2)    10mM 
pH to 7.0 with Sodium hydroxide NaOH (FW 40) 
2.1.3 1X formaldehyde-agarose (FA) gel running buffer 
10X FA gel buffer        100ml 
37% (12.3M) Formaldehyde HCHO (FW 30.03)    20ml 
RNAse-free water (DEPC water)      880ml 
2.1.4 1.2% Formaldehyde–agarose gel preparation 
Agarose         0.6g 
10X FA gel buffer        5ml 
RNase-free water (DEPC water)      45ml   
To prepare formaldehyde-agarose gel, 0.6g was weighed, mixed into FA gel buffer and 
top up with DEPC water. The mix was boiled to dissolve the agarose and cooled to 65ºC 
before adding 0.9ml 37% formaldehyde and 0.5µl 10mg/ml ethidium bromide. The 
solution was swirled gentled before being poured into a gel castor. 
2.1.5 5 X RNA Loading Buffer 
Saturated aqueous bromophenol blue solution    16µl 
500mM EDTA, pH 8.0       80µl 
37% (12.3M) formaldehyde       720µl 
100% glycerol         2 ml 
Formamide                   3084 µl 
10X FA gel buffer        4 ml 
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RNase-free water (DEPC water)     top up to 10ml 
Stored at -200C 
3.2 DNA gel electrophoresis 
3.2.1 Agarose gel resolution range  




0.9                                                                                           500-7,000 
1.2 400-6,000 
1.5 200-3,000 
 2.0 100-2,000 
 
3.2.2    10 X Tris-Borate-EDTA (TBE) Buffer, pH 8.3 
Tris base         218g 
Boric Acid         111.3g 
EDTA          7.31g 
All components are in powdered form. They were dissolved with 1800ml H20 and pH to 
8.3 with hydrochloric acid.  The final volume was made up to 2000ml. 
3.2.3 1X TBE 
10X TBE          10ml 
ddH2O.         90ml 
The 1x TBE was mixed thoroughly before use and stored at room temperature. 
3.2.4 6 X DNA Gel Loading Buffer (For Agarose Gels) 
Bromophenol Blue   0.09%     9mg 
Xylene cyanol FF   0.09%     9mg 
EDTA     60mM     0.18g 
Glycerol    60%     6ml 
Tris-base    50mM     0.06g 
dH2O          4ml 
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The components were dissolved in water and pH adjusted to 8.0.  The solution was 
aliquoted and stored at room temperature. 
3.3     8% polyacrylamide gel for PCR product amplified in DENN isoforms study 
3.3.1 Preparation of Hoefer vertical slab gel electrophoresis for PAGE (Pharmacia 
Biotech, SE600) 18 x 16 cm 
• Glass plates, gel castor, spacers, 15 well 1.5mm combs and 16cm clamp 
assemblies for glass plates were washed with detergent and scrubbed thoroughly 
to remove excess PAGE residues 
• They were wiped dry and swapped the plates with 70% ethanol until it dries 
• On a clean and clean surface,  two glass plates were aligned with a 1.5mm thick 
glass spacer in between them 
• The plates were carefully placed vertically onto the gel holder/castor and clamped 
firmly at the bottom of the holder 
• All the reagents were mixed together except for 10% APS and TEMED and 
filtered through a 0.45um filtered-pump system. 
• Subsequently, the mix was degassed for 20’after filteration 
• Next, the last two reagents were added and mixed 
• Then, the polyacrylamide mix was added into the glass plates with 15-well comb 
for polymerization. 
• When, the plates were filled with polyacrylamide solution, the end were clipped 
with big paper clip to secure and tighten the plates 
• The plates were placed horizontally and left to solidified at rt, overnight 
• Finally, they were chilled in cold room for better resolution 
3.3.2 Polyacrylamide gel electrophoresis 
• The Hoefer vertical slab electrophoresis unit was connected to an enclosed 
circulating water bath system to cool the unit to 4°C 
• The polymerized gel glass slabs were carefully clamped onto the supporting unit 
• The tank was filled with 1x TBE buffer before placing the solidified 
polyacrylamide gel in glass plates into the holder 
3.3.3 PAGE visualization 
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• The vertical glass slides were removed from the holder and carefully detached one 
of the glass plate from side of the slab 
• The PAGE gel was carefully transferred into a plastic container of the same size 
as the gel 
• The gel was gently rinsed with distilled water and discarded 
• Next, the gel was soaked in solution containing the following compositions: 
• 0.5x TBE         200ml 
• Glycerol         2ml 
• Gelstar nucleic acid stain (BMA, cat no) 10,000x    10µl 
• After the gel was incubated in dark for 15’, rt with gentle mixing 
• Subsequently, the gel was destaining in dH20, dark for 10’, rt with gentle mixing 
• Finally, a gel photo was taken under uv light 
3.3.4 PAGE densitometry 
• The computer terminal connected to Amersham Pharmacia Biotech, Molecular 
Dynamics, Typhoon Scanner (model. no. ) were switched on for 10’ before use to 
initialize the scanner device 
• The same gel was carefully placed onto the scanning panel of the Pharmacia 
Typhoon scanner 
• For the typhoon , the ‘Fluorescence’ option, ‘532/610 Ethidium bromide’ setup, 
‘+3mm’ platen, ‘200 picoxels’ for scanning resolution 
• The scanned gel was saved as a .gel file automatically 
• The background and contrast of the PCR bands to gel area was altered to optimal 
differences (background changed to white) 








APPENDIX 4: REAGENT FOR PROTEIN MANIPULATION 
4.1 Protein extraction from CNE-2 cell line culture 
3.1.1 10x Protease Inhibitor Cocktail 
One tablet of complete mini protease inhibitor cocktail (Roche) was dissolved in 
1ml distilled water (stored at 4°) 
3.1.2 Lysis buffer                                                     Final concentration 
1M Tris-HCl, pH 7.4                                             100 mM 
1M NaCl                                                                   150 mM 
NP-40 (Amersham Pharmacia)                        0.1 % 
Sodium deoxycholate                                           1 % 
10x protease inhibitor cocktail              1x 
ddH2O 
Lysis buffer were stored at 4ºC. Protease inhibitor cocktail was added prior to use. 
3.2 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Acrylamide gel resolution range: 
Acrylamide percentage (%) gel           Resolution of separation (kDa) 
15        15 to 45 
12.5        15 to 60 
10        18 to 75 
 7.5  30 to 120 
 5.0  60 to 212 
 
3.2.1 10 % Polyacrylamide resolving gel (10ml) 
Deionised H2O          3.7ml 
30% acrylamide (BioRad)       2.5ml 
1.5M Tris-HCl, pH 8.8       3.75ml 
10% SDS         100ul 
10% APS         100ul 




3.2.2 5% Stacking gel (3ml) 
Deionised H2O          2.3ml 
30% acrylamide (BioRad)          0.3ml 
1M Tris-HCl, pH 6.8        0.3ml 
10% SDS         50ul 
10% APS         50ul 
TEMED         5ul 
3.2.3 Sample buffer                           Final concentration 
1M Tris-HCl, pH 6.8                                 250 mM 
10% SDS                                      10 % 
1M Dithiothreitol                         0.1 M 
Glycerol                                        50 % 
Bromophenol blue                     0.01 % 
ddH2O 
3.2.4 10X Laemmli Running Buffer           Final concentration 
Tris Base                                           30 g 
Glycine                                                    144 g 
SDS                                                              10 g 
ddH2O                               
Volume prepared to 1 litre. Stock buffer was diluted 1:10 prior to use for each 
electrophoretic run 
3.2.5 Transfer buffer-Stock solution 10X 
30g Tris, 144g Glycine dissolved into 1 litre of deionised water.  The pH should 
be between 8.1 and 8.4 without adjustment.  
4.2.6 Transfer buffer-Working solution 1X, freshly prepared and chilled at 4°C 
10X transfer buffer stock       100ml 
Methanol         200 
dH2O          700 
4.2.7 Ponceau S stain 




Sodium chloride         8.76g 
Tris base          1.82g  
Tween 20         0.5ml  
All components were dissolved in deionised water to a volume of 1 litre and adjust to 
pH7.4 with 5M HCl. The buffer was stored at room temperature.  
4.2.9 Coomassie Blue Solution 
Coomassie brilliant blue R-250      0.25g 
Glacial acetic acid        10ml 
Methanol         50ml 
All components were mixed in deionised water to a volume of 100ml and store at room 
temperature. 
4.2.10 Destain solution 
Glacial acetic acid           10ml 
Methanol         40ml 
All solutions were mixed in deionised water to a volume of 100ml and stored at room 
temperature 
 












7.6 7) Blue 
18.4 6) Violet 
32.5 5) Orange 
45.7 4) Red 
78 3) Green 
132 2) Magenta 
216 1) Blue 
Size (kDA) Colour 
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APPENDIX 5:  REAGENT USED IN TRANSMISSION ELECTRON 
MICROSCOPY (TEM) 
5.1     Stock fixative agents (stored at 4°C) 
10% paraformaldehyde solutions 
25% Glutaraldehyde (TAABS Labs, England) 
5.2     2 X fixative agent (stored at 4°C) 
4 % Glutaraldehyde + 4% Paraformaldehyde + 2 X PBS, pH 7.4 
5.3   1 X fixative agent (stored at 4°C) 
2% Glutaraldehyde + 2% Paraformaldehyde + 1X PBS, pH 7.4 
5.4    Osmium Tetraoxide (stored at -20°C) 
1% osmium tetraoxide/0.2M cacodylate buffer, pH 7.2-7.4 added with a few 
crystals of potassium ferrocyanide and mixed thoroughly to produce light brown 
solution.  Osmium oxide waste must be disposed into to predesignated container 
before disposal. 
5.5     Low Viscosity Epoxy Resin (LVER) 
Low viscosity kit (TED PELLA. Inc) for LVER, is a water-immiscible embedding media 
 
18306 ERL or VCD Vinylcyclohexene dioxide    10g 
18310 DER Diglycidyl ether of polypropyleneglycol   4g 
18301 NSA Nonenyl succinic anhydride      26g 
18315 DMAE Dimethylaminoethanol      0.4g 
 
The exact weights of each component were weighed out one by one in a fume hood.  This 
formulation will produce harder block due to low concentration of DER.  DMAE 
functions as an accelerator in the hardening of the resin.  In between each component, the 
fume hood was reactivated to remove the toxic fumes.  During the preparation of LVER, 
minimal exposure to atmospheric moisture is recommended.  Finally, the mixture was 
gently and thoroughly mixed before storage in disposable 50ml centrifuge tube in -20°C. 
All materials like 50ml, 15ml centrifuge tubes, sticks, plastics pipettes, containers were 
dried at 60°C overnight before use.  This is reduced introduction of moisture into 
embedding media LVER.  LVER is a yellow, highly viscous embedding media, unit of 
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7.8 centipoise (cps) at 25°C.  Fresh LVER is used for the penetration process.  The LVER 
can be stored in -20°C for up to 2 months; ‘aged’ LVER should be used for better 
infiltration process. LVER waste must be incubated at 60°C, overnight before disposal. 
